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The Par-1 family of serine/threonine protein kinases functions to regulate cell polarity
and is conserved from yeast to humans. Par-1 is encoded by one of six Par (partitioningdefective) genes (Par-1-6) originally identified in a genetic screen conducted in
Caenorhabditis elegans (C. elegans). The mammalian Par-1 family is comprised of four
members (Par-1a, b, c and d). Par-1 kinases are regulated by two arms of the Protein
Kinase C (PKC) pathway. Atypical Protein Kinase C (aPKC) phosphorylates Par-1b on a
conserved threonine residue (T595) and I participated in studies demonstrating that novel
Protein Kinase C (nPKC) activates Protein Kinase D (PKD) to directly phosphorylate
Par-1b on serine 400 (S400), a residue that is conserved in all four mammalian Par-1
kinases as well as the fly ortholog. Phosphorylation of Par-1b on T595 and S400 causes
Par-1b to relocate from membranes to the cytosol and to bind 14-3-3 proteins. In 2004,
Brajenovic, et al. reported the results of a study that used tandem affinity purification
(TAP) to isolate human Par-1d along with associated proteins. Nrdp1/RNF41, a RING
finger E3 ligase was identified in their screen along with 14-3-3 and aPKC. I found that
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Par-1b binds to RNF41 and I identified RNF41 as a novel cell polarity determinant. My
work demonstrated that phosphorylation of RNF41 on S254 by Par-1b is necessary for
establishing epithelial cell polarity.
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Introduction
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The Par proteins in development and disease
The Par proteins are important for establishing cell polarity in the embryo and are
found to play crucial roles in a variety of human diseases. In the Caenorhabditis elegans
(C. elegans) embryo the Par proteins are required for asymmetric cell division of the
embryo (Kemphues et al., 1988) and in epithelial cells for the establishment of apicalbasal cell polarity (Rodriguez-Boulan and Nelson, 1989). In mice, Par-1b (one of the
Par-1 mammalian orthologs) has been show to be important for fertility, immune
homeostasis, learning, and memory as well as glucose metabolism(Hurov et al., 2007). It
has been suggested that epithelial cell polarity may exert a tumor suppressive function in
mammals through its participation in the establishment and maintenance of the 3D
organization of epithelial tissues as a whole. Par-1, a serine/threonine protein kinase, is
phosphorylated and activated by the Par-4 (LKB1) tumor suppressor (Fig. 1.3) and LKB1
is mutated in Peutz-Jeghers cancer syndrome (PJS) (Baas et al., 2004b). It is important to
note that a common theme in establishing and maintaining cell polarity is the antagonistic
relationship between the Par proteins through the addition of posttranslational
modifications such as phosphorylation. Moreover, phosphorylation of Par proteins also
affects protein-protein interactions.
The par genes and Par proteins: Asymmetric localization and fundamental for cell
polarization
The par genes are required for asymmetric cell division of the C. elegans embryo
into two daughter cells (Kemphues et al., 1988) and epithelial cells depend on the
asymmetric organization of cellular components along their apical-basal axes. It is the
activity of asymmetrically localized proteins and protein complexes that regulate this
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polarity (Rodriguez-Boulan and Nelson, 1989). Par-1 is one of six par (partitioningdefective) genes (Par-1, Par-2, Par-3/ASIP, Par-4/LKB1, Par-5/14-3-3, and Par-6)
identified in a genetic screen conducted in C. elegans (Guo and Kemphues, 1995). Par-1
orthologs have subsequently been identified and studied in a number of organisms,
including yeast, Drosophila, and mammals (Drewes et al., 1997; Elbert et al., 2005; La
Carbona et al., 2004; Shulman et al., 2000; Trinczek et al., 2004) and have been
implicated in regulating cell polarity and other cellular functions, such as mitogenic and
Wnt signaling (Bohm et al., 1997; Cox et al., 2001; Muller et al., 2001; Ossipova et al.,
2005; Shulman et al., 2000; Sun et al., 2001; Tomancak et al., 2000). In mammals there
are four Par-1 family members: mPar-1a (C-TAK1/MARK3), mPar-1b (EMK/MARK2),
mPar-1c (MARK1), and mPar-1d (MARKL1, MARK4). Mammalian orthologs have
been identified for all of the par genes except for Par-2.
In the C. elegans embryo, all of the Par proteins are enriched at or near the cell
cortex, and most of the proteins adopt asymmetric localization patterns as cell
polarization is established (Kemphues, 2000). Par-3 and Par-6 become enriched in the
anterior cortex during the one-cell stage, and Par-1 and Par-2 become enriched in the
posterior cortex (Fig.1.1). Par-4 (LKB1) and Par-5 remain symmetrically distributed and
are both cortical and cytoplasmic. Par proteins drive their own asymmetric localization
by regulating motors or by establishing the conditions necessary in the cell cortex for
asymmetric movements of cellular components (Goldstein and Macara, 2007). The
anterior Par proteins are required to prevent posterior Par proteins from localizing
anteriorly, and vice versa (Kemphues, 2000). Par-5 is required for the exclusion of both
anterior and posterior Par domains (Cuenca et al., 2003; Morton et al., 2002). Par-1
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membrane association at the posterior pole is dependent in part on Par-2 (Boyd et al.,
1996).
The C. elegans one-cell embryo becomes polarized by the contraction of the
actomyosin cortex to one side of the cell (Fig. 1.1) (Munro, 2006). The fertilizing sperm
delivers two cues for the contraction: the sperm-derived centrosomes and a RhoGAP
called CYK-4. Rho affects myosin organization and activates myosin-based contraction
and CYK-4 locally inactivates Rho, thus resulting in an inhibition of mysosin and
breaking the actomyosin on one side of the cell allowing the cortex to contract away from
the site of sperm entry (Goldstein and Macara, 2007). The contraction of the cortex to
one side moves the Par-3/Par-6/atypical protein kinase C (aPKC) complex toward the
anterior; however, Par-6 and Par-2 associate with the moving cortex, suggesting that Par
proteins may exchange rapidly on and off of the moving cortex rather than be moved
(Munro et al., 2004). Once the polarity is established at the anterior of the embryo and
anterior Par proteins are in place, posterior Par proteins can then associate with the
posterior cortex (Cuenca et al., 2003; Munro et al., 2004).
Once the two Par domains are established, the Par proteins function to maintain
polarity on each end of the C. elegans embryo. Two distinct domains are maintained in a
positive feedback loop using phosphorylation as a means to maintain this polarity. aPKC
at the anterior of the embryo and Par-1 at the posterior inhibit specific proteins from
associating locally. In the anterior, aPKC phosphorylates Par-2 in order to prevent Par-2
cortical association (Hao et al., 2006). In the posterior, Par-2 prevents reverse cortical
flow and blocks anterior Pars from associating by allowing Par-1 to accumulate at the
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posterior cortex where it can cause disassembly of the anterior Par complexes (Cuenca et
al., 2003).
Epithelial polarization in C.elegans, Drosophila, and mammals
The formation and maintenance of epithelial sheets of cells with apical-basal
polarity is essential throughout development and in adult organisms. Junctions between
the epithelial cells provide adhesion and control the permeability of the sheets to ions and
molecules. The physiological functions of epithelial cells depend on the asymmetric
organization of cellular components such as the plasma membrane, organelles, and the
cytoskeleton along the apical-basal axis (Rodriguez-Boulan and Nelson, 1989). In the C.
elegans embryo this organization and establishment of cell polarity has been shown to be
dependent on the antagonistic relationship between Par-1 and the Par-3/Par-6/aPKC
complex, and the same is likely true in epithelial cells of developed eukaryotic organisms.
The fly ortholog of Par-3 functions in Drosophila epithelial cells to also drive apicalbasal polarization (Kuchinke et al., 1998); furthermore, in mammalian epithelia, Par-3 is
localized to tight junctions at the apical/lateral boundary and functions in their assembly
(Chen and Macara, 2005). This discussion of polarity proteins extends to Par-1, as the
phosphorylation of Par-1 by aPKC and PKD permits binding of Par-5 (14-3-3) and
blocks membrane binding (Fig. 1.2) (Hurov et al., 2004; Suzuki et al., 2004; Watkins et
al., 2008). Conversely, Par-1 present at the lateral membrane can phosphorylate any Par3 molecule that is located in its vicinity (Fig. 1.2). Phosphorylated Par-3 binds Par-5 (143-3) and is released from the cell membrane, thus preventing the spread of Par-3 into the
lateral membrane occupied by Par-1. Therefore, the segregation of the Par proteins into
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separate domains is maintained by exclusion which is driven by phosphorylation and Par5 (14-3-3) binding.
Par-1 and Par-4 also participate in epithelial polarization. In mammalian cells
Par-1 determines the organization of microtubules, which establish the position of the
luminal surface (Cohen et al., 2004). Hyperactive Par-1 converts columnar epithelial
cells with vertical microtubules and an apical luminal surface into a hepatic type of
epithelial cells with horizontal microtubules and lumens that form between adjacent cells.
Par-1 is phosphorylated and activated by Par-4 (LKB1) (Fig. 1.3). Mammalian Par-4
(LKB1) is mutated in Peutz-Jeghers cancer syndrome (PJS). This disease involves the
epithelial cells of the gastrointestinal tract, pancreas, lungs, and reproductive organs
(Baas et al., 2004b) even though Par-4 is expressed ubiquitously (Alessi et al., 2006).
PJS patients frequently have mutations that truncate the kinase domain or result in loss of
expression of LKB1 (Par-4). In mammals, LKB1 (Par-4) functions as a master kinase
that can phosphorylate and activate many downstream kinases, including Par-1, and it has
been implicated in metabolic control, cell growth, and mitosis, in addition to cell
polarization and asymmetric cell division (Alessi et al., 2006). High Par-4/LKB1 activity
can drive the polarization of isolated epithelial cells even in the absence of cell-cell
contacts; however, the downstream kinase necessary for this is not Par-1, but AMPK, a
kinase primarily thought of as a metabolic regulator that responds to energy deprivation
(Lee et al., 2007; Mirouse et al., 2007). It is interesting to note that a constitutively active
AMPK can rescue many of the polarity defects that occur in Drosophila lkb1 null
mutants through phosphorylation of the myosin light chain, and loss of either AMPK or
Par-4/LKB1 results in a stress-dependent loss of epithelial cell polarity. On the other
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hand, activation of AMPK by energy deprivation can drive epithelial cell polarization.
These results reveal a link between energy metabolism and the polarity/proliferation
pathways.
Par-1b and Par-1a knockout mice
Another link between energy metabolism and the polarity/proliferation pathways
is mammalian Par-1b/MARK2/EMK (mPar-1b). Knockout studies of mice performed by
our laboratory suggest that polarity kinase Par-1b/MARK2/EMK is required for
regulating fertility, immune homeostasis, as well as glucose metabolism in vivo (Hurov et
al., 2007). Par-1b knockout mice are lean, insulin hypersensitive, resistant to high-fat
diet-induced weight gain, and hypermetabolic. Thus, mammalian Par-1b is a regulator of
glucose metabolism and adiposity in the whole animal and may be a valuable drug target
for the treatment of both type 2 diabetes and obesity.
Similar to Par-1b/MARK2/EMK knockout mice, our lab has also shown that Par1a/MARK3/C-TAK1 null mice exhibit increased energy expenditure, reduced adiposity
with unaltered glucose handling, and normal insulin sensitivity (Lennerz et al., 2010).
Par-1a knockout mice are protected against high-fat diet-induced obesity and display
attenuated weight gain, complete resistance to hepatic steatosis, and improved glucose
handling with decreased insulin secretion (Lennerz et al., 2010). Overnight starvation led
to complete depletion of hepatic glycogen supply, associated hypoketotic hypoglycemia,
increased hepatocellular autophagy, and increased glycogen synthase levels in Par-1a null
but not in control or Par-1b null mice. When Par-1a null mice were intercrossed with
Par-1b null mice it was noticed that at least one of the four alleles is necessary for
embryonic survival. Interestingly, the loss of one Par-1b allele in Par-1a null mice
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conveyed milder phenotypes than the loss of one Par-1a allele in Par-1b null mice. Thus,
although Par-1a and Par-1b can compensate for one another during embryogenesis, their
individual and specific disruption gives rise to unique metabolic phenotypes in adult mice.
Par-1b protein domains and known posttranslational modifications
Par-1 is a serine/threonine protein kinase comprised of an amino-terminal kinase
domain, followed by a ubiquitin-associated domain (UBA), a nonconserved spacer region,
and ending with a conserved region of about 100 amino acids that terminates with the
sequence glutamate-leucine-lysine/asparagine-leucine (Fig. 1.3) (Marx et al., 2006). This
region has been referred to as the “ELKL” domain and murine EMK derived its name
from ELKL motif kinase. Par-1 is activated by phosphorylation within its activation loop
on Threonine (T)208 (Fig. 1.3). Activation loop phosphorylation can be catalyzed by
Par-1b itself, by the tumor suppressor LKB1 (Par-4) (Lizcano et al., 2004) or by
MARKK (Timm et al., 2003). The presence of a UBA domain adjacent to the catalytic
domain suggests potential interactions between Par-1b and proteins involved in the
ubiquitin proteasome pathway, DNA repair, and/or cell signaling (Brajenovic et al., 2004;
Hofmann and Bucher, 1996; Mueller and Feigon, 2002). However, one study reported
that the UBA domain of Par-1b may not bind ubiquitin, but rather serve as an inhibitory
domain (Murphy et al., 2007; Panneerselvam et al., 2006).
Downstream of the UBA domain is a region that is not highly conserved among
Par-1 orthologs. We identified two phosphorylation sites (Serine (S)400 and T595)
within this region that are conserved among many orthologs (Fig. 1.3) (Hurov et al.,
2004; Watkins et al., 2008). Furthermore, our work has demonstrated that these sites are
regulated by two different arms of the Protein Kinase C (PKC) pathway. T595 is
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phosphorylated by aPKC (Hurov et al., 2004) whereas my work has shown that S400 is
phosphorylated by PKD through activation of novel PKCs (nPKCs) (Watkins et al.,
2008). The nPKC pathway is activated by the PKC activator phorbol-12-myristate-13acetate (PMA) in vivo. Moreover, both phosphorylation sites contribute to interactions
between Par-1b and 14-3-3 proteins (Benton and St Johnston, 2003; Goransson et al.,
2006; Suzuki et al., 2004). 14-3-3 proteins, themselves members of the Par family (Par5), interact with phospho-Ser or phospho-Thr motifs and modulate diverse cellular
processes (Fu et al., 2000; Mackintosh, 2004; Muslin and Xing, 2000). In addition to
directly binding to 14-3-3 proteins, Par-1 proteins also phosphorylate other proteins to
regulate their interactions with 14-3-3 proteins: the kinase suppressor of Raf-1 (KSR1),
which functions as a docking platform for components of the Ras-MAPK pathway
(Muller et al., 2001); protein-tyrosine phosphatase H1, which regulates cell-cycle
progression and attenuates T-cell-receptor signaling (Zhang et al., 1997); plakophilin2, a
desmosomal protein (Muller et al., 2003), and PAR-3 (Benton and St Johnston, 2003).
RNF41 protein domains
In an effort to identify Par-1 interacting proteins, human Par protein complexes
were mapped out using tandem affinity purification (TAP) and the resulting network of
proteins identified novel interactors of human Par-1 (hPar-1d/MARK4) such as the
ubiquitin ligase NRDP1 (neuregulin receptor degradation protein-1)/RNF41 (Brajenovic
et al., 2004). RNF41 is composed of an N-terminal RING domain, two zinc-finger
domains collectively called the B-Box, a coiled-coil segment, and a C-terminal receptor
binding domain (Abdullah et al., 2001; Bouyain and Leahy, 2007) (Fig. 1.4). Out of the
six par genes in C. elegans, orthologs of every gene except Par-2 have been identified in
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mammals. Par-2 is a RING finger-containing protein and has homology with RNF41 in
both the RING domain and a portion of the C-terminus leaving open the interesting
possibility that RNF41 is an ortholog of Par-2.
While the N-terminal motif of RNF41 is characteristic of a family of E3 ubiquitin
ligases, called TRIM/RBCC (Tripartite Motif/Ring B-Box Coiled-coil) proteins, it is the
diversity of the C-terminal ends of these proteins that is thought to be involved in
selectively recognizing target proteins. Of interest is the C-terminal end of RNF41 as it
has no homology with other proteins of known structure (Diamonti et al., 2002; Qiu and
Goldberg, 2002) and binds specifically to its substrates, such as ErbB3, BRUCE,
PARKIN, and others via specific residues (Bouyain and Leahy, 2007). Unlike most other
membrane receptors, ErbB3 does not undergo degradation by lysosomes (Levkowitz et
al., 1999; Qiu and Goldberg, 2002; Waterman et al., 1998), but rather is degraded by the
proteasome and this process is catalyzed by the ubiquitin ligase RNF41 (Qiu and
Goldberg, 2002). Mutation of cysteine, histidine, and aspartate residues in the RING
domain of RNF41 inhibits its E3 ligase activity and thus degradation of ErbB3.
Additionally, the RING and B-box motifs at the N-terminus of RNF41 are not required
for binding to ErbB3 (Qiu and Goldberg, 2002) yet are required for ERBB3 degradation.
Interestingly, expression of an RNF41 mutant containing only the coiled-coil and Cterminal domains caused ErbB3 to accumulate (Diamonti et al., 2002; Qiu and Goldberg,
2002). Therefore, RNF41 binds ErbB3 receptors through its C-terminal end; however, it
is its N-terminal RING domain which provides its function as an E3 ubiquitin ligase and
signal for ErbB3 degradation.
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RNF41 regulation
RNF41 is extremely unstable when transfected or transduced in a variety of cell
lines, often requiring treatment of cells with the proteasome inhibitor MG132 in order to
detect endogenous RNF41 protein by Western blot. Point mutations in the RING finger
domain that disrupt zinc ion coordination and thus coupling to E2 ubiquitin conjugating
enzymes stabilize RNF41 protein, suggesting that the lability of RNF41 protein may be
due in a large part to autoubiquitination (Carraway).
In order to elucidate mechanisms of RNF41 regulation, interacting proteins were
identified by affinity chromatography/tandem mass spectrometry. Among the proteins
identified was USP8 (Wu et al., 2004), a deubiquitinating enzyme. After characterization
of this protein-protein interaction, it was found that the carboxy terminal domain of
RNF41 binds to the rhodanese domain of USP8, and that USP8 very efficiently
deubiquitinates and stabilizes RNF41 (Wu et al., 2004). Moreover, it was observed that
treatment of cells with the growth factor Neuregulin-1! (NRG1!) stabilizes RNF41
through USP8 (Cao et al., 2007). NRG1! stimulation of the ErbB2/ErbB3 heterodimer
activates phosphatidylinositol 3-kinase (PI3K), in turn activating AKT, which
phosphorylates murine USP8 on threonine 907. USP8 phosphorylation leads to its
activation and stabilization, thus stabilizing RNF41. The resulting feedback loop
provides a mechanism for ligand-induced degradation of ErbB3, and furthermore it has
been demonstrated that RNF41 or USP8 knockdown in MCF7 breast tumor cells
suppresses NRG1!-stimulated ErbB3 ubiquitination and degradation(Cao et al., 2007).
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ErbB receptor tyrosine kinase signaling and breast cancer
The ErbB family of receptor tyrosine kinases regulates various cellular processes
such as proliferation, differentiation, cell survival, migration, and invasion (Yarden and
Sliwkowski, 2001; Yen et al., 2006). Members of this family include the epidermal
growth factor receptor (EGFR/ErbB1), HER2/c-neu (ErbB2), HER3 (ErbB3), and HER4
(ErbB4). Furthermore, aberrant expression of these receptors is commonly found in
human cancers and is associated with aggressive disease (Hynes and Stern, 1994;
Salomon et al., 1995; Yarden and Sliwkowski, 2001; Yen et al., 2006).
The ErbB signaling network is complex due to the existence of multiple ligands,
each with specificity for distinct members of the ErbB family. The ErbB receptors signal
through the formation of ligand-induced homodimers and heterodimers between the
different family members (Alroy and Yarden, 1997; Carraway and Cantley, 1994; Riese
and Stern, 1998; Yen et al., 2006), which then activate diverse signaling pathways (Alroy
and Yarden, 1997; Carraway and Cantley, 1994). Binding of peptides of the EGF-related
growth factor family to the extracellular domain of ErbB receptors results in the
formation of these homo- and heterodimers. Ligand binding induces the intrinsic
receptor kinase activity, leading to stimulation of the intracellular signaling cascades
(Yarden and Sliwkowski, 2001). Moreover, the ErbB3 receptor has impaired kinase
activity (Guy et al., 1994), whereas the ErbB2 receptor has no known ligand. Thus, both
receptors must form receptor heterodimers in order to signal. Neuregulin-1 (NRG1)
growth factor binds to its ErbB3 receptor preferentially resulting in ErbB2/ErbB3
heterodimer formation (Citri et al., 2003; Yen et al., 2006) and initiating extracellularrelated kinase/ mitogen-activated protein kinase (ERK/MAPK) and PI3K pathway
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activation (Alimandi et al., 1995; Ben-Levy et al., 1994; Holbro et al., 2003; Peles et al.,
1992; Yen et al., 2006).
It has widely been demonstrated that ErbB receptor tyrosine kinases, in particular
ErbB1 and ErbB2, have roles in human cancer development, thus making them attractive
targets for cancer therapies (Hynes and Stern, 1994; Mendelsohn and Baselga, 2000;
Salomon et al., 1995; Shawver et al., 2002). ErbB2 overexpression, which is generally
due to gene amplification, occurs in 25-30% of breast cancer and correlates with shorter
time to relapse and lower overall survival (Slamon et al., 1987). Overexpressed ErbB2 is
constitutively phosphorylated in breast cancer cell lines and in human tumors (Alimandi
et al., 1995). It has been observed that targeting overexpressed active ErbB2 results in
efficient inhibition of breast cancer cell proliferation (Lane et al., 2000; Munster et al.,
2002; Neve et al., 2000; Yakes et al., 2002).
Interestingly, expression of ErbB3 is seen in many tumors that express ErbB2,
including breast (Naidu et al., 1998), bladder (Chow et al., 2001), and others.
Furthermore, in many ErbB2-overexpressing breast tumors, ErbB3 has elevated levels of
phosphotyrosine (Alimandi et al., 1995). Several groups have shown that inactivation of
ErbB2 leads to a decrease in ErbB3 tyrosine phosphorylation (Basso et al., 2002; Lane et
al., 2000; Motoyama et al., 2002; Neve et al., 2000). ErbB3, which contains six docking
sites for the p85 adaptor subunit of PI3K, efficiently couples to this pathway (Fedi et al.,
1994; Prigent and Gullick, 1994). Interestingly, it has been observed that a major
consequence of targeting overexpressed ErbB2 is decreased PI3K (Basso et al., 2002;
Lane et al., 2000; Neve et al., 2000), suggesting a role for ErbB3 in stimulation of this
pathway downstream of active ErbB2.
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Finally, it has been shown in breast cancer cells that constitutive tyrosine
phosphorylation on ErbB3 depends on the activity of overexpressed ErbB2 (Holbro et al.,
2003). Activity of the PI3K pathway depends fully on the recruitment of p85 to phosphoErbB3. Importantly, inactivation of ErbB3 blocks proliferation of breast cancer cells as
efficiently as inhibiting ErbB2 signaling (Holbro et al., 2003). Expression of
constitutively active PI3K rescues the proliferative block induced due to the loss of
ErbB2 or ErbB3 signaling. Taken together, these results suggest that the ErbB2/ErbB3
dimer functions as an oncogenic unit to drive tumor cell proliferation.
RNF41 involvement in ErbB3 overexpression in mammary tumors
Several mechanisms account for ErbB3 overexpression in tumors. Amplification
of the erbB3 gene has been reported, but PCR and FISH results suggest that this is not as
prevalent as erbB2 amplification (Sassen et al., 2008; Zaczek et al., 2008) and does not
account for the frequency of elevated ErbB3 protein observed in tumors. Although
ErbB3 overexpression is a common occurrence in breast tumors, and ErbB3 levels may
be regulated post-transcriptionally in mouse mammary tumors (Miller et al., 2008; Siegel
and Muller, 1996; Yen et al., 2006), the question remains whether the RNF41 pathway is
deregulated in tumors, and if so, whether deregulation contributes to tumor initiation or
progression. It has previously been observed that RNF41 protein is lost in ErbB2-driven
mammary tumors from transgenic mice and this loss cannot be attributed to a reduction in
message levels (Carraway). Furthermore, RNF41 protein is suppressed in 57% of tumors
when comparing patient-matched normal and tumor breast tissues, and there is a strong
inverse correlation between RNF41 and ErbB3 protein levels in patient tumors (Yen et al.,
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2006). All of this data is suggestive that loss of RNF41 contributes to ErbB3 protein
overexpression in both human and mouse tissue samples.
Surprisingly, crossing MMTV-RNF41 mice into an ErbB2 overexpression model
had little effect on tumor latency or burden, or on ErbB3 protein overexpression (Ingalla
et al.), even though RNF41 transcript levels were 10-fold higher in bigenic animals than
in MMTV-ErbB2 mice. Immunoblotting studies revealed that the ErbB2-induced mouse
mammary tumors lacked both endogenous and overexpressed RNF41 protein. Consistent
with this, cultured ErbB2-positive breast tumor cells are resistant to the expression of
exogenous RNF41, while non-transformed cells efficiently support RNF41 expression
(Ingalla et al.). These observations indicate that like ErbB2 and ErbB3, RNF41 levels are
deregulated in tumor cells by posttranscriptional mechanisms.
3D models of glandular epithelium
Under 3D culture conditions, normal epithelial cells proliferate and organize into
spheroids (acini), which are known to have a centrally-localized, hollow lumen with
polarized cells surrounding this lumen (Fig. 1.5) (Debnath et al., 2003; Petersen et al.,
1992; Streuli and Bissell, 1990). These 3D culture systems address some of the
limitations of monolayer (2D cell culture) cell cultures, mouse models, or human tissues.
3D cell cultures are easily manipulated experimentally and can be analyzed
biochemically and using microscopy. Furthermore, 3D cell cultures contain essential
structural features of glandular epithelium in vivo. Early studies revealed that human
breast tumor cell lines did not form acini when grown in 3D culture; rather, they develop
into nonpolarized clusters (Petersen et al., 1992). These experiments illustrated the
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difference in behavior between normal and tumor cells in 3D culture, even though subtle
difference were noted when the same cells were grown as monolayers.
The cells comprising glandular epithelial tissues exhibit a characteristic polarity,
such that their apical poles point towards the central lumen. This polarity is often
disrupted in carcinomas, which is generally considered a poor prognostic sign. MDCK
cyst models have demonstrated that epithelial cells possess hard-wired mechanisms for
generating polarity within the context of a 3D tissue structure. Furthermore, it has been
demonstrated that the ECM plays a fundamental role in directing these mechanisms
(O'Brien et al., 2002).
Epithelial cell polarity and cancer
The majority of human cancers are derived from epithelial tissues, and display
loss of cell polarity and often, as a consequence, tissue disorganization. Although the
tumor suppressive function of polarity complexes is well established in Drosophila, it
remains unclear whether a loss of cell polarity is a consequence or cause of human
cancers. However, it is now suggested that epithelial cell polarity may exert a tumor
suppressive function in mammals through its participation in the establishment and
maintenance of the 3D organization of epithelial tissues as a whole. This is supported by
the findings that polarity proteins are cellular targets of oncogenes and tumor suppressors
(Royer and Lu).
Apical-basal polarity has two fundamental roles in epithelial cells that are linked
to tumor suppression: the regulation of asymmetric cell division and the maintenance of
the apical junctional complex (AJC). In epithelial stem cells, polarity proteins control
asymmetric cell divisions by regulating the localization of cell fate determinants and the
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correct orientation of mitotic spindles. Thus, asymmetric cell division has a role in the
control of progenitor or stem cell numbers and differentiation. This is of interest in the
context of the cancer stem cell theory, as shifting from asymmetric division of epithelial
stem cells or cancer-initiating cells towards symmetric divisions would result in
dedifferentiation and an increase in cancer-initiating cells. Thus, a defect in asymmetric
division could contribute to the development of tumors.
In addition to their role in the prevention of tumor initiation, core epithelial cell
polarity mechanisms may also behave as a barrier to tumor metastasis and malignancy
through their close connection to the AJC. The AJC contains both tight and adherens
junction complexes, and its structure is dependent on the integrity of the apical and
basolateral polarity complexes. The loss of one of the key components of adherens
junctions, E-cadherin, often occurs in later stages of tumorigenesis and is thought to
contribute to epithelial mesenchymal transition (EMT), which represents a crucial step in
metastasis. The importance of the AJC in supporting cancer malignancy is supported by
cancer genome sequencing data which show that a large number of AJC components are
frequently mutatated in human cancers.
Evidence indicates that loss of cell polarity is not merely a byproduct of abnormal
cell proliferation, but rather is caused by the direct disruption of cell-polarity mechanisms
by oncogenic signaling (Fig. 1.6). One example, E6 oncogenes, found in human
papilloma virus (HPV), target cell polarity proteins Dislarged (Dlg) and Scribble (Scrib)
for proteolytic degradation (Fig. 1.6) (Lee and Vasioukhin, 2008). The ability to degrade
these cell polarity proteins correlates with the malignant potential of E6 oncogenes. In
addition to viral oncogenes, malignant transformations can be induced by the abnormal
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activation of various growth factor signaling pathways such as transforming growth
factor ! (TGF!), resulting in the stimulation of cell proliferation and disruption of apicalbasal polarity, cell-cell adhesion, and sometimes a complete epithelial-mesenchymal
transition (EMT). AJC-localized Par6 directly interacts with TGF! receptors and is a
substrate for TGF!RII-mediated phosphorylation (Ozdamar et al., 2005). Activation of
TGF! signaling results in phosphorylation of Par6, which promotes its interaction with
the E3 ubiquitin ligase Smurf1. Localized to the AJCs, Smurf1 targets junctional RhoA
for degradation. RhoA is crucial for the maintenance of the actin cytoskeleton and
stabilization of AJCs; thus, activation of TGF! signaling results in the destabilization and
loss of AJCs and the initiation of EMT (Fig. 1.6).
Abnormal activation of the receptor tyrosine kinase ErbB2 is implicated in human
breast, ovarian, gastric, esophageal, and endometrial cancers (Hynes and Lane, 2005;
Linggi and Carpenter, 2006; Moasser, 2007). Whereas ErbB2 stimulates cell
proliferation by activating the PI3K pathway, it can also directly disrupt cell polarity and
provide protection from apoptosis through its interaction with the Par6-aPKC protein
complex (Aranda et al., 2006). Activation of ErbB2 results in the dissociation of Par3
from the Par6-aPKC complex (Fig 1.6). Inhibition of this dissociation restores correct
cell polarity and abrogates the anti-apoptotic effects of ErbB2. These findings indicate
that growth-factor receptors can use independent mechanisms to regulate proliferation
and polarity, and that it is possible to activate cell proliferation without inducing cellpolarity defects.
In addition to oncogenes and proto-oncogenes, tumor suppressors are also
involved in the regulation of apical-basal cell polarity. Mutations in the von Hippel-
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Lindau (VHL) tumor suppressor are responsible for von Hippel-Lindau disease, which is
characterized by the development of hemangioblastoma, clear-cell renal carcinoma and
pheochromocytomas (Kaelin, 2005; Kaelin, 2007). VHL polyubiquitinates and targets
the transcription factor hypoxia-inducible factor 1 (HIF1) for degradation. VHL directly
impacts cell polarity pathways by ubiquitin-mediated degradation of activated aPKC (Fig
1.6) (Okuda et al., 2001). Furthermore, interaction between VHL and the Par3-Par6aPKC complex is involved in VHL-mediated regulation of polarized microtubule growth
and formation of primary cilia (Schermer et al., 2006). This function makes VHL an
important regulator of cell polarity because polarized growth of microtubules is crucial
for cell polarization.
Phosphatase and tensin homolog (PTEN) is another tumor suppressor protein that
is implicated in the regulation of cell polarity. PTEN negatively regulates the PI3K
pathway (Rossi and Weissman, 2006). Spatial membrane segregation of PI3K pathway
regulators is important for apical-basal cell polarity (Fig.1.6)(Martin-Belmonte et al.,
2007). Thus, PTEN is necessary for the establishment and maintenance of apical-basal
cell polarity.
Finally, in addition to PTEN, LKB1 is another dual-function protein that is
directly involved in both cell polarity and tumor suppression. As previously described,
mutations in LKB1 are responsible for Peutz-Jeghers syndrome. LKB1 is a homologue
of the Drosophila and C. elegans cell polarity protein Par4 and its function is also
important for establishing polarity in mammalian cells (Baas et al., 2004a). LKB1
phosphorylates and activates several other serine/threonine protein kinases including
AMP-activated protein kinase (AMPK) and Par1 (Fig 1.6) (Lizcano et al., 2004). AMPK
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controls cell polarity by regulating the acto-myosin cytoskeleton via phosphorylation of
the non-muscle myosin regulatory light chain (MRLC) protein (Lee 2007). The
discovery of AMPK as a regulator of cell polarity indicates that LKB1-mediated control
of cell growth and polarity are connected to each other.
Summary
The major goal of my thesis work was to investigate functional interactions
between the Par-1b protein kinase and the RNF41 E3 ubiquitin ligase. Atypical Protein
Kinase C (aPKC) phosphorylates Par-1b on a conserved threonine residue (T595) and I
participated in studies demonstrating that novel Protein Kinase C (nPKC) activates
Protein Kinase D (PKD) to directly phosphorylate Par-1b on serine 400 (S400), a residue
that is conserved in all four mammalian Par-1 kinases as well as the fly ortholog.
Phosphorylation of Par-1b on T595 and S400 causes Par-1b to relocate from membranes
to the cytosol and to bind 14-3-3 proteins. In 2004, Brajenovic, et al. reported the results
of a study that used tandem affinity purification (TAP) to isolate human Par-1d along
with associated proteins. Nrdp1/RNF41, a ring finger E3 ligase was identified in their
screen along with 14-3-3 and aPKC. I found that Par-1b also binds to RNF41 and
identified RNF41 as a novel cell polarity determinant. My work demonstrated that
phosphorylation of RNF41 on S254 by Par-1b is necessary for establishing epithelial cell
polarity.
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Par-3
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PKC-3

Par-2

Par-1
Fig.1.1 Mechanisms that localize Par proteins.
Sperm-contributed nucleus and centrosome-nucleated microtubules are on the
right side of the C. elegans embryo. Arrows indicate spread of the cortex to which
Par-2 associates as actomyosin contraction occurs. [Adapted from (Goldstein and
Macara, 2007)]
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Fig. 1.2 Mechanisms of establishing epithelial cell polarity.
Par-1 that has diffused onto the apical domain is phosphorylated by
aPKC, thus inhibiting the Par-1 kinase activity and inducing binding of
Par-5/14-3-3, which in turn triggers release of Par-1 into the cytoplasm.
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Fig. 1.3 Diagram of the domains of Par-1b protein and upstream
signaling. [(*) indicates autophosphorylation] LKB1 phosphorylates
Par-1b to activate Par-1b signaling. Additionally, Par-1b is
phosphorylated by two arms of the PKC pathway on two sites (S400
and T595).
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Fig. 1.4 Diagram of the domains of RNF41 protein.
Indicated are amino acids known to be of importance for substrate binding
and/or E3 ligase activity. Serine 254, a site phosphorylated by Par-1b, is
indicated in bold.
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Fig. 1.5 Events in MCF10A morphogenesis in 3D culture.
During the early stages of 3D culture, apical-basal polarization becomes evident
within cell clusters before evidence of lumen formation. At day 5-8 in culture,
two distinct populations of cells become evident within each acinus: an outer
layer of cells in direct contact with the matrix (marked by laminin 5 staining on
day 4) and inner cells lacking matrix contact. Throughout morphogenesis, this
outer cell layer remains polarized with respect to the acinus center (indicated by
the apical orientation of the golgi protein, GM130). Starting at day 8,the
centrally located cells undergo cell death, which involves apoptosis,
characterized by the expression of active caspase 3. This cell death contributes
to the formation of a hollow lumen. The acinus remains hollow thereafter.
[Adapted from (Debnath and Brugge, 2005)]

-25-

Fig. 1.6 Oncogenic and tumor suppressor signaling pathways target cellpolarity mechanisms. (A) Viral E6 oncogene from human HPV targets Dlg and
Scrib proteins for ubiquitin-mediated degradation. (B) Activation of TGF! signaling
results in phosphorylation of Par6, and targeting of the E3 ubiquitin ligase Smurf1 to
the AJCs, where Smurf1 destroys RhoA, disrupts the integrity of AJCs and causes
EMT. (C) Activation of ErbB2 signaling results in disruption of the apical Par6Par3-aPKC polarity complex by promoting dissociation between Par3 and Par6aPKC. (D) TheVHL tumor suppressor ubiquitinates active aPKC and targets it for
proteasome-mediated degradation. In addition, interaction between VHL and the
Par3-Par6-aPKC polarity complex is necessary for correct orientation of the
microtubules and for primary cilia formation. (E) During polarization of epithelial
cells PTEN is targeted to the future apical membrane domain (F) The tumor
suppressor LKB1 controls cell polarity, growth and proliferation by regulating the
activities of AMPK and Par1 protein kinases. [Adapted from (Lee and Vasioukhin,
2008)]
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Abstract
The Par-1 protein kinases are conserved from yeast to humans where they
function as key polarity determinants. The mammalian Par-1 family is comprised of four
members (Par-1a, b, c and d). Previously, we demonstrated that atypical protein kinase C
(aPKC) phosphorylates the Par-1 kinases on a conserved threonine residue (T595) to
regulate localization and kinase activity. Here we demonstrate that Par-1b is also
regulated by another arm of the PKC pathway, one that involves novel PKCs (nPKC) and
Protein Kinase D (PKD). Treatment of cells with the PKC activator phorbol-12myristate-13-acetate (PMA) potently stimulated phosphorylation of Par-1b on serine 400
(S400), a residue that is conserved in all four mammalian Par-1 kinases as well as the fly
ortholog. We demonstrate that PMA stimulates nPKC to activate PKD, which in turn
directly phosphorylates Par-1b on S400 to positively regulate 14-3-3 binding and to
negatively regulate membrane association. Thus, two arms of the PKC pathway regulate
interactions between Par-1b and 14-3-3 proteins: one involving aPKC and the other
nPKC/PKD.
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Introduction
Establishing and maintaining cellular polarity is critical for the homeostasis of
unicellular and multicellular organisms alike. The PAR (partitioning-defective) genes
(PAR 1-6) were identified in Caenorhabditis elegans as essential determinants of
asymmetric cell division and polarized cell growth(Kemphues, 2000; Kemphues et al.,
1988). Par-1 is a serine/threonine protein kinase and Par-1 homologues have been
identified and studied in a number of organisms, including yeast, fruitflies, frogs and
mammals (Goldstein and Macara, 2007; Tassan et al., 1994). These studies have revealed
disparate roles for Par-1 not only as a regulator of cell polarity but also as a component of
mitogenic and Wnt signaling (Hurov and Piwnica-Worms, 2007; Tassan et al., 1994). In
mammals there are four Par-1 family members named Par-1a (C-TAK1/MARK3), Par-1b
(EMK/MARK2), Par-1c (MARK1), and Par-1d (MARKL1, MARK4).
Several Par-1 substrates have been identified, including Par-3 (Benton and St
Johnston, 2003; Hurd et al., 2003). An antagonistic relationship between Par-1 and the
Par-3/Par-6/aPKC complex has been revealed. In C. elegans embryos Par-1 is located at
the posterior cortex whereas the Par3/Par6/aPKC complex is located at the anterior cortex.
In epithelial cells, the Par3/Par6/aPKC complex is found at tight junctions whereas Par1
is located laterally beneath tight junctions. Par-1 phosphorylates Par-3 to exclude it from
lateral membranes of epithelial cells (Benton and St Johnston, 2003; Hurd et al., 2003),
whereas aPKC in complex with Par-3/Par-6 phosphorylates Par-1 to dislodge it from
plasma membranes(Hurov et al., 2004a; Suzuki et al., 2004). Thus, the establishment
and/or maintenance of cell polarity likely require that Par-1 be physically sequestered
from the Par-3/Par-6/aPKC complex and phosphorylation of Par-1 by aPKC may enforce
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the mutual exclusion of Par-1 and Par-3/Par-6/aPKC. Negative regulation of Par-1b by
the Par-3/Par-6/aPKC complex is also observed in hippocampal neurons (Chen et al.,
2006). Here, we identify another protein kinase pathway that regulates Par-1 localization.
We demonstrate that treatment of cells with PMA activates nPKCs to activate PKD and
that PKD directly phosphorylates Par-1b on S400. Phosphorylation of S400, like
phosphorylation of T595, regulates Par-1b/14-3-3 interactions and the ability of Par-1b to
associate with cellular membranes.
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Results
Using a combination of site-directed mutagenesis and tryptic phosphopeptide
mapping, we identified serine 400 (S400) as a potential site of Par-1b phosphorylation in
vivo (data not shown). To verify that Par-1b is indeed phosphorylated on S400 in vivo, a
phosphospecific antibody was generated and used in Western blotting experiments (Fig.
2.1A, upper panel). Whereas the pS400 antibody recognized Par-1b (lane 2), mutation of
S400 eliminated its recognition by the antibody (lane 4). Thus, the antibody is specific for
Par-1b when it is phosphorylated on S400 and ectopically expressed Par-1b is
phosphorylated on S400 in cultured cells. In addition, phosphorylation of S400 did not
require the kinase activity of Par-1b as a kinase-inactive mutant of Par-1b was also
phosphorylated on S400 in vivo (lane 3). The status of endogenous Par-1b
phosphorylation was interrogated in several mammalian cell lines using the pS400
antibody (Fig. 2.1B). Two electrophoretic forms of Par-1b that arise by alternative
splicing (Hurov et al., 2001; Hurov et al., 2004b) were detected in each cell line and both
splice variants reacted with the phosphospecific antibody. Thus, endogenous Par-1b is
phosphorylated on S400 in vivo.
Members of the Par-1 family share a conserved amino-terminal kinase domain,
followed by a UBA domain, a divergent region of unknown function and a conserved Cterminal region of approximately 100 amino acids (Fig. 2.S1). Serine 400 resides within
the divergent region and is conserved in all four human Par-1 kinases as well as the fly,
but not worm ortholog (Fig. 2.1C). Par-1a also reacted with the pS400 antibody
demonstrating that Par-1a is also phosphorylated on S410 (S400 equivalent) in vivo (Fig.
2.S1B). The pS400-specific antibody did not recognize Par-1c and Par-1d and this is
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likely due to the fact that the phosphopeptide used to generate the pS400-specific
antibody varies significantly in sequence from residues surrounding the equivalent
phosphorylation sites in Par-1c and Par-1d (Fig. 2.1C).
Interestingly, sequences inclusive of and surrounding S400 resemble a mode I 143-3 binding motif (Muslin et al., 1996; Yaffe et al., 1997) and Par-1b binds 14-3-3
proteins (Benton and St Johnston, 2003; Goransson et al., 2006; Meek et al., 2004a;
Suzuki et al., 2004). We tested whether S400 regulated interactions between Par-1b and
14-3-3 proteins in two ways. First, co-precipitation of 14-3-3 proteins with wild type and
mutant forms of Par-1b were examined and secondly Far Western analysis with purified
14-3-3 proteins was employed. As seen in Fig. 2.2A, co-precipitation of 14-3-3 proteins
with wild-type (WT, lane 2) and kinase-inactive Par-1b (lane 3) was observed.
Substitution of S400 with alanine diminished, but did not eliminate, 14-3-3 binding to
Par-1b (lane 4). Far Western analysis confirmed that mutation of S400 reduced
interactions between Par-1b and 14-3-3 proteins (Fig. 2.2B, lane 5). A truncation mutant
of Par-1b consisting of amino acids 1- 470 but lacking S400 failed to bind 14-3-3
proteins (lane 6) indicating that phosphorylation of S400 regulated interactions between
14-3-3 proteins and the amino terminus of Par-1b. Additional 14-3-3 binding site(s) must
reside within the C-terminus of Par-1b given that mutation of S400 diminished but did
not eliminate interactions between 14-3-3 proteins with full length Par-1b (Fig. 2.2A). A
previous study reported that 14-3-3 binding is facilitated by T595 phosphorylation
(Suzuki et al., 2004). We monitored WT and mutant forms of Par-1b for their ability to
bind to 14-3-3 proteins and to be phosphorylated on S400 and T595 in vivo (Fig. 2.2C,
2.S1C). We observed that substitution of T595 with alanine reduced interactions between
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Par-1b and 14-3-3 proteins as did substitution of S400 with alanine. Simultaneous
mutation of both phosphorylation sites severely compromised binding of 14-3-3 proteins
to Par-1b.
In our search to identify signaling pathways that regulate Par-1b in vivo, we
observed that treatment of cells with the protein kinase C (PKC) activator PMA potently
stimulated phosphorylation of endogenous (Fig. 2.2D) and ectopically-produced (Fig.
2.2E, lane 2) Par-1b on S400 in vivo. In addition, Far Western analysis demonstrated that
PMA-treatment enhanced the binding of 14-3-3 proteins to Par-1b (Fig. 2.2E, lane 4).
Although PMA enhanced the binding of 14-3-3 proteins to Par-1b, its relative binding to
WT and mutant forms of Par-1b was not significantly altered in PMA-treated cells (Fig.
2.S1D). Enhanced Par-1b phosphorylation on S400 by PMA implicated members of the
PKC family as upstream regulators of Par-1b. In particular, both the conventional PKC
(cPKCs) and novel PKCs (nPKC) are activated by DAG or phorbol esters (Newton,
1997). Sequences surrounding and inclusive of S400 (KVQRSVpSA) do not form a
consensus PKC phosphorylation site but rather more closely resemble that of a PKD
consensus site (Fig. 2.1C) (Nishikawa et al., 1997). A major pathway for the activation of
PKD is translocation to membrane compartments via binding to DAG or phorbol esters
followed by phosphorylation of activation loop residues by novel PKCs (!, ", #, $),
which are directly activated by PMA (Rozengurt et al., 2005). As seen in Fig. 2.S1E,
PMA treatment resulted in activation loop phosphorylation of both PKD1 (lane 2) and
PKD2 (lane 4) indicative of PKD activation.
Several experiments were performed to determine if Par-1b is directly regulated
by PKD. First, the phosphorylation status of Par-1b was monitored after co-production
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with wild type and mutant forms of PKD1 and PKC! (Fig. 2.3A). Enhanced S400phosphorylation was observed when Par-1b was co-produced with either WT PKD1 (lane
3), WT PKC! (lane 4) or both PKD1 and PKC! (lane 5). In addition, the stimulatory
effects of PKD1 and PKC! on Par-1b S400-phosphorylation were blocked by kinaseinactive PKC! (lane 6) and kinase-inactive PKD1 (lane 7), respectively. Importantly,
kinase–inactive PKC! was unable to block the stimulatory effects of constitutively active
PKD1 on Par-1b S400 phosphorylation (lane 8). These findings suggest that PKC!
functions upstream of PKD to regulate phosphorylation of Par-1b on S400. Next, kinase
assays were performed in vitro to determine if Par-1b was a direct substrate of either
PKC! or PKD1 (Fig. 2.3B). PKD1 phosphorylated a kinase-inactive mutant of Par-1b on
S400 in vitro (lane 2, bottom panel). Although PKC! phosphorylated activation loop
residues of PKD1 (lane 6, bottom panel), it was incapable of phosphorylating Par-1b on
S400 in vitro (lane 1, bottom panel). In addition, PKD1 did not phosphorylate Par-1b on
T595, the aPKC site, in vitro (Fig. 2.4A, bottom panels). Interestingly, S400 (Fig. 2.4A,
upper panels) but not T595 (Fig. 2.4A, lower panels) was a site of Par-1b
autophosphorylation (lane 1). To determine if auto/trans phosphorylation contributed
significantly to S400 phosphorylation in vivo, WT and mutant forms of Par-1b were
expressed in Par-1b null MEFs (Hurov et al., 2001). Note that kinase-active (Fig. 2.4B,
lane 2) and kinase-inactive (lane 3) forms of Par-1b were similarly phosphorylated on
S400. Thus, although Par-1b is capable of phosphorylating itself on S400, additional
cellular kinase(s) also serve this function in vivo.
Next, siRNA was used to knockdown expression of PKD1 and PKD2 in Hela
cells. As seen in Fig. 2.4C, stimulation of S400 phosphorylation was not observed in
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PMA-treated cells deficient for PKD1 and PKD2 (lane 4) whereas control cells (lane 2)
or cells incubated with scrambled siRNA (lane 3) showed a robust stimulation of S400 in
response to PMA-treatment. Taken together, these results suggest that PMA stimulates a
signaling pathway from nPKCs to PKD to Par-1b to regulate S400-phosphorylation and
14-3-3 binding.
Phosphorylation of Par-1b by aPKC induces dissociation of Par-1b from the
plasma membrane into soluble fractions in a T595-dependent manner (Suzuki et al.,
2004). To test the consequences of S400 phosphorylation, PMA-treated HeLa cells were
fractionated by sequential centrifugation and membrane (P) and soluble (S) fractions
were analyzed for endogenous Par-1b by Western blotting (Fig. 2.4D). As expected,
phosphorylated PKD was found in membrane fractions whereas 14-3-3 proteins were
observed in soluble fractions. Importantly, endogenous Par-1b phosphorylated on S400
was present predominantly in soluble fractions.
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Discussion
In this study, we identified S400 as a novel Par-1b phosphorylation site.
Phosphorylation of S400 was shown to regulate interactions between Par-1b and 14-3-3
proteins and to be mediated by PKD. Par-1b is also phosphorylated on T595 and this is
catalyzed by atypical PKC (Hurov et al., 2004b; Suzuki et al., 2004). Thus, Par-1b is
regulated by two arms of the PKC pathway: one arm is indirect involving activation of
nPKCs which, in turn, activate PKD to phosphorylate Par-1b on S400, the second arm is
direct and involves phosphorylation of T595 by aPKCs.
Previous studies reported that 14-3-3 binding to Par-1 either does not involve Par1 phosphorylation (Benton et al., 2002) or is facilitated by T595 phosphorylation (Suzuki
et al., 2004). Another study reported 17 new Par-1b phosphorylation sites and mutation
of all 17 of these residues eliminated 14-3-3 binding. Surprisingly S400 was not
identified as a site of phosphorylation in this study (Goransson et al., 2006). Here, we
report that mutation of the two PKC-regulated sites (S400 and T595) is sufficient to
ablate 14-3-3 binding to Par-1b. It may be that mutation of 17 residues of Par-1b
indirectly effected phosphorylation at S400 and this, in turn, explains the loss of 14-3-3
binding in the Goransson et al. study (Goransson et al., 2006).
The PKC family of protein kinases are subdivided into conventional PKCs that
are activated by calcium, acidic phospholipids and diacylglycerol (DAG); novel PKCs
activated by DAG and acidic phospholipids but insensitive to calcium and atypical PKCs
that are activated, in part, by PKD1 (Newton, 1997). The PKD family consists of three
members. PKD1 was originally reported to be a novel PKC and was given the name
PKCµ. However, it was later appreciated that the PKD family distinguished itself from
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the PKC family in amino acid composition, domain structure, regulation, and substrate
specificity (Rykx et al., 2003). A major pathway for the activation of PKD is
translocation to membrane compartments via binding to DAG or phorbol esters followed
by phosphorylation of activation loop residues by the nPKCs, which are directly activated
by PMA (Rozengurt et al., 2005). Stimulation of S400 phosphorylation by PMA
implicated members of the PKC family as regulators of Par-1b. However, sequences
inclusive of and surrounding S400 do not conform to a typical PKC consensus sequence
but rather more closely resembles that of a PKD phoshorylation site (Nishikawa et al.,
1997). The experimental evidence leading to the conclusion that PKD directly
phosphorylates Par-1b on S400 in a nPKC-dependent manner is as follows: enhanced
S400-phosphorylation was observed when Par-1b was co-produced with PKD1 and/or
PKC! (Fig. 2.3A); the stimulatory effects of PKD1 and PKC! on Par-1b S400phosphorylation were blocked by kinase-inactive forms of each kinase (Fig. 2.3A);
importantly kinase–inactive PKC! was unable to block the stimulatory effects of
constitutively-active PKD1 on Par-1b S400 phosphorylation (Fig. 2.3A); PKD, but not
nPKC, directly phosphorylated Par-1b on S400 in vitro (Fig. 2.3B) and finally,
stimulation of S400 phosphorylation by PMA was not observed in cells deficient for
PKD1 and PKD2 (Fig. 2.4C). Taken together this data argues that PMA stimulates
nPKCs to activate PKD and PKD, in turn, directly phosphorylates Par-1b on S400.
PKD functions downstream of activated G-protein coupled receptors and receptor
tyrosine kinases that signal through phospholipase C. PKD is activated by any agent that
activates nPKCs and, as such PKD functions to regulate a diverse set of cellular
processes including proliferation, apoptosis, stress responses, vesicle trafficking from
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golgi, neuronal development, and immune cell signaling (Toker, 2005; Van Lint et al.,
2002; Wang, 2006). If Par-1b is an important downstream target of PKD in each of these
pathways, it may explain the diverse phenotypes observed in mice disrupted for Par-1b
(Hurov and Piwnica-Worms, 2007). It has been demonstrated that the regulated cycling
of Par-b on and off lateral membranes is critical for maintenance of apicobasal polarity in
mammalian cells (Suzuki et al., 2004). Our study provides mechanistic insight into how
Par-1b shuttling is regulated. Phoshorylation of Par-1b on S400 by PKD, like
phosphorylation of T595 by aPKC, not only promotes the binding of 14-3-3 proteins to
Par-1b but also promotes the release of Par-1b off of cellular membranes. Furthermore,
these results implicate a role for PKD in regulating cellular polarity through
phosphorylation of Par-1b.
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Materials and Methods

Cell Culture
HeLa, HEK-293 and HCT116 cells were routinely maintained in Dulbecco's modified
Eagle's medium (DMEM, Gibco-BRL) supplemented with 10% bovine growth serum
(Hyclone, Logan, UT), 100 units/ml penicillin and streptomycin, and 1mM L-glutamine.
MCF7 cells were grown in the presence of 10% FBS (Hyclone). Par-1b null MEFs
(Hurov et al., 2001) were cultured in DMEM, 10% FBS (Hyclone) and 1 mM Lglutamine, 0.2 mM nonessential amino acids, 140 mM 2-mercaptoethanol, 100 U/ml
penicillin G and 100 µg/ml streptomycin.

Plasmids and reagents
PMA was purchased from Sigma Chemical Company (St. Louis, MO). Purified PKC!
and the PKC lipid activator were purchased from Upstate Cell Signaling (Lake Placid,
NY). Sf9 cell purified HA-PKD and HA-PKD (K612W) as well as plasmids
pcDNA3.HA-PKD1, pcDNA3.HA-PKD1(K612W), pcDNA3.HA-PKD1 (S738ES742E)
have been described (Storz et al., 2003; Storz et al., 2004). Plasmids encoding
PKC!(WT) and PKC!(KD) and Flag tagged Par-1b, Par-1b(D193N) and Par-1b(T595A)
have been described (Cenni et al., 2002; Hurov et al., 2004a). Substitution of alanine for
serine at position 400 and/or threonine at position 595 was accomplished using the
QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, LaJolla. CA). DNA
sequencing was performed to verify the mutant sequence. siRNAs specific for PKD1 and
PKD2 were purchased from Dharmacon Inc. (Lafayette, CO) as well as SiGenome Smart
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Pool reagent to Human PRKCM (PKD1) and Smart Pool reagent to Human PRKD2
(PKD2). The control siRNA sequence was: 5’UAAGGCUAUGAAGAGAUACUU.
Transient transfections were performed using TransIT HeLa MONSTER reagent (Mirus
Bio Corporation, Madison, WI), with Superfect reagent (Qiagen, Valencia, CA) or with
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Par-1b null MEFs have been
described (Hurov et al., 2001)

Antibodies and Western Blotting
Antibodies against 14-3-3 (K19) and glutathione S-transferase (GST) were purchased
from Santa Cruz (Santa Cruz, CA). Other antibodies used in this study were specific for
PKD1 (Abcam or Cell Signaling Technology), PKD2 (Abcam, Cambridge. MA),
phosphoPKD (Cell Signaling Technology, Boston, MA) and PKC! (Upstate Cell
Signaling). Antibodies used for experiments shown in Fig. S1E include a rabbit
polyclonal antibody specific for PKD1 raised against a NH2-MAECQNDSGEMQDPamide peptide (amino acids 372-385 in human PKD1), a rabbit polyclonal antibody
specific for PKD2 was from Upstate Cell Signaling (Charlottesville, VA), and a rabbit
polyclonal antibody specific for PKD3 from Bethyl Laboratories (Montgomery, TX).
These antibodies are specific for the respective PKD isoenzyme and do not cross react
with other PKD family members. Antibodies specific for Par-1b have been described
(Hurov et al., 2001). Antibodies specific for Par-1b phosphorylated on serine 400 were
generated by immunizing rabbits with the phosphopeptide CQRSV-pS-ANPKQ coupled
to keyhole limpet hemocyanin (KLH). Antibodies specific for Par-1b phosphorylated on
T595 have been described (Hurov et al., 2004b). Flag-fusion proteins were precipitated
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with anti-Flag M2 antibody-agarose affinity gel (Sigma Chemical Co) and detected by
Western blotting with anti-Flag M2 monoclonal antibody (Sigma Chemical Co.). For
Western blotting, antibodies were diluted in 5 % milk in TBST (50 mM Tris-HCl pH 8.0,
0.15 M NaCl, 0.02 % Tween-20), and membranes were washed 4 times in TBST after
application of both primary and secondary antibody. Bound primary antibodies were
detected with horseradish peroxidase-conjugated goat anti-mouse (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA), goat anti-rabbit (Invitrogen,
Carlsbad, CA), or donkey anti-goat (Santa Cruz) secondary antibodies, and visualized
using the ECL reagent (GE Healthcare, Piscataway, NJ) or Super Signal West Femto
reagent (Pierce Biotechnology, Rockford, IL).

Immunoprecipitations
Cells were lysed in MCLB (50 mM Tris-HCl pH 8.0, 0.1 M NaCl, 5 mM EDTA, 0.5 %
NP-40, 1 mM DTT) supplemented with 1 µM microcystin-LR and protease inhibitors (2
mM PMSF, 0.15 U/ml aprotinin, 20 µM leupeptin, and 20 µM pepstatin.). Lysates were
clarified by centrifugation at 16, 000 x g. Cell lysates were pre-cleared with protein A
agarose for 1 hour at 4 °C, then incubated with anti-FLAG agarose (Sigma Chemical Co.)
for 1 h at 4°C. Beads were washed four times in MCLB, and bound proteins eluted by
boiling in SDS–PAGE sample buffer.

14-3-3 Far Western Analysis
Samples were subjected to SDS-PAGE and transferred to nitrocellulose membranes as
for a Western blot. Proteins bound to the membrane were denatured by incubating for at
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least 1 h in denaturation buffer (50 mM Tris-HCl pH 8.0, 6 M guanidine-HCl, 6.25 mM
EDTA, 1 mM DTT, 10 % glycerol, 0.05 % Tween-20), then renatured by incubating for
at least 1 h in renaturation buffer (denaturation buffer without guanidine-HCl or DTT).
Membranes were blocked for 1 h in 5 % milk in TBST, rinsed in TBST, then incubated
for 2 h at room temperature or overnight at 4°C in TBST containing 0.1 µg/ml GST-14-33! and ", and 1 mg/ml bovine serum albumin. GST-14-3-3 proteins were purified as
described (Meek et al., 2004b). Membranes were washed 4 times in TBST, then
incubated for 1 h with anti-GST primary antibody in 5% milk / TBST. Bound primary
antibody was detected with horseradish peroxidase-conjugated secondary antibody, and
visualized using ECL reagent, as for Western blotting.

Co-precipitation of 14-3-3 proteins with WT and mutant forms of Par-1b
HeLa cells at 75% confluency were transfected using Lipofectamine 2000 reagent for 24
h. Cells were lysed in MCLB supplemented with 1µM microcystin and protease
inhibitors. Lysates were clarified by centrifugation at 16,000 x g. Cell lysates were preincubated with protein A agarose for 1 hour at 4 °C, then incubated with anti-FLAG
agarose for 1 h at 4°C. Bound proteins were eluted by incubating 1 h with a 3X flag
peptide (Sigma Chemical Co.).

Kinase Assays
Kinase reactions were carried out in the presence of 0.5 µg bacterially-purified GST-Par1b, GST-Par-1b (S400A), or GST-Par-1b (D160N) with 250 ng Sf9 cell purified HA-
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PKD or HA-PKD (K612W) or with 5 ng active PKC! (Upstate Cell Signaling) and a
buffer consisting of 12 µM ATP, 2 mM DTT, 10 mM MgCl2, and 50 mM Tris pH 7.5
supplemented with sonicated PKC lipid activator containing phosphatidyl serine and
diacylglycerol (Upstate Cell Signaling). Samples were incubated at room temperature for
30 min. Reactions were terminated by the addition of SDS sample buffer followed by
o

incubation for 10 min at 37 C.

RNAi Experiments
RNA interference (RNAi) was performed using protocols supplied by Dharmacon, Inc.
siRNA duplexes were transfected into HEK293 cells using Dharmafect #2 at a final
concentration of 10 nM. After ~30 h cells were transfected a second time with siRNA at
10 nM final concentration. Cells were incubated an additional 48 h and then incubated in
the absence or presence of 200 ng/ml PMA for 1 min. Cells were lysed in MCLB and
analyzed by Western blotting.

Cell Fractionation
HeLa cells were grown to near confluency on 10 cm tissue culture dishes. Cells were
treated with 200 ng/ml PMA for 1 min prior to harvest. Cells were trypsinized and
washed in ice cold PBS. Cells were suspended in 800 µl of hypotonic buffer (HB: 12.5
mM Tris pH 7.5, 1 mM EDTA, 1 mM DTT) supplemented with 5 mM NaP4PO4, 1 µM
microcystin, 1 mM sodium orthovanadate, 2 mM PMSF, 0.15 U/ml aprotinin, 20 µM
leupeptin, and 20 µM pepstatin for ~40 min. Cells were dounce homogenized and when
the majority of cells were lysed, cell lysates were centrifuged at 1000 x g for 5 min. The
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resulting supernatant was transferred to a fresh tube and the pellet was washed once with
200 µl of HB. The washed supernatant was added to the first collected supernatant (=
total (T)). A portion of this was reserved for Western blotting and the remainder was
centrifuged at 100,000 x g for 30 min. The supernatant was transferred to a fresh tube (=
soluble (S) fraction) and the pellet was vortexed in 100 µl HB and recentrifuged at
100,000 x g for 15 min. The supernatant was added to the soluble fraction and the pellet
(= membrane (M) fraction) was resuspended in 300 µl of MCLB supplemented with 1
µM microcystin, 1 mM sodium orthovanadate and protease inhibitors. Fractions were
resolved by SDS-PAGE and proteins visualized by Western blotting using Super Signal
West Femto reagent.
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Fig. 2.1 Par-1b is phosphorylated on serine 400 in vivo.
(A) HeLa cells were transfected with plasmids encoding the indicated proteins using
HeLa MONSTER reagent for 48 h. Flag-tagged Par-1b proteins were resolved by SDSPAGE and Western blotting was performed with an antibody specific for Par-1b
phosphorylated on S400 (top panel). Blots were stripped and re-probed with an antibody
specific for the flag epitope (bottom panel). (B) Lysates prepared from the indicated cell
lines were resolved by SDS-PAGE and Western blotting was performed with an antibody
specific for Par-1b phosphorylated on S400 (top panel). Blots were stripped and reprobed with an antibody specific for Par-1b (bottom panel). (C) Sequence alignment of
Par-1 orthologs illustrates conservation of the S400 phosphorylation site. The mode I 143-3 binding motif, the PKD phosphorylation motif and the phosphopeptide used to
generate the pS400-specific Par-1b antibody are also indicated.
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Fig. 2.2 Phosphorylation of Par-1b on S400 regulates 14-3-3 binding and is
stimulated by PMA.
(A) HEK293 cells were transfected with plasmids encoding WT Par-1b (WT), kinaseinactive Par-1b (D193N) or a phosphorylation-site mutant of Par-1b (S400A) using
Superfect reagent for 48 h. Lysates were resolved directly by SDS-PAGE (lanes 5-8) or
were incubated with anti-flag agarose prior to SDS-PAGE (lanes 1-4). Western blotting
was performed with an antibody specific for the flag epitope to detect Par-1b (top panel)
or with an antibody specific for 14-3-3 proteins (bottom panel). Relative levels of 14-3-3
in each precipitate were determined from Western blots using the ImageJ program and
are indicated below the blot. (B) HEK293 cells were transfected with plasmids encoding
the indicated fusion proteins using Superfect reagent for 48 h. Lysates were incubated
with anti-flag agarose and precipitates were resolved by SDS-PAGE. Precipitates were
subjected to Western blotting to monitor Par-1b levels (lanes 1-3) or to Far Western
analysis to monitor 14-3-3 binding (lanes 4-6). (C) HeLa cells were transfected with
plasmids encoding the indicated flag-tagged proteins using Lipofectamine 2000 for 24 h.
Lysates were incubated with flag agarose. Precipitates were resolved by SDS-PAGE and
analyzed by Western blotting using the indicated antibodies. Relative levels of 14-3-3 in
each precipitate were determined from Western blots using the ImageJ program and are
indicated below the blot (Fig. S1C). A representative experiment is shown in panel C. (D)
Lysates prepared from HeLa cells that had been cultured in the absence of serum for 16 h
and then treated with vehicle (lane 1) or with 400 ng/ml PMA for 10 min. (lane 2) were
resolved by SDS-PAGE and Western blotting was performed with pS400 antibody (top
panel). Blots were stripped and re-probed with a Par-1b specific antibody (bottom panel).
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(E) HEK293 cells were transfected with plasmid encoding Flag-Par-1b using Superfect
reagent for 48 h. Cells were cultured in the absence of serum for 3 h and then treated with
vehicle (lanes 1, 3) or with 400 ng/ml PMA for 20 min (lanes 2, 4). Flag-tagged Par-1b
was precipitated using anti-flag agarose and resolved by SDS-PAGE. Flag-Par-1b was
subjected to Western blotting to monitor S400 phosphorylation (lanes 1, 2) or to Far
Western analysis to monitor 14-3-3 binding (lanes 3, 4). The pS400 blot was stripped and
probed with antibody specific to the flag epitope (lanes 5, 6).
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Fig. 2.3 Phosphorylation of Par-1b on S400 is regulated by nPKC/PKD pathway
(A) HEK293 cells were transfected with the indicated plasmids using Superfect reagent
for 24 h. Lysates were resolved by SDS-PAGE and subjected to Western blotting. (B)
Kinase assays were performed in vitro with a kinase-inactive mutant of Par-1b and the
indicated purified protein kinases. Western blotting was performed to monitor levels of
each protein in the assay (top 3 panels) and to monitor the phosphorylation status of Par1b (bottom panel, lanes 1-5) and PKD1 (bottom panel, lane 6).
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Fig. 2.4 Phosphorylation and localization of Par-1b regulated by PKD in vivo.
(A) Kinase assays were performed in vitro with kinase-active Par-1b alone (lane 1) or in
the presence of kinase-active (lane 2) or kinase-inactive (K612W, lane 3) PKD1.
Reactions were resolved by SDS-PAGE and subjected to Western Blotting. The
phosphorylation status of Par-1b was monitored using the indicated phospho-specific
antibodies. (B) Par-1b null MEFs (Hurov et al., 2001) were transfected with plasmids
expressing the indicated proteins using Lipofectamine 2000 for 24 h. Lysates were
incubated with anti-flag agarose and precipitates were resolved by SDS-PAGE.
Precipitates were subjected to Western blotting with antibodies specific for Par-1b
phosphorylated on S400 (top panel). Blots were stripped and re-probed with Flag-specific
antibodies (bottom panel). (C) HeLa cells were untreated, incubated with control siRNAs
or with siRNAs specific for PKD1 and PKD2 as described in the methods section. Cells
were incubated for 1 min with 200 ng/ml PMA, lysed and subjected to Western blotting
with the indicated antibodies. Relative levels of S400 phoshorylation and Par-1b protein
are indicated above each blot. (D) Lysates from PMA-treated HeLa cells (T) were
fractionated into soluble (S) and membrane (M) compartments. Fractions were probed for
the indicated proteins by Western blotting. Arrows denote two isoforms of Par-1b.
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Fig. 2.S1 Par-1a is phosphorylated on serine 400 in vivo.
(A) The kinase-, UBA- and ELKL-domains of Par-1b are indicated. Black boxes
represent regions that are absent in spliced variants of human Par-1b. The signaling
pathways regulating phosphorylation of S400 and T595 are indicated. (B) HeLa cells
were transfected with plasmid encoding flag-tagged Par-1a using Lipofectamine 2000 for
24 h. Lysates from control cells (lane 1) or cells expressing flag-tagged Par-1a (lane 2)
were resolved directly by SDS-PAGE. Western blotting was performed with indicated
antibodies. (C) HeLa cells were transfected with plasmids encoding the indicated flagtagged proteins using Lipofectamine 2000 for 24 h. Lysates were incubated with flag
agarose. Precipitates were resolved by SDS-PAGE and analyzed by Western blotting
using the indicated antibodies. Relative levels of 14-3-3 in each precipitate were
determined from Western blots using the ImageJ program and are indicated below the
blot. The mean +/- SEM for five independent experiments is shown. Student’s t test was
performed for comparisons between groups. p value designations are as follows: *
(p<0.005), **(p<0.001). A representative Western blot is shown in Figure 2C. (D) HeLa
cells were transfected with plasmids encoding the indicated flag-tagged proteins using
Lipofectamine 2000 for 24 h and then incubated with 200 ng/ml PMA for 1 min. Lysates
were incubated with flag agarose and precipitates were resolved by SDS-PAGE and
analyzed by Western blotting for the indicated proteins. Relative levels of 14-3-3 in each
precipitate were determined from Western blots using the ImageJ program and are
indicated below the blot. (E) HeLa cells were cultured in the absence of serum for 16 h
and treated with vehicle (lanes 1, 3, 5) or with 400 ng/ml PMA for 10 min (lanes 2, 4, 6).
PKD1, PKD2 and PKD3 were immunoprecipitated and samples were resolved by SDS-
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PAGE. Immunoblotting was performed with a phospho-specific antibody that recognizes
activated PKD1. Blots were stripped and re-probed with PKD1-, PKD2- or PKD3specific antibodies (bottom panel).
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Abstract
Establishing and maintaining cellular polarity is critical for the homeostasis of
unicellular and multicellular organisms alike. The PAR (partitioning-defective) genes
(PAR-1–6) were identified in Caenorhabditis elegans (C. elegans) as essential
determinants of asymmetric cell division and polarized cell growth. Orthologs of PAR-1,
3, 4, 5, and 6 but not PAR-2 have been identified in mammals. The mammalian Par-1
family is comprised of four members (Par-1a, b, c and d). We have shown that Par-1b
and the RING finger containing protein RNF41 bind one another. RNF41 and Par-2
share homology in their RING finger domain and part of their C-terminal domain
suggesting that RNF41 may be an ortholog of Par-2. RNF41 binds the N-terminal kinase
and ubiquitin associated (UBA) domains of Par-1b and Par-1b phosphorylates RNF41 on
serine 254. MCF-10A cells knocked down for RNF41 failed to form polarized acini-like
spheroids when grown in either collagen I matrix or in Matrigel. Polarity was rescued
when knockdown cells were engineered to express wild-type RNF41 but not the
phosphorylation-site mutant of RNF41 encoding alanine for serine at position 254. This
study identifies RNF41 as a novel substrate of Par-1 and demonstrates that
phosphorylation of RNF41 by Par-1 is required for mammary epithelial cells to polarize
when grown in three-dimensional cultures.
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Introduction
Epithelial cells depend on the asymmetric organization of cellular components
along their apical- basal axis and it is the activity of these asymmetrically localized
proteins and protein complexes that regulate polarity (Rodriguez-Boulan and Nelson,
1989). Par-1 encodes a serine/threonine protein kinase and is one of six Par
(partitioning-defective) genes (Par-1, Par-2, Par-3/ASIP, Par-4/LKB1, Par-5/14-3-3, and
Par-6) identified in a genetic screen conducted in Caenorhabditis elegans (C. elegans)
(Kemphues et al., 1988). The Par genes are required for the asymmetric cell division of
the C. elegans zygote(Kemphues et al., 1988). Orthologs of each of the C. elegans Par
genes have been identified except for Par-2. Par-2 is a RING finger containing protein
that co-localizes with Par-1 to the posterior pole of the C. elegans zygote and cooperates
with other Par gene products to establish polarity during early embryonic development.
In epithelial cells, the organization and establishment of cell polarity is dependent
on the antagonistic relationship between Par-1 and the Par-3/Par-6/atypical protein kinase
C (aPKC) complex. The Par-3/Par-6/aPKC complex localizes to tight junctions and the
integrity of this complex is required for maintaining polarity (Etienne-Manneville and
Hall, 2003; Izumi et al., 1998; Joberty et al., 2000). Mammalian Par-1 kinase is excluded
from tight junctions and instead localizes to basolateral membranes (Bohm et al., 1997).
Par-1 phosphorylates Par-3 to exclude it from tight junctions (Benton and St Johnston,
2003; Hurd et al., 2003) whereas aPKC in complex with Par-3/Par-6 phosphorylates Par1 on T595 to displace it from membranes (Chen et al., 2006; Hurov et al., 2004; Suzuki et
al., 2004). In mammals there are four Par-1 family members: Par-1a (C-TAK1/MARK3),
Par-1b (EMK/MARK2), Par-1c (MARK1) and Par-1d (MARKL1, MARK 4) (Drewes et
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al., 1997; Espinosa and Navarro, 1998; Hurov et al., 2001; Inglis et al., 1993; Kato et al.,
2001; Muller et al., 2001; Peng et al., 1998).
A proteomic screen employing tandem affinity purification (TAP) followed by
tandem mass spectrometry identified a complex of proteins that associate with one of the
human Par-1 orthologs (Par-1d/MARK4) (Brajenovic et al., 2004). This screen identified
both known (aPKC and 14-3-3) and novel Par-1 interacting proteins (Brajenovic et al.,
2004). Of particular interest was the identification of the RING finger E3 ubiquitin ligase
RNF41 as a Par-1d interacting protein. RNF41 is also known as NRDP1 (neuregulin
receptor degradation protein-1) based on its role in facilitating the ubiquitin-mediated
proteolysis of ErbB3(Diamonti et al., 2002). RNF41 contains an N-terminal RING
domain, two zinc-finger domains (B-Boxes), a coiled-coil domain, and a C-terminal
domain that binds to various substrates (Abdullah et al., 2001; Bouyain and Leahy, 2007;
Diamonti et al., 2002; Qiu and Goldberg, 2002).
RNF41 has been shown to regulate the steady-state levels of ErbB3 and ErbB4
but not epidermal growth factor receptor (EGFR, ErbB1) or ErbB2 (Her2/neu). RNF41
associates with ErbB3 and ErbB4 independently of receptor stimulation (Diamonti et al.,
2002; Qiu and Goldberg, 2002) and elicits ligand-independent ErbB3 ubiquitination and
degradation (Qiu and Goldberg, 2002). Importantly a concomitant reduction in ErbB3
levels and neuregulin-1 (NRG1) growth factor signaling are observed when RNF41 is
overproduced whereas ErbB3 accumulates and NRG1 growth factor signaling is
enhanced when RNF41 is knocked down or a ligase-deficient (dominant-negative)
mutant is expressed (Yen et al., 2006). Finally, decreased RNF41 levels in tumors
correlates with higher levels of ErbB3 in both an in vivo transgenic mouse model of
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ErbB2-induced mammary tumorigenesis and in a panel of primary breast tumors (Yen et
al., 2006).
In addition to its role in regulating NRG1 growth factor signaling by modulating
ErbB3 levels, RNF41 also regulates ligand-independent expression of the interleukin-3
and erythropoietin cytokine receptors (Sausville et al., 2001) by controlling receptor
degradation and shedding (Wauman et al.) and RNF41 regulates Toll-like receptor
(TLR)-mediated responses through ubiquitination of MyD88 and TBK1(Singh et al.,
2009). Finally, RNF41 has been implicated in the ubiquitin-mediated proteolysis of two
ubiquitin ligases. These include the inhibitor of apoptosis BRUCE and PARKIN, a
protein involved in the onset of Parkinson's disease (Qiu et al., 2004; Zhong et al., 2005).
Although several targets of RNF41 have been identified, very little is known
regarding how RNF41 itself is regulated. RNF41 is subject to auto-ubiquitination and
proteolysis and this is counterbalanced by the activity of USP8, a deubiquinating enzyme
(Cao et al., 2007; Wu et al., 2004). In this study, we demonstrate that RNF41 is regulated
by the Par-1 polarity kinase and identify a novel role for RNF41 in regulating epithelial
cell polarity.
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Results
RNF41 co-precipitates with Par-1b.
A proteomic screen employing tandem affinity purification (TAP) followed by
tandem mass spectrometry identified RNF41 in a complex of proteins that associate with
Par-1d (MARK4) (Brajenovic et al., 2004). To determine if RNF41 interacted with a
second human Par-1 ortholog, HeLa and HEK 293T cells were transfected with control
plasmid (-), plasmid encoding human Flag-tagged CHK2 as a negative control or plasmid
encoding Flag-tagged Par-1b. Lysates were prepared and incubated with Flag agarose
followed by Western blotting. As seen in Fig. 3.1A, endogenous RNF41 was detected in
Par-1b (lanes 3 and 6) but not in control (lanes 1, 2, 4, 5) precipitates. Two
electrophoretic forms of RNF41 are present in HeLa and HEK 293T cells.
Members of the Par-1 family are characterized by having a conserved aminoterminal kinase domain, followed by a ubiquitin-associated (UBA) domain, a divergent
region of unknown function (spacer) and ending with a conserved region of about 100
amino acids known as the ELKL domain because it terminates with the sequence
glutamate-leucine-lysine/asparagine-leucine (Fig. 3.1B) (Inglis et al., 1993). Par-1b
deletion mutants that express only the amino-terminal domain or C-terminal domain were
expressed in cells to identify regions of Par-1b important for interactions with RNF41.
As seen in Fig. 3.1C, endogenous RNF41 co-precipitated with full length (FL) Par-1b
(lane 2) as well as the Par-1b mutant encoding the amino terminus and UBA domain (NUBA, lane 3). Removal of the UBA domain significantly reduced RNF41 binding (lane
5) and RNF41 did not associate with the C-terminal domain of Par-1b (lanes 4 and 6).

-77-

Par-1b phosphorylates RNF41 on S254 in vitro and RNF41 is phosphorylated on
S254 in vivo.
To determine if RNF41 is a substrate of Par-1b, kinase assays were performed in
vitro in conjunction with two-dimensional tryptic phosphopeptide mapping. RNF41 was
phosphorylated by Par-1b in vitro (Fig. 3.2A) and this occurred on one or more serine
residues (Fig. 3.2B). Mapping studies revealed several phosphopeptides and substitution
of alanine for threonine at position 254 resulted in the disappearance of a single
phosphopeptide (Fig. 3.2C) suggesting that Par-1b phosphorylates RNF41 on S254 in
vitro. To confirm that Par-1b phosphorylates RNF41 on S254 in vitro and that RNF41 is
phosphorylated on S254 in vivo, a phosphospecific antibody recognizing RNF41 only
when it is phosphorylated on S254 was generated (Fig. 3.2D). RNF41 consists of an
amino terminal RING domain followed by a B box, a coiled-coil domain and a Cterminal region that mediates interactions between RNF41 and ErbB3 (Receptor binding
domain) (Fig. 3.1B). Mutation of two residues within the RING domain (cysteine (C) 34
and histidine (H) 36) ablates the E3 ubiquitin ligase activity of RNF41 (Qiu and Goldberg,
2002). Due to the ability of RNF41 to auto-ubiquitinate and promote its own
proteosomal degradation, we generated a ligase deficient mutant of RNF41 encoding
serine for C34 and glutamine for H36 (denoted !CH) in order to produce adequate levels
of RNF41 in vivo. As seen in Fig. 3.2E, the pSer254 antibody recognized ectopic RNF41
(lane 2) and phosphorylation of S254 increased when RNF41 was co-produced with wildtype Par-1b in vivo (lane 3). In contrast, phosphorylation of RNF41 on S254 was reduced
in cells expressing kinase-inactive Par-1b (lane 4). Mutation of serine 254 eliminated
recognition of RNF41 by the phosphospecific antibody under similar conditions (lanes 5-
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7). These results demonstrate that the antibody is specific for RNF41 when it is
phosphorylated on S254 and that ectopically expressed RNF41 is phosphorylated on
S254 in vivo. Furthermore, the ability of kinase-active Par-1b to enhance S254
phosphorylation and kinase-inactive Par-1b to decrease S254 phosphorylation suggests
that phosphorylation of RNF41 on S254 is regulated in vivo by Par-1b.

Phosphorylation of endogenous RNF41 on S254 increases as MCF-10A cells polarize
in 3D culture.
We were unable to detect phosphorylation of endogenous RNF41 on S254 when
cells were grown in two-dimensional (2D) cultures (Fig. 3.3D, lane 1 and data not
shown). Given the critical role played by Par proteins in establishing and maintaining
apical-basal polarity, we investigated the phosphorylation status of both RNF41 and Par1b in mammary epithelial cells (MCF-10A) grown in 3D cultures. MCF-10A is a
spontaneously immortalized but untransformed mammary epithelial cell line. When
grown in 3D cultures, MCF-10A cells form polarized acini-like spheroids (Debnath et al.,
2003). Parental MCF-10A cells formed normal acinar architecture along with a hollow
lumen over a 20 day period when cultured in collagen I matrix and Matrigel (Fig. 3.3A).
Serial confocal cross sections of an acinus were stained with To-Pro-3 to detect nuclei
and antibody against either E-cadherin to detect adherins junctions; Alpha 6- Integrin to
detect basolateral membranes; GM130 to detect golgi at the apical surface; Laminin V to
detect basement membrane; and Flag epitope to detect ectopically expressed RNF41. The
results demonstrate that normal acinar architecture is formed under our culture conditions
and that cells are able to secrete Laminin V to form a basement membrane (Fig 3.3B,C).
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Spheroids were also isolated at various times during the 3D culturing period and
subjected to Western blotting. As seen in Fig. 3.3D, enhanced phosphorylation of Par-1b
on both S400 and T595 was observed in 3D cultures (lanes 2-5) relative to the 2D
cultures (lane 1). Two electrophoretic forms of RNF41 were detected in MCF-10A cells
and the faster migrating form was phosphorylated on S254 in cells grown in 3D (lanes 25) but not 2D (lane 1) cultures.

RNF41 is required for polarization of MCF-10A cells in 3D cultures.
Knockdown experiments were conducted to determine if RNF41 is required for
MCF-10A cells to polarize into acini-like spheroids in 3D cultures. We employed a
lentiviral vector that concurrently knocks down and rescues expression of a target gene in
the same cell (Feng et al., 2010). Lentiviral vectors encoding shRNAs specific for
luciferase (shLuc) as a control or shRNA specific for sequences within the 3’UTR of
RNF41 (shRNF41) were generated. In addition, vectors simultaneously expressing
shRNF41 with the coding regions of either RNF41 (WT) or RNF41 (S254A) with a Cterminal flag epitope followed by six histidines (FlagHis6) were generated. In this way
we could determine whether phenotypes observed upon knockdown of RNF41 could be
rescued by expression of either wild-type RNF41 or the S254A mutant of RNF41.
The maximum knockdown of RNF41 we were able to achieve in MCF-10A cells
was ~ 50%. In the experiment shown in Fig. 3.4B, shRNA treatment resulted in a 48%
knockdown of RNF41 (lane 2). The ectopically produced tagged form (FlagHis6) of
RNF41 co-migrated with the slower electrophoretic form of endogenous RNF41 and as
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seen in Fig. 3.4B expression of WT and mutant forms of RNF41 (lanes 3-5) restored
RNF41 levels in knockdown cells to approximately those detected for endogenous
RNF41 in control cells (lane 1). Despite only achieving a 50% knockdown of RNF41,
dramatic effects were observed when MCF-10A were cultured in 3D. As seen in Fig.
3.4A, cells expressing RNF41 shRNA formed abnormal architecture after growing for 20
days in collagen matrix or Matrigel. Cells expressing RNF41 shRNA and grown in
collagen matrix were not able to establish apical-basal polarity or adherins junctions (Fig.
3.4A-E). Furthermore, the polarity defect was rescued when wild-type RNF41 but not
the S254A mutant of RNF41 was expressed in MCF-10A cells knocked down for RNF41
(Fig. 3.4A-E) suggesting that phosphorylation of RNF41 on S254 is essential for
establishing apical-basal cell polarity.
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Discussion
In this study, we identified RNF41 as a novel substrate of the Par-1 polarity
kinase and discovered a role for RNF41 in regulating epithelial cell polarity. The Par-1
protein kinase regulates cell polarity in worms, flies, frogs and mammals (Bohm et al.,
1997; Cohen et al., 2004; Cohen and Musch, 2003; Cox et al., 2001; Muller et al., 2001;
Ossipova et al., 2005; Shulman et al., 2000; Sun et al., 2001; Tomancak et al., 2000). In
order to identify Par-1 binding proteins, mammalian Par-1 orthologs were used as bait in
a Tandem Affinity Purification (TAP) screen (Brajenovic et al., 2004). The RING finger
containing E3 ubiquitin ligase RNF41/NRDP1 was found in Par-1d complexes.
Mammalian orthologs of 5 out of 6 C. elegans Par genes have been identified. The
exception is Par 2, which encodes a RING finger containing protein that co-localizes
with Par-1 in the C. elegans zygote. Par-2 and RNF41 share homology in their RING
finger and C-terminal domains leaving open the interesting possibility that RNF41 is a
Par-2 ortholog. Here we show that human RNF41 binds to the amino terminal domain of
human Par-1b. This region contains both the kinase and UBA domains of Par-1b and
deletion of the UBA negatively impacted binding of RNF41 to Par-1b. Since RNF41
undergoes ubiquitination, this may indicate that a ubiquitinated form of RNF41 binds to
the UBA domain of Par-1b.
In the early C. elegans embryo, Par-1 is among several partitioning-defective
mutants that disrupt asymmetric cell division, blastomere cell fate, localization of P
granules, and mitotic spindle orientation (Kemphues et al., 1988; Kirby et al., 1990).
Some of the mutations are within the kinase domain of Par-1, indicating kinase activity
is necessary for its polarity function(Guo and Kemphues, 1995). Of the reported Par-1
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substrates, only Par-3 is known to play a role in regulating polarity. Par-3 in complex
with Par-6 and aPKC localizes to tight junctions and the integrity of this complex is
required for maintaining polarity (Etienne-Manneville and Hall, 2003; Izumi et al., 1998;
Joberty et al., 2000). Par-1 phosphorylates Par-3 to exclude it from tight junctions and
this, in turn disrupts epithelial cell polarity(Benton and St Johnston, 2003; Hurd et al.,
2003).
Here we identify a second substrate of Par-1 (RNF41) that also plays a role in
regulating cell polarity. Par-1 phosphorylates RNF41 on S254, a site that is conserved in
mammals and frogs but not in flies or the C. elegans Par-2 protein. MCF-10A cells
knocked down for RNF41 failed to polarize when grown in either collagen I matrix or
Matrigel. Interestingly, 50% knockdown of RNF41 was sufficient to prevent MCF-10A
cells from forming polarized acini-like spheroids in 3D culture. Polarity could be rescued
if WT RNF41 was expressed in knockdown cells. Phosphorylation of RNF41 on S254
was observed to increase as MCF-10A cells polarized in 3D cultures and expression of
the S254A mutant of RNF41 failed to rescue the polarity defect of RNF41-deficient
MCF-10A cells. These results indicate that phosphorylation of S254 is important for the
polarity function of RNF41.
Serine 254 resides within the C-terminus of RNF41, and this region of RNF41 has
been shown to bind to both targets of RNF41 (ErbB3 and BRUCE)(Diamonti et al., 2002;
Qiu et al., 2004) and regulators of RNF41 (USP8) (Wu et al., 2004). USP8 is a
deubiquitinating enzyme that binds to RNF41 and stabilizes it through deubiquitination.
Serine 254 lies within the USP8 binding domain and also neighbors residues involved in
ErbB3 binding (Avvakumov et al., 2006; Bouyain and Leahy, 2007). Future experiments
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will be directed at determining if phosphorylation of RNF41 on S254 regulates its
interactions with USP8 and ErbB3.
Preliminary studies indicate that ectopic RNF41 localizes to basolateral
membranes in polarized MCF-10A cells grown in 3D cultures whereas a significant
fraction of the S254A mutant protein appears to reside in the cytoplasm of the same cells.
Future experiments will also be directed at determining if S254 phosphorylation regulates
the intracellular localization of RNF41. The failure of the S254A mutant of RNF41 to
localize properly or to bind to key substrates would account for its failure to rescue
polarity in RNF41 deficient MCF-10A cells.
The establishment and maintenance of cell polarity is an essential property
governing organismal homeostasis and loss of polarity is a common feature of
transformed cells. For example, the polarity proteins Scribble, lethal giant larvae (LGL)
and discs large (DLG) were isolated as tumour-suppressor mutations in Drosophila
melanogaster, based on the distinctive ‘giant larvae’ phenotype of zygotic mutant
animals(Bilder, 2004). Little is known about their roles in human disease, but the loss or
decreased expression of human homologues of Scribble and LGL has been found in
colorectal cancers and malignant melanoma (Gardiol et al., 2006). RNF41 is an E3
ubiquitin ligase that regulates steady state levels of ErbB3 (Diamonti et al., 2002). ErbB3
is overexpressed in a subset of breast cancers. There is a correlation between decreased
levels of RNF41 and increased levels of ErbB3 in a transgenic mouse model of ErbB2induced mammary tumorigenesis and in a panel of primary breast tumors (Yen et al.,
2006). It has been assumed that higher levels of active ErbB3 signaling is the major
contributing factor driving tumorigenesis under these conditions. Our study suggests that
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disruption of polarity due to RNF41 loss may also be a contributing factor driving
tumorigenesis.
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Materials and Methods

Cell culture. HeLa cells were routinely maintained in DMEM (Gibco-BRL)
supplemented with 10% Bovine Growth Serum (HyClone), 100 units per mL of penicillin
and streptomycin, and 1 mM L-glutamine. HEK293T cells were grown in the presence of
10% FBS (HyClone). MCF-10A cells were maintained in DMEM/F12 (Invitrogen)
supplemented with 5% Horse Serum (Invitrogen), 20 ng/ml Epidermal Growth Factor
(EGF), 0.5 mg/ml Hydrocortisone, 100 ng/ml Cholera Toxin, 10µg/ml Insulin, and 100
units per mL of penicillin and streptomycin.

Cloning and mutagenesis. The Flag3-Par-1b N-Term, C-Term, N-UBA, and C-UBA
deletion mutants were cloned by PCR from the pFLAG3-CMV-10-Par-1b plasmid
(Watkins et al., 2008) and ligation into pFLAG3-CMV-10 plasmid (Sigma Chemical Co).
GST-RNF41 was cloned by PCR from the pCDNA3.1-RNF41-Flag plasmid (Diamonti et
al., 2002) and ligation into the pGex2T vector (GE Healthcare). The
pFLRU6RNF41shRNA-cmv-MCS-FH plasmid was generated by PCR. First, PCR of the
U6 promoter from the pFLRU6Luc-cmv-MCS-FH plasmid was performed followed by
PCR of the RNF41shRNA sequence targeted against the 3’UTR of RNF41
(5’GCCACATTGTTGGCAATTTAA 3’). The final PCR was performed with the U6
promoter and RNF41shRNA template generated in the previous step in order to create a
U6-RNF41shRNA fusion. The fusion PCR product was ligated into the Xba I and Xho I
restriction sites of the pFLRcmv-MCS-FH plasmid. The pFLRU6RNF41shRNAcmvRNF41-FlagHis6-FH (WT and S254A) plasmids were generated by PCR of RNF41

-86-

(WT and S254A) from the appropriate pCDNA3.1-RNF41-Flag plasmid and inserted into
the pFLRU6RNF41shRNA-cmv-MCS-FH plasmid. The RNF41-Flag C34S/H36Q
(!CH), RNF41-Flag C34S/H36Q/S254A, and GST-RNF41 S254A mutants were
generated by using the QuickChange XL Site-Directed Mutagenesis Kit (Stratagene).
The sequences of all constructs were verified by sequencing.

Plasmids. Plasmids encoding Flag3-Par-1b, Flag3-Par-1b (D193N) (KD), GST-Par-1b
(Hurov et al., 2004) and pCDNA3.1-RNF41-Flag have been described (Diamonti et al.,
2002). The pFLRU6Luc-CMV-MCS-FH and pFLRCMV-MCS-FH plasmids were a
generous gift from Dr. Greg Longmore (Washington University in St. Louis).

Transient transfections. Transient transfections were performed using Lipofectamine
2000 reagent according to the recommendations of the manufacturer (Invitrogen). Cells
were harvested 24 h post transfection.

MCF-10A-derived cell lines. HEK293T cells were plated at 8 x 105 cells/6 cm dish the
day before transfection. The next day, cells were transfected with a mixture of 1 µg viral
DNA encoding the gene of interest and 1 µg pHR’8.2deltaR packaging plasmid at a ratio
of 8:1 with pCMV-VSV-G envelope plasmid using Mirus LTR1 transfection reagent
(Mirus). MCF-10A cells were plated at 1 x 106 cells/10 cm dish the day before infection
with the lentivirus. After HEK293T cells were transfected with viral DNA for 48 h,
target MCF-10A cells were infected in the presence of 10 µg/ml protamine sulfate for 4 h
and then the virus was removed and media replaced. Infected cells were allowed to
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recover for 24 h and then were re-infected with lentivirus. Infected cells were trypsinized
and plated in media containing 1 µg/ml puromycin 48 h after the first infection with
lentivirus. RNF41 protein expression of selected cells was measured by Western blot.

Antibodies and Western blotting. Antibodies specific for RNF41 (Bethyl), Flag M2
(Sigma Chemical Co.), Alpha Tubulin (Sigma Chemical Co.), and GAPDH (IMGENEX)
were purchased. Par-1b was detected with ascites made from a monoclonal antibody that
has been previously described (Hurov et al., 2001). Par-1b protein phosphorylated on
S400 or T595 was detected using previously described phospho-specific antibodies
(Hurov et al., 2004; Watkins et al., 2008). The antibody specific for RNF41
phosphorylated on serine 254 was generated by immunizing rabbits with the
phosphopeptide ENAHER-pS-WPQGLATC, coupled to keyhole limpet hemocyanin
(KLH). Par-1b fusion proteins were precipitated with anti-Flag M2 antibody-agarose
affinity gel (Sigma Chemical Co.) and detected by Western blotting with anti-Par-1b
ascites. RNF41-FlagHis6 fusion protein was precipitated with anti-Flag M2 antibodyagarose affinity gel (Sigma Chemical Co.) and detected by Western blotting with antiFlag M2 monoclonal antibody (Sigma Chemical Co.). Indirect immunofluorescence was
performed with FlagM2 (Sigma Chemical Co.), GM130 (BD Biosciences), Alpha6Integrin (Millipore), E-cadherin (BD Biosciences), and Laminin V (Millipore) antibodies.

Immunoprecipitation. HeLa and HEK293T cells were transfected with the indicated
plasmids using Lipofectamine 2000 reagent (Invitrogen) at 75% confluence. Cells were
grown for 24 h before washing in ice-cold phosphate-buffered saline (PBS) once and
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harvesting in ice-cold mammalian cell lysis buffer (MCLB: 50 mM Tris HCl pH 8.0, 100
mM NaCl, 2 mM DTT, 5 mM EDTA, 0.5% NP-40, 1 µm microcystin, 1 mM sodium
orthovanadate, 2 mM PMSF, 0.15U/ml aprotinin, 20 µm leupeptin, and 20 µm pepstatin).
One mg of total cell lysate was used for the indicated immunoprecipitations (IP). M2
Flag-agarose (Sigma Chemical Co.) (1:1 slurry in MCLB, 10 µl) was used to
immunoprecipitate Flag3-Par-1b and RNF41-FlagHis6 proteins for 1 h at 4oC.
Immunoprecipitations were washed 6 times with ice-cold MCLB before boiling in SDSPAGE sample buffer and loading on an SDS gel.

Expression and purification of proteins in bacteria. JM109 cells were transformed
with a plasmid encoding GST-RNF41. Cultures were grown at 37oC to an A600 of 0.6,
and isopropyl-1-thio-!-D-galactopyranoside (IPTG) was added to a final concentration of
0.5 mM. After growing for an additional 4 h at 30oC, cells were pelleted by
centrifugation. Cell pellets were washed with PBS buffer and resuspended in STE (100
mM NaCl, 10 mM Tris-HCl, pH 8.0 and 1 mM EDTA) supplemented with 2 mM
phenylmethylsulfonyl fluoride (PMSF), 0.15 unit/ml aprotinin, 20 µM leupeptin, 20 µM
pepstatin (referred to as 1 x protease inhibitors), and 1.0 mg/ml lysozyme. After rocking
at 4oC for 20 min, Sarkosyl was added to a final concentration of 1.5%, and lysis was
accomplished by sonication. Lysates were clarified by centrifugation, and Triton X-l00
was added to a final concentration of 2%. Proteins were precipitated with GSH agarose
and washed twice in STE, twice in LiCl buffer (0.5 M LiCl, 50 mM Tris-HCl, pH 8.0),
and twice in 50 mM Tris-HCl, pH 7.4. GST-fusion proteins were eluted with 20 mM
glutathione in 50 mM Tris-HCl (pH 7.4), and the concentration of each GST-fusion
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protein was estimated by comparison to known Bovine Serum Albumin (BSA) standards
after SDS- PAGE and Coomassie Blue staining.

To express GST-Par-1b in bacteria, the E. coli strain JM109 was transformed with GSTPar-1b and cultures were grown at 37oC until reaching an A600 of ~0.6. Cells were
induced with 100 µM IPTG, grown at 28oC for 11 h, collected by centrifugation and
resuspended in STE buffer supplemented with 1x protease inhibitors and 1.0 mg/ml
lysozyme. After rocking at 4oC for 20 min, cells were lysed by sonication and
centrifuged at 3,000 x g for 10 min. Proteins were precipitated with GSH agarose and
washed as described above. Finally, precipitated proteins were washed with incomplete
kinase buffer (50 mM Tris-HCl, pH 7.5, 12.5 mM MgCl2, 1 mM DTT).

Kinase assays. Recombinant GST-Par-1b bound to GSH agarose was incubated with 5
µg of recombinant GST-RNF41 in complete kinase buffer (50 mM Tris-HCl, pH 7.5,
12.5 mM MgCl2, 1 mM DTT, 440 µM ATP, and 7 µCi !32P ATP [>4000 Ci/mmol]) at
37oC for 30 min. Samples were boiled, resolved by SDS-PAGE, and transferred to
nitrocellulose.

Mapping studies. The nitrocellulose containing radiolabeled GST-RNF41 was blocked
with 0.5% polyvinylpyrrolidone (PVP-40) in 100 mM acetic acid for 30 min at 37oC,
followed by washing 6 times with water. Radiolabeled GST-RNF41 was digested in a
solution containing 0.2 mg of trypsin (Worthington) per ml in 50 mM ammonium
bicarbonate. Tryptic phosphopeptides were separated in the first dimension by thin layer
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chromatography at pH 1.9 and in the second dimension by ascending chromatography in
a buffer consisting of n-butanol-pyridine-acetic acid-water in a ratio of 75/50/15/60. For
PAA analysis, washed tryptic labeled peptides were boiled in 6N hydrochloric acid for 90
min, followed by washing six times with water (van der Geer and Hunter, 1994).

Three-dimensional (3D) cultures. Each well of a 6-well plate was coated with 500 µl of
a mixture of collagen type 1 (BD Biosciences), 1N Sodium Hydroxide, Horse Serum
(Invitrogen), 5x DMEM (Sigma Chemical Co.) and sterile water at a
1.0/0.02/0.08/0.3/0.3 ratio. The collagen coating was allowed to polymerize in a tissue
culture incubator for 30 min at 37oC. MCF-10A cells or transduced MCF-10A cells
selected with puromycin were trypsinized and 7.49 x 104 cells were added to mixture
consisting of collagen type 1, 1N Sodium Hydroxide, Horse Serum, 5x DMEM and
sterile water mixture (1.0/0.02/0.08/0.3/0.06 ratio) on ice. The cell/collagen mixture was
gently mixed so that cells were in suspension and 1 ml of the mixture was added to each
of 3 wells of the 6-well plate. The cell/collagen mixture was allowed to polymerize in a
tissue culture incubator for 1 h at 37oC and then 2 ml of media with or without 1 µg/ml
puromycin was added to each well. Cells were harvested after 8, 10, 14 or 20 days in
culture. Cells were harvested by pooling each piece of polymerized collagen and cells
from each of 3 wells and incubating them in 20 mg/ml Collagenase A (Roche) in PBS for
5 min at 37oC. The cells were washed three times with ice-cold PBS and either spotted
on a glass slide for analysis by indirect immunofluorescence microscopy or lysed in icecold MCLB followed by Western blotting.

-91-

For cells grown in Matrigel (BD Biosciences), each well of a 6-well plate was coated
with 300 µl of Matrigel and the coating was allowed to polymerize in a tissue culture
incubator for 30 min at 37oC. MCF-10A cells or transduced MCF-10A cells selected
with puromycin were trypsinized and 6 x105 cells were suspended in 1.2 ml matrigel per
well and plated. The cell/Matrigel mixture was allowed to polymerize in a tissue culture
incubator for 1 h at 37oC and then 2 ml of media with or without 1 µg/ml puromycin was
added to each well. Cells were harvested after 8, 10, 14 or 20 days in culture. Cells were
harvested by washing each well twice with 2 ml ice-cold PBS and then adding 6 ml of
ice-cold 5mM Ethylenediaminetetraacetic acid (EDTA) in 1X PBS. Cells were rocked in
buffer containing EDTA/PBS at 4oC until all of the Matrigel was dissolved. The cells
were washed three times with ice-cold PBS and either spotted on a glass slide for analysis
by indirect immunofluorescence microscopy or lysed in ice-cold MCLB and analyzed by
Western blotting.

Indirect immunofluorescence microscopy. MCF-10A cells grown in 3D culture were
spotted onto microscope slides and fixed with 4% Paraformaldehyde (PFA) in PBS for 20
min at room temperature. Slides were washed two times with room temperature PBS and
three times (10 min each wash) at room temperature in 100 mM glycine in PBS. Fixed
cells were blocked in IF blocking solution (10% normal goat or donkey serum, 0.2%
Triton X-100, 0.1% BSA (radioimmunoassay grade, Sigma Chemical Co.) and 0.05%
Tween 20 in PBS, pH 7.4) for 1.5 h at room temperature in a humidified chamber. Fixed
cells were stained with primary antibody diluted in IF buffer (IF blocking solution
without 10% normal goat or donkey serum) for 2 h at room temperature in a humidified
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chamber. Slides were washed three times for 20 min in IF buffer in a Coplin jar at room
temperature with gentle shaking. Cells were then incubated with a secondary antibody
(Alexa488 or Alexa594) diluted in IF buffer for 45 min at room temperature in a
humidified chamber. Slides were washed once with IF buffer for 20 min and then two
times with PBS for 10 min at room temperature with gentle shaking. Finally, cells were
stained with 1 µM TO-PRO-3 Iodide (Invitrogen) for 10 min at room temperature in a
humidified chamber, slides were washed once with PBS for 10 min with gentle shaking,
and slides were mounted with Prolong Antifade mounting media (Molecular Probes).
Images were obtained using an Olympus FV-500 confocal microscope with a 60x water
objective. Images were processed using the Olympus FLUOVIEW Ver.2.1a Viewer
software.
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Fig. 3.1 RNF41 binds to the amino terminus of Par-1b.
(A) HeLa (lanes 1-3) and HEK293T (lanes 4-6) cells were transfected with plasmids
encoding Flag3-Chk2 (lanes 2 and 5) or Flag3-Par-1b (lanes 3 and 6) for 24 h. Cells were
harvested and lysates resolved by SDS-PAGE or incubated with anti-Flag agarose before
SDS-PAGE. Total lysates and immunoprecipitations were analyzed by Western blotting
using the indicated antibodies. (B) Schematic representation of Par-1b and RNF41
proteins. Protein domains, point mutations and deletion mutants are indicated. (C)
HEK293T cells were transfected with plasmids encoding Flag3-Par-1b full length (FL)
(lane 2), N-UBA (lane 3), C-UBA (lane 4), N-Term (lane 5), or C-Term (lane 6) deletion
mutants. Cells were harvested 24 h later and lysates were resolved by SDS-PAGE or
were incubated with anti-Flag agarose prior to SDS-PAGE. Total lysates and
immunoprecipitations were analyzed by Western blotting using the indicated antibodies.
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2
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Fig. 3.2 Phosphorylation of RNF41 by Par-1b.
(A, B, C) Bacterially produced GST-Par-1b was incubated in the absence or presence of
bacterially produced GST-RNF41 and kinase assays were performed in vitro.
Radiolabeled reaction products were resolved by SDS-PAGE (panel A) and
phosphotryptic peptides were subjected to phosphoamino acid analysis (PAA analysis)
(panel B). A kinase assay was also performed with GST-Par-1b and GST-RNF41 (WT
or S254A) and two-dimensional phosphopeptide mapping (panel C) was performed.
Arrows indicate the direction of electrophoresis (x axis) and chromatography (y-axis).
(D) Kinase assays were performed in vitro using GST-RNF41 WT (lanes 1 and 3) or
GST-S254A (lanes 2 and 4) with (lanes 3 and 4) or without GST-Par-1b (lanes 1 and 2).
Proteins were resolved by SDS-PAGE and detected by Western blotting using the
indicated antibodies. (E) Lysates prepared from mock-transfected HEK293T cells (lane
1) or from HEK293T cells expressing RNF41-Flag!CH (lanes 2-4) or RNF41-FlagS254A
!CH (lanes 5-7) with Flag3-Par-1b WT (lanes 3 and 6) or Flag3-Par-1b KD (lane 4 and 7)
were resolved by SDS-PAGE and immunoblotted with the indicated antibodies.
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Fig. 3.3 RNF41 is phosphorylated on S254 as MCF-10A cells polarize in 3D cultures.
(A) MCF-10A cells were grown in collagen I matrix or in Matrigel and harvested at the
indicated times. (B,C) Cells described in panel A were fixed and proteins were detected
using indirect immunofluorescent staining and confocal microscopy. (D) MCF-10A cells
were grown in 2D or 3D culture. Cells grown in 3D culture were harvested at the
indicated times. Cell lysates were resolved by SDS-PAGE and immunoblotted with the
indicated antibodies.
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Fig. 3.4 RNF41 is required for MCF-10A cells to polarize in 3D cultures.
(A) MCF-10A cells expressing either lucshRNA, RNF41shRNA, RNF41shRNA +
RNF41WT-Flag His6, or RNF41shRNA + RNF41S254A-Flag His6 were grown in plastic
culture dishes (2D), in collagen I matrix, or in Matrigel. Cells were harvested and lysates
were resolved by SDS-PAGE (panel C lanes 1-5) or incubated with anti-Flag agarose
prior to SDS-PAGE (panel C, subpanel *). Total lysates and immunoprecipitates were
analyzed by Western blotting using the indicated antibodies. (D, E) Cells described in
panel A were grown in collagen I matrix, and harvested after 20 days. Cells were fixed
and proteins were detected using indirect immunofluorescent staining and confocal
microscopy. (F) The number of polarized acini-like spheroids were counted in 3 separate
experiments (n = 3). A one way ANOVA was performed and p<0.0001 (****). A
Tukey’s multiple comparison posttest showed p values as described on the graph (*** =
p<0.001, ** = p<0.01).
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CHAPTER 4
Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to
hepatic steatosis, and defective gluconeogenesis.
(Published in 2010. Mol. Cell. Biol. 30(21):5043-5056)
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Contributions:
Results of my study of the protein levels of glycogen synthase (GS) and
phosphoryalted glycogen synthase (pGS) in the liver of fasted Par-1a -/- or Par-1b -/mice were published in Figure 4.5 of this paper (Lennerz et al., 2010). I analyzed protein
lysate from Par-1a or Par-1b null mouse livers and showed that upon short-term
starvation, Par-1a null mice had increased levels of GS and pGS protein in the liver
whereas Par-1b null mice do not (Fig. 4.5F). Since Par-1a null mice demonstrate
resistance to steatosis (accumulation of lipids, leading to fatty liver) as well as defective
gluconeogenesis, I probed for UCP2 (an uncoupling protein) in fasted and nonfasted liver
samples but found similar protein levels (Fig. 4.S1A). Most recently, autophagy has been
linked to lipid (Singh et al., 2009) as well as glycogen/glucose homeostasis (Kotoulas et
al., 2004; Kotoulas et al., 2006). Therefore, I detected LC-3 protein levels by Western
blot as a marker for membrane formation and early stages of autophagy, but observed no
differences (Fig. 4.S1B).
In summary, livers from Par-1a null mice are depleted of lipid and glycogen
stores, upregulate glycogen synthase, and activate autophagy. The increase in total
glycogen synthase protein might be to compensate for the decreased levels of stored
glycogen. However, we also observe an increase in the inhibited (phosphorylated) form
of glycogen synthase (pGS). Thus, it is unclear whether glycogen synthase activity is
altered in the livers of Par-1a null mice even though an increase in total glycogen
synthase protein is observed.
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Abstract
Par-1 is an evolutionarily conserved protein kinase required for polarity in worms,
flies, frogs and mammals. The mammalian Par-1 family consists of four members.
Knockout studies in mice implicate Par-1b/MARK2/EMK in regulating fertility, immune
homeostasis, learning and memory as well as adiposity, insulin hypersensitivity and
glucose metabolism. Here we report phenotypes of mice null for a second family member
(Par-1a/MARK3/C-TAK1), which exhibit increased energy expenditure, reduced
adiposity with unaltered glucose handling and normal insulin sensitivity. Knockout mice
were protected against high-fat diet-induced obesity, displayed attenuated weight gain,
complete resistance to hepatic steatosis and improved glucose handling with decreased
insulin secretion. Overnight starvation led to complete hepatic glycogen depletion,
associated hypoketotic hypoglycemia, increased hepatocellular autophagy and increased
glycogen synthase levels in Par-1a-/-, but not in control or Par-1b-/- mice. Intercrossing of
Par-1a-/- with Par-1b-/- mice revealed that at least one of the four alleles is necessary for
embryonic survival. Severity of phenotypes followed a rank-order whereby loss of one
Par-1b allele in Par-1a-/- mice conveyed milder phenotypes than loss of one Par-1a allele
in Par-1b-/- mice. Thus, although Par-1a and Par-1b can compensate for one another
during embryogenesis, their individual disruption gives rise to distinct metabolic
phenotypes in adult mice.
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Introduction
Cellular polarity is a fundamental principle in biology (Banks and Humbert, 2008;
Geldner, 2009; Lindsey, 2004). The prototypical protein kinase originally identified as a
regulator of polarity was termed partitioning defective (Par-1) due to early embryonic
defects in C. elegans (Kemphues et al., 1988). Subsequent studies revealed that Par-1 is
required for cellular polarity in worms, flies, frogs and mammals (Arimura and Kaibuchi,
2007; Krummel and Macara, 2006; Lizcano et al., 2004; Martin and St Johnston, 2003;
Nance, 2005; Shin et al., 2006; Sodha et al., 2002). An integral role for Par-1 kinases in
multiple signaling pathways has also been established and although not formally
addressed, multi-functionality for individual Par-1 family members is implied when
reviewing the list of recognized upstream regulators (Table 4.1A) and downstream
substrates (Table 4.1B). Interestingly, for many Par-1 substrates the phosphorylated
residues generate 14-3-3 binding sites (Dalal et al., 1999; Dequiedt et al., 2006;
Goransson et al., 2006; Kao et al., 2001; Kusakabe and Nishida, 2004; Lin et al., 2009;
Muller et al., 2001; Muller et al., 2003; Peng et al., 1998; Suzuki et al., 2004; Watkins et
al., 2008; Zhang et al., 1997). 14-3-3 binding, in turn, modulates both
nuclear/cytoplasmic as well as cytoplasmic/membrane shuttling of target proteins thus
allowing Par-1 activity to establish intracellular spatial organization (Bronisz et al., 2006;
Watkins et al., 2008). Phosphorylation of Par-1 itself promotes 14-3-3 binding thereby
regulating its subcellular localization (Goransson et al., 2006; Kusakabe and Nishida,
2004; Watkins et al., 2008).
The mammalian Par-1 family contains four members (Table 4.2). Physiological
functions of the Par-1b kinase have been studied using targeted gene knockout
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approaches in mice (Bessone et al., 1999; Hurov et al., 2001). Two independently derived
mouse lines null for Par-1b, have implicated this protein kinase in diverse physiological
processes, including fertility (Bessone et al., 1999), immune system homeostasis (Hurov
et al., 2001), learning & memory (Segu et al., 2006), positioning of nuclei in pancreatic
beta cells (Fu et al., 2009; Granot et al., 2009) as well as growth and metabolism (Hurov
et al., 2007).
Beyond Par-1b, most information regarding the cell biological functions of the Par-1
kinases comes from studies on Par-1a. Specifically, Par-1a has been implicated in
pancreatic- (Parsa, 1988), and hepato-carcinogenesis (Kato et al., 2001), as well as
colorectal tumors (Parsons et al., 2005), hippocampal function (Wang et al., 2007), CagA
(Helicobacter pylori) associated epithelial cell polarity disruption (Saadat et al., 2007)
and Peutz-Jeghers-Syndrome (Jansen et al., 2006), although the later association has
recently been excluded (Jansen et al., 2006). As a first step towards determining unique
and redundant functions of Par-1 family members, mice disrupted for a second member
of the family (Par-1a/MARK3/C-TAK) were generated. We report that Par-1a-/- mice are
viable and develop normally; adult mice are hypermetabolic, have decreased white and
brown adipose tissue mass, and unaltered glucose/insulin handling. However, when
challenged by high-fat diet, Par-1a-/- mice exhibit resistance to hepatic steatosis,
resistance to glucose intolerance and delayed onset of obesity relative to control
littermates. Strikingly, overnight starvation results in a complete depletion of glycogen
and lipid stores along with an increase in autophagic vacuoles in the liver of Par-1a-/- but
not Par-1b-/- mice. Correspondingly, Par-1a-/- mice develop hypoketotic hypoglycemia.
These findings reveal unique metabolic functions of two Par-1 family members.
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Results
Gene targeting was employed to determine the consequences of Par-1a loss in
mice (Fig. 4.1A). The targeted Par-1a allele was introduced by electroporation into RW4
embryonic stem (ES) cells, derived from the mouse strain 129X1/SvJ. Southern blot
analysis identified correct targeting events (Fig. 4.1B). Southern blotting and PCR
analysis demonstrated that the agouti offspring produced by the chimeric males were
heterozygous for the Par-1a locus (data not shown). F1 heterozygous offspring were
inter-crossed and F2 offspring were genotyped by PCR (Fig. 4.1C). Western blotting
demonstrated that the targeted disruption of Par-1a produced a null allele of the locus
(Fig. 4.1D) and multi-tissue Western blotting confirmed ablation of Par-1a/b in all
tissues of the corresponding null-mice (Fig. 4.1E).
Higher levels of Par-1a were noted in several tissues of Par-1b null mice
including brain, BAT, thymus and muscle (Fig. 4.1 E, lanes 2, 5, 17, 26), which may
provide an explanation for Par-1a compensation of Par-1b loss (see below). However,
increased Par-1b levels were not observed in Par-1a null tissues. Also observed in Fig.
4.1E is the differential expression of Par-1a splice variants in various mouse tissues. The
NCBI database contains 5 Par-1a splice variants with their respective protein products
ranging from 659 to 753 amino acids. It is not known whether functions differ among the
various splice variants.
Par-1a-/--mice are hypermetabolic and show 9% reduction in body weight
When Par-1a heterozygotes were intercrossed, the offspring contained WT, HET
and KO pups, although genotype proportions deviated significantly from expected
Mendelian ratios with loss of homozygous KO mice (n=750; WT=30%, HET=52%,
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KO=17%; !2=27.864, P<0.0001). All pups developed without any visible dysmorphisms
or obvious external pathology; and animals survived to adulthood. Par-1a null mice
exhibited significant weight differences compared with their wild-type littermates (e.g. at
32 weeks: WT (n=6) 33.4±0.94g; vs. Par-1a-/- (n=6) 25.5±0.42g; P<0.0001, t-test). In
contrast to Par-1b null mice that show reduced weights at 6 weeks of age (Bessone et al.,
1999; Hurov and Piwnica-Worms, 2007), in Par-1a null mice the difference was not
discernable this early (Fig. 4.2A, 4.2B).
Body weight represents a net balance of food intake and energy expenditure.
Based on the decreased weight in Par-1a null mice we measured total energy expenditure
(EE), total metabolic rate (MR) and respiratory quotients of male mice on a regular chow
diet. Par-1a null mice exhibited higher O2 consumption (MR: ~9% increase; Fig. 4.2C)
and higher EE (10% increase; Fig. 4.2D). We also compared the respiratory quotient
(RQ=VCO2/VO2) as a measure of fuel-partitioning patterns and RQ ranged from 0.760.78 (Fig. 4.2E; P=0.32, t-test). Food intake in Par-1a null mice was slightly lower than
WT littermates, although this difference was not statistically significant (WT 3.15±0.09
vs. Par-1a-/- 2.94±0.04; P=0.16, t-test; Fig. 4.2F). Thus, unlike Par-1b null mice, Par-1a
null mice are not hyperphagic (Hurov et al., 2007). The lack of effect on RQ suggests that
there was no difference in fuel selection between carbohydrates and lipids, leading us to
explore whether the increase in energy expenditure might occur secondarily to increased
thermogenesis. However, body temperatures of Par-1a null mice were similar to WT
littermates (WT 34.3±0.5 vs. Par-1a-/- 34.1±0.8; P=0.8, t-test) and expression of
uncoupling proteins in selected tissues showed no significant difference (Fig. 4.S1).
Lastly, Par-1a null mice showed similar levels of activity (comparison to WT; P=0.96)
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and basic sensorimotor testing as well as open field tests showed no significant difference
(P=0.64; not shown).
Par-1a-/--mice are normoglycemic, normoinsulinemic and show no insulin sensitivity
Serum levels of insulin, glucagon, leptin, adiponectin, triglycerides, cholesterol
and free fatty acids in Par-1a null mice were measured and compared to values from WT
and Par-1b null mice (20-week-old on regular chow diet; Table 4.3). Male Par-1a null
mice exhibited 1.6-fold higher levels of adiponectin when compared to WT littermates.
Par-1b null mice showed a significant decrease in female adiponectin values. In contrast
to Par-1b null mice, Par-1a null mice showed no difference in serum insulin levels
(Table 4.3) and blood glucose was normal (WT 152±18mg/dl vs. Par-1a-/- 147±5 mg/dl;
P=0.216, t-test). Par-1a null mice on CD exhibited ITT curves identical to that of WT
littermates (Fig. 4.2G; P=0.87; 1-way ANOVA). On CD, Par-1a null mice showed no
significant difference in GTT relative to WT littermates (Fig. 4.3C) (P=0.15; t-test and
P=0.181, 2-way ANOVA for entire time course; Par-1b-/- not shown).
Par-1a-/- mice show delayed weight gain on high-fat diet
The striking resistance to high fat diet (HFD)-induced weight gain in Par-1b null
mice (Hurov et al., 2007), prompted us to challenge Par-1a null mice with a similar HFD
for 16 weeks (Fig. 4.3A, 4.3B). The main finding was reduced weight gain of Par-1a null
mice compared to WT littermates on HFD (Fig. 4.3A). Specifically, while Par-1b null
mice on HFD showed statistically significant lack of weight gain after 7 weeks
[t(7w)=3.297 P<0.05 to t(17w)=7.234; P<0.001, 2 way ANOVA with Bonferroni
posttests; weight gain: +5%; CD: 19±0.75g vs. HFD: 20.3±1.34, P=0.4097, t-test], Par1a null mice on HFD continued to gain weight during the entire experiment (Par-1a-/-:
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+39%, CD: 23.47±1.6g vs. HFD: 32.4±1.47, P=0.004, t-test), albeit at a reduced rate and
significantly different from WT littermates (WT: +70%, CD: 27.12±0.5g vs. HFD:
46±0.9, P=0.001; t-test). HFD food intake of Par-1a null mice was similar to that of WT
littermates (P=0.39, t-test). While the Par-1a phenotype with reduced rate of weight gain
is at first glance less dramatic than that observed in Par-1b null mice [Par-1a-/- vs. WT:
t(all)=2.779, P<0.05, 1 way ANOVA with Bonferroni’s Multiple Comparison test], it is a
highly significant finding (Fig. 4.3B, P=0.001). Par-1a null mice required 7 additional
weeks of HFD to reach the original weight of their WT littermates.
Par-1a-/--mice show resistance to glucose intolerance on high-fat diet
Next, Par-1a null mice fed a HFD were subjected to glucose tolerance testing (Fig.
4.3C). As expected, WT mice on HFD exhibited glucose intolerance relative to WT mice
on CD with prolonged elevation of blood glucose of ~400% from 15 min onwards
(t=3.645, P<0.01; 2-way ANOVA). Strikingly, Par-1a null mice exhibited improved
glucose tolerance on HFD relative to WT-controls on the same diet [Fig. 4.3D; P=0.041,
t-test (two genotypes); t=3.38; P<0.01; 1-way ANOVA (all genotypes)]. GTT response in
Par-1a null mice under HFD-conditions was essentially identical to WT and Par-1a null
mice on CD [Fig. 4.3D; P=0.4781, t-test (two genotypes); t=0.346; P>0.05 1-way
ANOVA (all genotypes); not shown]. We conclude that Par-1a-disruption leads to
maintenance of normal glucose tolerance even under HFD-conditions; accordingly Par1a null mice on HFD were normoglycemic (P=0.3, t-test). Next, we examined serum
insulin levels in HFD-fed mice during the first 60 min of the GTT (Fig. 4.3D) and found
significantly lower levels in Par-1a null mice (t=3.16, P=0.0194, t-test (two genotypes);
F=6.454, P=0.018, 1-way ANOVA). Although we did not formally assess insulin
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tolerance in Par-1a null mice on HFD, the combination of improved glucose tolerance
and reduced insulin secretion during the GTT is indicative of peripheral insulin
hypersensitivity. Thus, Par-1a null mice demonstrate normal insulin and glucose
sensitivity, unless challenged by HFD. In contrast Par-1b null mice exhibited insulin
hypersensitivity even on a CD (Hurov et al., 2007). Direct assessment of pancreatic islets
has proven difficult in Par-1 mice (Granot et al., 2009), however, morphological and
morphometric differences were not observed in the islet organ of Par-1a null mice (not
shown).
Par-1a-/--mice show diet-dependent reduced adiposity
Next, we determined whether the reduced body weight of Par-1a null mice was
reflected disproportionately in different tissues (Fig. 4.4A). Measurements of tissue
weights in Par-1a null mice indicated that decreased weights of most organs were
proportional to total body weight and consistent with a decrease in overall body mass,
rather than in specific organs. However, two tissues did not follow this rule and were
disproportionately smaller: white-adipose tissue (WAT from gonadal fat pads) and
brown-adipose tissue (BAT). We also performed dissection of tissues in the mice on
HFD and, as expected, the energy excess in WT-mice led to a disproportionate increase
in overall adiposity (Fig. 4.4A; BAT-CD vs. BAT-HFD P=0.001; WAT-CD vs. WATHFD P=2.5e-5; t-tests). Par-1a null mice showed a similar disproportionate increase in
overall adiposity (BAT-CD vs. BAT-HFD P=0.007; WAT-CD vs. WAT-HFD P=1.4e-9;
t-tests) with a weight increase in BAT and gonadal WAT that eliminated the reduced
adiposity observed under chow diet (Fig. 4.4A columns a vs. b and c vs. d, both P=0.08;
t-tests).
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Dissection of the gonadal fat pads (Fig. 4.4B), representative of the WAT showed
a disproportionate decrease in fat mass of Par-1a null mice relative to WT on CD (Fig.
4.4C; raw weight values provided). The weight difference corresponds to ~48% (Par-1a-/) and ~36% (Par-1b-/-) of the WT-WAT weight, respectively (Fig. 4.4C). Although we
did not quantitatively assess abdominal fat, during dissection the dimensions of
mesenteric root, omental-, and retroperitoneal fat content were strikingly lower in Par-1a
null mice and this difference is not accounted for in the displayed values of gonadal
WAT (Fig. 4.4C).
Dissection of the interscapular fat depot, representative of BAT, is shown in Fig.
4.4E. The weight difference corresponds to ~52% (Par-1a-/-) and ~38% (Par-1b-/-) of the
WT-BAT weight, respectively (Fig. 4.4F). For both adipose tissues, the difference
significantly exceeded the overall ~9% weight difference observed in Par-1a null mice.
Adipocyte counts from six independent samples of WAT and BAT indicated no
differences in adipocyte size from WT and Par-1a null mice: WAT (WT 436±100
adipocytes per mm2 vs. Par-1a-/- 419±74; P=0.137, t-test) and BAT (WT 1894±349 vs.
Par-1a-/- 1385±434; P=0.382, t-test). Thus, we conclude that the observed decrease in
adipose tissue of Par-1a null mice is due to decreases in total adipocyte cell number, not
cell size; findings similar to those made in Par-1b null mice (Hurov et al., 2007).
We also determined the weight of muscle samples (tibialis anterior,
gastrocnemius, plantaris, diaphragm, extensor digitorum longus), typically used for
assessment of myogenic phenotypes and fiber-type composition (Corbett et al., 2001;
Sanoudou et al., 2006), which, under HFD conditions showed significantly decreased
weights (Fig. 4.4A, subheading e; WT: P=3.7e-6; Par-1-/-: P=0.006, both t-tests). Skeletal
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muscle plays an integral role in the coordination of fuel homeostasis (Hegarty et al.,
2009) and is the most important site of insulin-stimulated glucose disposal (DeFronzo et
al., 1981). We therefore performed functional- (motor, biodistribution and microPET
analysis), biochemical- (glycogen quantification) and morphologic- (routine, PAS, fibertype analysis and ultrastructure) screening of skeletal muscle but observed no differences
between wild-type and Par-1a null mice (not shown). Thus, the reduced body weight of
Par-1a mice on HFD is likely accounted for by a combination of reduced muscle mass
(Argiles et al., 2007; Sitnick et al., 2009) and reduced adiposity; although the latter is not
reflected in the gonadal WAT measurements (Fig. 4.4Ac,d).
Par-1a loss causes decreased WAT glucose uptake in the absence of BAT-phenotype
MicroPET imaging of WAT was performed (not shown); however the reduced
size of Par-1 null mice and high tracer concentrations in kidneys, bladder and skeletal
muscle precluded meaningful quantification of uptake in retroperitoneal, gonadal, and
calf-fat deposits, respectively. We therefore applied invasive biodistribution analysis and
in contrast to Par-1b null mice, WAT of Par-1a null mice showed significantly decreased
glucose uptake under normal dietary conditions [Fig. 4.4D; WT: 0.52±0.08%ID/g (n=9)
vs. Par-1a-/-: 0.32±0.05%ID/g (n=8); U=14, P=0.036, Mann-Whitney U test; P=0.05, ttest]. When challenged with HFD, Par-1a null mice showed a statistically significant
increase in 18F-FDG-uptake compared to Par-1a null mice on chow diet that eliminated
the difference of glucose uptake in comparison to WT on HFD (Fig. 4.4D).
We next examined glucose uptake in BAT of chow fed Par-1a null mice by
microPET analyses of the interscapular BAT (Fig. 4.4G). We evaluated 4 different
conditions at 1h post 18F-FDG injection: the fed and fasted state using acute insulin
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challenge vs. saline. As part of the HFD-trial, we also examined BAT glucose uptake via
biodistribution analysis in all genotypes. We found that loss of Par-1a did not
significantly alter BAT glucose uptake in any of these 6 tested conditions (not shown).
Although Par-1a null mice exhibited reduced fat mass on chow diet, and delayed
weight gain relative to WT on HFD, sampled gonadal adipose mass in Par-1a null mice
was not significantly different compared to WT after 16 weeks of HFD conditions [Fig.
4.4C, F; P=0.12/P=0.13, both t-tests; WAT/BAT; n=8 Par-1a-/- vs. n=17 WT]. In contrast,
the BAT/WAT mass in Par-1b null mice remained reduced under HFD conditions when
compared to WT-mice on the same diet [Fig. 4.4C, F; P=0.002/P=0.04, t-tests
(WAT/BAT); n=6 Par-1b-/- vs. 17 WT].
Par-1a-/--mice show resistance to hepatic steatosis
Chronic exposure of mice to HFD causes liver injury via accumulation of lipids,
leading to fatty liver (steatosis) (Bradbury, 2006; Postic et al., 1999). The absence of
steatosis in Par-1a null mice was apparent from gross examination of the liver, which
was notably darker than that of the WT littermates (not shown) and histologic
examination that showed abundant panlobular, macrovesicular steatosis in WT (Fig.
4.5Ab, inset) but not Par-1a null livers (Fig. 4.5Ad). Remarkably, with respect to hepatic
steatosis, Par-1a null mice on HFD were no different than WT mice on CD (compare Fig.
4.5Ad with 4.5Aa). Based on previous findings (Hurov et al., 2007), we quantified
hepatic lipid content in fresh-frozen sections stained with Oil-red O and found 14.6-25%
in WT vs. 6.4-7.7% in Par-1a null mice, when expressed as percent fat per high-power
field (Fig. 4.5B). The quantitative difference in the WT on chow diet (Fig. 4.5B)
corresponds to an absence of centrilobular (Zone III) lipid accentuation in Par-1a null
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mice (compare WT Fig. 4.5Aa to Fig. 4.5Ac). In addition, biodistribution studies
demonstrated identical 18F-FDG-uptake in livers of Par-1a null- and WT-mice on chow
standard CD and HFD (not shown). Similarly, microPET examination of the liver using
four different metabolic conditions (see methods) did not show significant differences (Pvalue range: 0.12-0.71, t-tests). These findings indicate that Par-1a null mice show
resistance to steatosis in the absence of altered hepatic glucose uptake under both normal
and HFD-conditions.
Decreased glycogen deposition in Par-1a-/--livers leads to hypoketotic hypoglycemia
Storage and utilization of glucose is one of the main contributors to the
pathophysiologic changes in diabetes (Cline et al., 1994; Shulman et al., 1990). Periodic
acid Schiff (PAS) staining was used to detect glycogen content (Fig. 4.5C). Fasted WT
liver showed partially depleted liver glycogen stores (Fig. 4.5Ca), whereas liver sections
from fasted Par-1a null mice exhibited complete depletion of hepatic glycogen content
(Fig. 4.5Cc; PAS-quantification (fasted): WT 23.6±8.5 vs. Par-1a-/- 0.17±0.13, P=0.01, ttest). This depletion was not observed in Par-1b null mice (Fig. 4.5Ce; Par-1b-/26.68±2.8, P=0.73, t-test). Two hours after glucose administration, glycogen levels were
substantially elevated and visible as confluent PAS-positive in livers of WT mice (Fig.
4.5Cb). In contrast Par-1a null mice showed absence of restoration of hepatic glycogen
content with only spotty PAS-positive islands (Fig. 4.5Cd). Quantitative enzymatic
analysis of glycogen was consistent with the PAS staining such that fasted and glucosestimulated liver glycogen was significantly decreased in Par-1a null animals (Fig. 4.5D)
with no significant difference in Par-1b null mice. After feeding glycogen levels were
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normal and no significant histological differences were observed between groups (not
shown).
To test the physiologic significance of hepatic glycogen depletion in Par-1a null
mice we performed an extended fasting experiment and observed significantly decreased
glucose levels in Par-1a null mice after overnight fasting (20 h) when compared to WT
littermates (Fig. 4.5E). After 4 additional hours without external energy sources, Par-1a
null animals blood glucose levels further declined (P=0.04 in comparison to WT, t-test)
and the mice developed hypoketotic hypoglycemia (Fig. 4.5E). In contrast, Par-1b null
mice showed an absence of physiologic decline of blood glucose levels with
appropriately low ketone levels (Fig. 4.5E).
To test whether the tissue differences in glycogen levels relate to glycogen
synthesis we determined total and phospho-glycogen synthase (GS) levels (pGS; Fig.
4.5F) and found increased levels of GS and pGS in the livers of Par-1a null mice. Since
Par-1a null mice demonstrate resistance to steatosis as well as defective gluconeogensis
we probed for UCP2 in fasted and non-fasted liver samples but found similar protein
levels (Fig 4.S1). Most recently autophagy has been linked to lipid (Singh et al.) as well
as glycogen/glucose homeostasis (Kotoulas et al., 2004; Kotoulas et al., 2006). Therefore,
we monitored LC-3 as a marker for membrane formation and early stages of autophagy
but observed no differences (Fig. 4.S1). Electron microscopic examination of livers from
fasted WT mice demonstrated irregularly shaped glycogen islands (Fig. 4.5Ga, 4.5Gb)
and variably sized lipid vacuoles (Fig. 4.5Gb) in close proximity to mitochondria with
normal morphology (Fig. 4.5Gc). In striking contrast, livers from fasted Par-1a null mice
did not have lipid vacuoles (Fig. 4.5Gd, 4.5Ge) were completely depleted for glycogen
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(Fig. 4.5Gd, 4.5Ge) and had abundant autophagocytic vacuoles throughout the
hepatocytes (Fig. 4.5Ge, 4.5Gf). These autophagic vacuoles were normally configured
and frequently associated with mitochondria (Fig. 4.5Gf). Our ultrastructural findings
with WT mice indicate a catabolic state whereas the findings in Par-1a null liver are
indicative of more extreme energy deprivation with self-digestion of organelles (Fig.
4.5Gf).
Par-1b/Par-1a-double mutants are not viable and at least one allele is necessary for
embryonic survival
Next, crossbreeding experiments were performed to obtain mice disrupted for
both Par-1a and Par-1b. After an initial experiment where 24 intercrosses were
performed and only 6 of the 9 possible genotypes were obtained, genotype frequencies in
ongoing HH x HH crosses were monitored. Eventually 2 of the 3 missing genotypes were
obtained (Fig. 4.6A) but at a substantial deviation from the expected Mendelian ratio
[Chi-squared (8)>944= 2.18e-198] and with a complete absence of mice lacking both Par1a and Par-1b (KK). In addition, there was a drastic reduction in numbers of KH and HK
mice (0.5% and 2.7%, respectively). Instead of the expected 12.5% (corresponding to an
estimated n of 308 mice; grey background in Fig. 4.6A), we obtained a total of 14 KH
and 69 HK mice (out of n=2466). Next, pregnant females that had been superovulated
from HH intercrosses were sacrificed and fetuses at day 10.5 (n=4) or day 8.5 (n=4); post
coitum were isolated. None of the obtained sets of embryos (total n=31) included the KK
genotype (expected frequency: ~2 mice). All other genotypes were obtained (not shown).
These results illustrate Par-1b/Par-1a double mutants are not viable and that at least one
allele of either Par-1a or Par-1b is necessary for viability and likely embryonic survival.
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When normalized to age-matched WT-controls, Par-1b null mice are ~20%
reduced in body weight (Hurov et al., 2007) and Par-1a null mice are ~9% reduced in
body weight (this study). Loss of one Par-1a allele in Par-1b null mice (KH) led to a
more pronounced reduction in body weight (30%) than that observed in Par-1a null mice
containing a single allele of Par-1b (HK, 23%; Fig. 4.6B). HK and KH mice were not
healthy and a high proportion of these animals died shortly after birth (not shown). The
severity of phenotypes observed in each genotype followed the order:
KK>KH>HK>KW>WK>WW and suggests an intriguing gene-dosage effect at the
organism level.
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Discussion
This study describes metabolic phenotypes arising in mice disrupted for Par-1a
and the consequences of intercrossing of Par-1a with Par-1b deficient mice. Par-1a null
mice are hypermetabolic, show reduced body weight, decreased adiposity, resistance to
hepatic steatosis and hypofertility; features reminiscent of the Par-1b null phenotype
(Hurov et al., 2007). Metabolic phenotypes of Par-1a null mice not shared by Par-1b
null mice include 1) hepatic glycogen depletion after starvation associated with
hypoketotic hypoglycemia and increased autophagic vacuoles in the liver; and 2) a
modestly reduced glucose uptake by WAT when mice were fed a standard chow diet.
Features observed in Par-1b null mice but not in Par-1a mice include 1) hyperphagy
(food intake of Par-1a null mice was equivalent to controls); 2) reduced serum insulin
levels under both fed and fasting conditions on a standard CD (serum insulin levels in
Par-1a null mice were lower than those measured in WT littermates fed a HFD but not
standard CD); 3) increased insulin sensitivity on standard CD (Par-1a null mice were
insulin sensitive on a HFD but not standard CD); 4) resistance to HFD-induced weight
gain (Par-1a null mice showed a reduced rate of weight gain relative to control
littermates when fed a HFD); 5) enhanced glucose uptake in BAT (loss of Par-1a did not
affect glucose uptake in BAT under any condition); and 6) resistance to hepatic steatosis
accompanied by enhanced glucose uptake in liver (Par-1a null mice, resistance to hepatic
steatosis was not accompanied by enhanced hepatic glucose uptake).
Strikingly, Par-1a null mice on HFD exhibited profound resistance to the
development of glucose intolerance (Fig. 4.3D) as well as delayed weight gain on HFD
(Fig. 4.2A). These findings are most likely related to peripheral insulin hypersensitivity
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as illustrated by resistance to glucose intolerance and decreased insulin secretion during
GTT (on HFD). Par-1a null livers maintained resistance to steatosis despite HFD
challenge (Fig. 4.5A, 5B). However, the adiposity and WAT glucose uptake measured in
Par-1a null mice fed a HFD were similar to those of WT littermates fed the same diet.
Although this study does not provide conclusive evidence for a hepatocyte-autonomous
role for either Par-1a or Par-1b in lipogenesis, the striking resistance to hepatic steatosis
seen in both models may suggest such a function.
Upon short-term starvation, the livers of Par-1a null mice exhibited profound
defects in both glycogen storage and glucose mobilization (gluconeogenesis), phenotypes
not observed in Par-1b null mice. Depletion of both lipid and glycogen stores,
upregulation of glycogen synthase as well as activation of autophagy are observed in the
livers of Par-1a null mice. The increase in total glycogen synthase might be a
compensatory response in light of the decreased glycogen storage. However, we also
observe an increase in the inhibited (phosphorylated form) of glycogen synthase. Thus, it
is unclear whether the net glycogen synthase activity is altered in the livers of Par-1a-/mice. Our ultrastructural findings of increased autophagy in the absence of glycogen or
lipid vacuoles in the livers of Par-1a null mice, suggests substantial energy deprivation
with self-digestion of organelles. The absence of both hepatic glycogen mobilization and
gluconeogenesis required to maintain normal blood glucose levels during starvation, in
turn, leads to hypoglycemia and hypoketosis in Par-1a null mice.
The underlying molecular mechanisms driving the hypermetabolic phenotype and
resistance to hepatic steatosis in Par-1a null mice and the inability of these mice to
maintain metabolic homeostasis during periods of starvation remain unclear. The
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regulation of lipogenesis, glucose metabolism and autophagy are coordinated, at least in
part, through the Par-1 related kinase AMPK. It is tempting to speculate that Par-1 may
regulate these pathways via a common mechanism. To test this, we monitored the
activation state of the mTOR pathway by assessing levels of phospho- and total AKT,
phospho- and total AMPK, phospho- and total p70S6K, phospho- and total pS6
ribosomal protein, and LC3 in the livers of Par-1 deficient mice during starvation and
upon re-feeding. We did not observe any consistent alterations in the levels or activation
state of these proteins. Curiously, although both AMPK and SIK kinases negatively
regulate lipogenesis via SREBP1c, the phenotypes of Par-1 null mice suggests Par-1 is a
positive regulator for lipogenesis in adipocytes and hepatocytes. The molecular
mechanism underlying the phenotypes of Par-1a null mice will require tissue specific
deletion and identification of specific downstream targets of Par-1a mediating these
effects.
Another major finding of this study is that Par-1b compensates more effectively
for loss of Par-1a than the reverse and that embryonic survival requires the presence of at
least one allele of Par-1a/b. Moreover, the presence of only one Par-1a allele in the
complete absence of Par-1b conveys the most severe phenotype (growth restriction);
supporting the notion of ranked redundancy with the most severe phenotype observed in
the very rare KH (Par-1b-/-/Par-1a+/-) mutant.
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Materials and Methods
Animal Procedures. The Washington University School of Medicine Animal
Studies Committee approved all animal procedures. Unless stated otherwise, animals
were fed a standard chow diet (Purina Mills, St. Louis, MO, Lab Diet 5063 containing
4.5% fat, 55% carbohydrate, 20% protein and 4.7% fiber) and were housed with free
access to food and water under a 12h light/dark cycle. Unless indicated, only male mice
were analyzed throughout this study.
Construction of the Par-1a targeting construct. A Par-1a genomic clone was
isolated from a 129X1/SvJ mouse embryonic (ES) cell genomic library by hybridization
with an isogenic 0.9 kb Par-1a-specific cDNA probe. The genomic organization of the
mouse Par-1a gene was disrupted by replacing a 1.9 kb Sac I/Hpa I fragment with a 1.2
kb neomycin phosphotransferase cassette (Fig. 4.1A). The replacement disrupts exon 2
encoding the ATP binding domain of Par-1a and also destroys the 5’ splice site between
introns 2 and 3. The insertion of the neomycin selection cassette alters the Pst I fragment
from a single 13.8 kb fragment to two fragments of 7.5 and 5.9 kb, and this change was
used to identify targeted ES cell clones and knockout animals by Southern blotting (Fig.
4.1B) using the 5’ and 3’probes indicated in Fig. 4.1A. Using mouse genomic DNA as
template, the 425 bp 5’-probe was amplified by PCR with primers of 5’TGGTGGTACACGCCTGTATTC and 5’-CTGATCTACACAATTCCAGGAC. The 204
bp of 3’-probe was amplified by PCR with primers of 5’GCATCTTGGGCTGTAAGTGATG and 5’-GGCTTACAACCATCTGTACAG.
PCR analysis. PCR of tail DNA/tissues was achieved using a three-primer PCR
reaction with one 5’ primer from exon 2 (5'-GGAGACGGGAGGCAAGAAGTCA), a 3’
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primer from the intronic sequence between exons 2 and 3 (5'GGCTCATTCCCTTGGTGTACTT), and a 3’ primer from the neomycin cassette
(5'GAGCAGCCGATTGTCTGTTGT), resulting in 400 bp (KO) or 300 bp (WT) bands,
respectively (Fig. 4.1C).
Generation of mice harboring the Par-1a mutation. RW4 ES cells were
electroporated with linearized targeting vector and selected with Geneticin (G418;
Invitrogen) using established protocols developed in the Murine Embryonic Stem Cell
Core of the Alvin J. Siteman Cancer Center at Washington University School of
Medicine and Barnes-Jewish Hospital; details available online http://escore.im.wustl.edu.
A total of 96 G418-resistant ES cell clones were analyzed for homologous recombination
by Southern blotting and 3 clones were found to be positive. Positive ES clones were
karyotyped and microinjected into 3.5 dpc C57BL/6 blastocysts, which were
subsequently implanted into the uteri of pseudopregnant C57BL/6 X C3HF1 foster
mothers. Male chimeras selected by percentage of agouti color were mated to C57BL/6
females. Germ line transmission was determined by agouti coat color. F1 animals were
tested for the targeted Par-1a allele by Southern blotting and PCR analysis of tail DNA.
Heterozygous F1 males/females were interbred to generate F2 littermates used for
subsequent breeding and analysis; referred to as wild type (WT), heterozygotes (HET)
and null (KO) pups/mice.
Western blotting. Tissues from wild-type (WT) and knock-out animals were
homogenized in 800 µl of mammalian cell lysis buffer (MCLB: 50 mM Tris-HCl pH 8.0,
5 mM EDTA, 0.1 M NaCl, 0.5% NP40, 2 mM DTT) containing 1 µM microcystin, 1 mM
sodium orthovanadate, 10 mM !-glycerol phosphate, 1 mM sodium fluoride, 2µM PMSF,
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plus protease- (Sigma, St. Louis, MO) and phosphatase-inhibitor cocktails (Calbiochem,
Gibbstown, NJ). Homogenates were rocked for 15 min at 4oC and then clarified twice by
centrifugation. Clarified lysates were resolved by SDS-PAGE on a 10% SDS gel
followed by Western blotting was carried out with antibodies specific to actin (1:4,000,
Sigma Chemical Co.), tubulin (Sigma, 1:1000), !-catenin (1:10,000, BD
Biosciences/Pharmagen) and Par-1a ascites (1:10,000) (Hurov et al., 2004), Glycogen
Synthase (1:1000; Cell Signaling), phospho-Glycogen Synthase (1:1000; Cell Signaling)
and LC-3 (1:1000; Cell Signaling). Par-1b was detected with ascites generated using a
monoclonal antibody produced against KLH-conjugated peptide corresponding to amino
acids 288-307 (PDYKDPRRTELMVSMGYTRE) of human Par-1b. Bound primary
antibodies were detected with horseradish peroxidase (HRP)-conjugated goat anti-mouse
antibody (Jackson, West Grove, PA) and proteins were visualized by chemiluminescence.
Tissue distribution. Distribution of Par-1a and Par-1b in various tissues was
examined using a modified Western blot protocol. In brief, mouse tissues harvested from
~6-month-old mice were homogenizing in 0.8 ml of Mammalian Cell Lysis Buffer (see
above). Lysates were rocked for 15 min at 4oC followed by centrifugation for 10 min at
20,800g. Clarified supernatants were transferred to pre-chilled tubes. Proteins were
resolved by SDS-PAGE on 7.5% gels until the 50 kDa molecular weight marker was at
the bottom of the gel. Proteins were transferred to nitrocellulose membranes in CAPS
buffer (Sigma C2632, St. Louis, MO) 0.1M 3-(cyclohexylamino)-1-propanesulfonic acid
and 10% methanol at 1.2 mA for 1.5 h. Membranes were blocked in 1xTBST (100 mM
Tris pH 8.0, 1.5 M Sodium Chloride, 2% Tween-20) containing 5% milk for 1h.
Membranes were probed with Par-1a ascites (1:10,000), Par-1b ascites (1:1,000), actin
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(1:4,000, Sigma Chemical Co.), or !-catenin antibody (1:30,000) by rocking overnight at
4oC. Membranes were washed 4 times for 13 min each in 1x TBST. Membranes were
then incubated with a goat anti-mouse antibody (dilution 1:30,000; Jackson West Grove,
PA) for 1 h at room temperature. Membranes were then washed 4 times in 1x TBST for
13 min each. Blots were developed using ECL detection reagent (GE Healthcare,
Piscataway, NJ).
Breeding, animal weights and growth measurements. Embryos and pups
generated from heterozygous crosses were weighed and genotyped by PCR analysis. Plug
observation was recorded as 0.5 days post coitis (dpc); embryos were harvested, rinsed
and weighed. Mean body weights at each time point were compiled from at least 6 mice
per genotype. Breeding schemes followed standard protocols and for double-knock-out
(DKO) experiments genotypes are abbreviated by a two-letter code (first letter: Par-1b;
second letter: Par-1a; W=+/+; H=+/-; K=-/-; e.g. HK). Binning and comparison within and
between genotypes via uni- and multivariate analysis tested trends over time. We
assessed number and genotype of litters in 10 superovulated timed pregnancies at 8.5 dpc
and 10.5 dpc. Offspring ratios for Par-1a-/-, Par-1b-/- as well as all genotypes in DKOexperiments were recorded as pups/litter and total number per genotype. Significance of
deviations from expected Mendelian ratios were tested using Chi-square statistics with 2degrees (WT, HET, KO) or 8-degrees of freedom (KK, WW, WK, KW, WH, HW, KH,
HK, HH) in Par-1a null and DKO experiments, respectively (two-tailed P values are
provide).
Metabolic measurements (indirect calorimetry). Metabolic measurements
followed previously established protocols (Bernal-Mizrachi et al., 2002; Hurov et al.,
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2007). Briefly, metabolic characterization included metabolic rate, energy expenditure,
activity, food consumption (in g/day), and body temperature. During data analysis,
energy expenditure and metabolic rate were normalized with respect to body weight.
Energy expenditure and respiratory quotient (RQ) were calculated from the gas exchange
data: RQ as the ratio of VCO2 to VO2, Heat = (3.815 + 1.232 * RQ) * VO2. Activity was
measured on an x- and z-axis using infrared photobeams to count the amount of beam
breaks.
High-fat diet (HFD) studies. HFD studies followed previously published
protocols (Hurov et al., 2007) and consisted of a total of 55 mice. In thirty-five 3-weekold mice (WT, Par-1a-/-, Par-1a-/-) the regular rodent chow diet (CD) was replaced with
Adjusted Calories Diet (42% fat) from Harlan Teklad (88137 ‘Western’ diet; Madison,
WI). The weight of the HFD chow was recorded and food consumption as well as mouse
weight was determined for individual mice on a weekly basis. Although resistance to
weight gain on HFD has been previously reported for Par-1b null mice (Hurov et al.,
2007), for direct comparison and determination of specific organ uptake values, the HFD
experiment included a new group of 9 Par-1b null mice and therefore consisted of six
different trial-groups: WT-CD, WT-HFD, Par-1a-/--CD, Par-1a-/--HFD, Par-1b-/--CD, Par1b-/--HFD. Metabolic profiling after a total diet time of 16 weeks consisted of a) fasting(n=18CD, 35HFD) and fed blood glucose levels (n=6 per genotype, randomly selected);
b) glucose tolerance testing (GTT) on 18 CD-mice (6 per genotype, randomly selected)
and all HFD-mice; c) 18F-FDG-biodistribution experiments (n=19CD, 31HFD), d) organ
weights and e) histologic examination. The HFD-trial was designed to allow at least 24h
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between GTT and 18F-FDG-biodistribution studies, during which animals were kept on
HFD.
Serum Factor Quantification. Serum levels of insulin, triglycerides,
adiponectin, leptin, and cholesterol were determined by Ani Lytics Incorporated
(Gaithersburg, MD; n!11 animals per genotype and sex); glucagon and free fatty acids
were determined according to previously established protocols (Chakravarthy et al.,
2005).
Glucose and insulin measurements and tolerance tests. Randomly fed or
fasted mice were analyzed and blood glucose levels were determined using a "-glucose
photometer and "-glucose cuvettes (HemoCue AB, Angelholm, Sweden) or Accucheck
Advantage glucometer (Roche Diagnostics Corp., Indianapolis, IN). Normoglycemia was
defined as blood glucose values between 90-130 mg/dl. Intraperitoneal (i.p.) glucose
tolerance tests (GTT) were performed on fasted (12 h) animals on CD and all HFD-trial
mice. Mice were injected i.p. with D-glucose (20% solution; 1 g/kg of body weight) and
blood glucose levels were determined at 15, 30, 60, 90 120 min and >24h post injection.
In addition, insulin levels were determined during GTT immediately before, at 15, 30 and
60 min after glucose injection. Therefore, ~20-30 µl of blood were collected using the
Microvette 200 capillary blood collection system (Sarstedt, Newton, NC) and centrifuged
at 30,000 g for 5 min. Fasting serum insulin levels were determined for 50 male mice on
CD (n=24WT, 8Par-1a-/-, 18Par-1b-/-) and 18 randomly selected mice on HFD (n=6 per
genotype) using rat insulin as a standard and ELISA as specified by manufacturer
(Crystal Chem, Inc, IL). Insulin tolerance tests (ITT) were performed on 6-h-fasted male
mice (n=9Par-1a+/+, 9Par-1a-/-). Insulin sensitivity in Par-1b null mice has been reported
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(Hurov et al., 2007) and was not repeated. Blood glucose values were measured
immediately before and at 15 min intervals for a total of 90 min after i.p. injection of
insulin (0.30 IU/kg HumulinR, Eli Lilly and Company, Indianapolis, USA).
MicroPET studies. MicroPET studies entailed imaging of cohorts of male WT
and Par-1a null mice that were repetitively imaged once a week for four consecutive
weeks, each time under a different metabolic condition. Brown adipose tissue (BAT),
skeletal muscle (SM), heart, liver and brain were examined under the following 4
conditions: mice were either fasted overnight or allowed access to CD (non-fasted). The
next morning, either 0.5 unit/kg insulin (Humulin N; Eli Lilly, Indianapolis, IN) or saline
was administered to mice by i.p. injection. Thirty minutes after the injection, mice were
lightly anesthetized with isoflurane followed by a tail vein injection of 18F-FDG (~200500 µCi in saline). Immediately after injection of radiotracer, mice were placed supine in
the microPET scanner (Focus120 or 220 scanner, Concorde MicroSystems, Knoxville,
TN) and imaged (acquisition time: ~10 min; 1 bed position; OSEM reconstruction). Mice
were allowed to recover, then anesthetized and imaged again at 1 h and 2 h post injection
of radiotracer. The Par-1b null and WT mice used for comparison were age matched
males and treated as above except that they were imaged on a R4 scanner (Hurov et al.,
2007). MicroPET images were corrected for decay, but not attenuation or scatter, then
stacked regions-of-interest (ROI) of relevant tissues and organs were analyzed with
AnalyzePC 6.0 software. ROI counts were converted to counts per gram of tissue (nCi/g),
assuming a tissue density of 1 g/ml. Data for accumulation of 18F-FDG on microPET
images were expressed as standard uptake values (SUV), representing counts per gram of
tissue divided by injected dose of radioactivity per gram of animal weight (Sharma et al.,
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2002; Sharma et al., 2005). After statistical analysis using a one-way ANOVA and
Student’s t-tests, comparison between genotypes and experiments was enabled by
normalization of the SUV to the corresponding WT littermates, data for Par-1a and Par1b disrupted mice against their littermate WT as normalized average SUV ± SEM; errors
were propagated (see below).
18

F-FDG biodistribution experiments. As previously reported, white adipose

tissue (WAT) cannot be analyzed by noninvasive microPET imaging (Hurov et al., 2007).
As an alternative we examined glucose-uptake of WAT and other organs by traditional
18

F-FDG biodistribution (Bigott et al., 2005; Cirrito et al., 2005; Kesarwala et al., 2006;

Sharma et al., 2005). Mice were anesthetized with isoflurane (2% vaporized in oxygen),
followed by tail vein injection of 18F-FDG (20 µCi in 100 µl saline). Sixty minutes after
18

F-FDG injections, mice were sacrificed by cervical dislocation (under anesthesia).

Blood, liver, heart, brain, muscle, WAT and BAT were rapidly removed, weighed and
their radioactivity was measured using a Beckman 8000 gamma counter. The percentinjected dose per gram of tissue (% ID/g) was calculated [(tissue µCi) (injected Ci)-1 (g
tissue)-1 x 100] and subsequently compared among tissues, genotypes and diets.
Biodistribution analysis was performed on 31 HFD-mice (17WT; 8Par-1a-/-; 6Par-1b-/-)
and 19 mice from the CD-arm (age-matched control group; total n=50). Tissue samples
from these mice were fresh-frozen and stored at -80oC. Subsequent cryostat sections
confirmed tissues, and allowed histomorphological/ histochemical comparison with
tissues obtained from animals that did not undergo 18F-FDG uptake (n=5; no differences
observed) or HFD (see results). For these HFD-trial biodistribution experiments, the 50
mice were prospectively assigned to one of 9 experimental days with an average of 6
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animals per experiment (range: 3-10 mice/day). Excluding the 16 weeks on HFD (see
above), these experiments were performed over a 10-month-period.
Starvation experiments. Starvation experiments consisted of determination of
blood glucose as well as ketone levels using a MediSense Precision Xtra Diabetes
Glucose and Ketone Monitor System (Abbott, Alameda, CA). After overnight fasting (20
h) measurements were repeated; one group of mice was subjected to extended fasting
(additional four hours) and the other group of mice was given an i.p. injection of 2 mg/g
glucose for 2 h. Tissues were collected at all time points and samples separated for
western blotting, routine histology, electron microscopy and glycogen determination.
Dissection and Histology. Organs were excised, weighed, rinsed in PBS; fixed in
10% neutral-buffered formalin, rinsed in PBS, and stored in 70% ethanol. Formalin fixed
tissues were paraffin embedded (FFPE) and sectioned at (~5 !m) using standard
procedures. For morphologic evaluation and fat content H&E and Oil-red-O staining was
performed on FFPE and fresh-frozen sections (stored at -80oC), respectively.
Morphological analysis was performed using multiple independent samples per site/organ
(13-26 samples per genotype) as well as all 55 animals on the HFD-trial. We quantified
BAT and WAT samples taken from the interscapular and gonadal fat pads, respectively.
Quantification was performed using digital image processing via ImageJ (v. 1.37v
http://rsb.info.nih.gov/ij/) and Photoshop CS3 (Adobe Systems) according to previously
established semi-automatic protocols (Brunt et al., 1999; Gustot et al., 2006). Specifically,
Oil-red-O positivity was quantified on >20 high-power fields, cell number or lipid
vacuoles were quantified on 6-20 randomly chosen images per sample and PAS-staining
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was quantified using integrated density measurements (IntDen: equivalent to the product
of area and mean grey value).
Glycogen determination. Fifty milligrams of liver and skeletal muscle samples
were extracted with 0.9 N perchloric acid and 99% ethanol to precipitate glycogen. The
glycogen from the pellet was dialysed, and digested to free glucose with
amyloglucosidase. Glucose concentrations were measured by the glucose oxidase method
(Glucose Analyzer II; Beckman Instruments, Fullerton, CA).
Electron microscopy (EM). EM was performed according to established
protocols (Schmidt et al., 2009). Tissues were fixed overnight at 4oC in modified
Karnovsky’s fixative containing 3% glutaraldehyde and 1% paraformaldehyde in sodium
cacodylate buffer pH 7.4. After rinsing in sodium cacodylate buffer, samples were
postfixed in phophate cacodylate-buffered 21% OsO4 for 1h, dehydrated in graded
ethanols with a final dehydration in propylene oxide and embedded in Embed-812
(Electron Microscopy Sciences, Hatfield, PA). One-micron thick plastic sections were
examined by light microscopy after staining with toluidine blue. Ultrathin sections (90
nm thick) of individual samples were cut onto formvar coated slot grids, which permit
visualization of larger cross sections. Sections were post stained with uranyl acetate and
Venable’s lead citrate and viewed with a JEOL model 1200EX electron microscope
(JEOL, Tokyo, Japan). Digital images were acquired using the AMT Advantage HR
(Advanced Microscopy Techniques, Danvers, MA). Plastic sections as well as
ultrastructural review was performed blinded to the genotype.
Digitization and image analysis. Analyses were performed using an Olympus
DP70 digital camera (Olympus, Tokyo, Japan) connected to an Olympus BX51 light
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microscope or a Scanscope XT whole slide scanner/ImageScope v10.0.36.1805 (Aperio,
Vista, CA). Image and pixel quantification employed established semiautomatic
threshold algorithms (Lennerz et al., 2008) using the software package ImageJ
[http://rsb.info.nih.gov/ij/; (Abramoff et al., 2004; Rasband, 1997-2007)]. Statistical
testing between groups was performed using Student’s t-test and Wilcoxon two-sample
test.
Statistics. Chi-squared, t-tests (two tailed), the non-parametric alternative MannWhitney U test, 1-way- and 2-way ANOVA, and Bonferroni post-tests to compare
replicate means were used when appropriate. In experiments with small n’s (defined as
n!12) the D’Agostino-Pearson omnibus K2 normality test (D'Agostino, 1986) was used
to approximate Gaussian distribution of values. Therein P values of <0.05 indicate nonGaussian distribution and we assessed these experiments with both parametric and nonparametric tests; both P values are provided when applicable. In all studies, the accepted
level of significance was P<0.05 and data are reported as mean ± SEM. In selected
experiments and for comparison between strains and experiments, values were
normalized to the corresponding WT and errors were propagated according to the
following formula:
" [ (#xɬWT/xɬWT)2 + (#xɬKO/xɬKO)2 ] . xɬNKO

adapted after (Meyer, 1975)

#xɬ = standard error of the mean; xɬ = average; xɬN = normalized average
Error propagation and statistical tests in general were chosen assuming the most
pessimistic situation (Rabinovich, 2000). All data were analyzed using Prism 5.0b
(GraphPad Software Inc., La Jolla, CA) or Microsoft Excel 2008 (Version 12.1.9;
Microsoft Corporation, Redmond WA).
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Fig. 4.1 Targeted disruption of Par-1a in mice and tissue distribution of Par-1a and
Par-1b.
A. Par-1a locus (top), targeting vector (middle) and chromosomal organization after
recombination (bottom). The Par-1a gene was disrupted by insertion of a neomycin (neo)
phosphotransferase cDNA as a selectable marker. Sizes of upstream (2 kb) and
downstream (3.8 kb) homologous arms are indicated (grey boxes), as is exon 2 (open
box). Black boxes indicate positions of the probes for genomic Southern blotting;
triangles depict locations of PCR primers for genotyping. Abbreviations: P=Pst I; B=Bgl
II; S=Sac I; Hp=Hpa I; N=Nco I; H=Hind III. B. Southern blot analysis demonstrating
homologous recombination at the Par-1a locus. Genomic DNA was digested with Pst I
and subjected to Southern blotting using the 5’ and 3’ probes indicated in panel A.
Genotypes are indicated (WT: wild-type mouse; HET: heterozygous, KO: homozygous).
C. PCR analysis of mouse DNA (tail), amplified with 3 PCR primers (a, b, and c) shown
in panel A. The WT-allele produces a 300 bp PCR product and null alleles produce a 400
bp PCR product. D. Western Blot analysis of Par-1a protein in brain lysates prepared
from C57BL/6-mice. E. Tissues from wild-type, Par-1a-/- and Par-1b-/- mice were
isolated. Protein lysates from the indicated tissues were resolved by SDS-PAGE and
subjected to Western blotting for the indicated proteins: Brain (0.2 mg), BAT=brown
adipose tissue (1.1 mg), WAT=white adipose tissue (1.1 mg), colon (0.4 mg),
Stom=stomach (0.4 mg), Thym=thymus (0.4 mg), Test=testis (0.4 mg), SPLN=spleen
(0.4 mg), SKM=skeletal muscle (0.4 mg), Liver (0.13 mg), W=wild-type; K=knock-out.
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Fig. 4.2 Par-1a-/--mice are growth retarded and hypermetabolic.
A. Body weights of mice from birth to 30 weeks of age (n=4-14 per genotype per time
point). B. Body weights at 6 and 20 weeks. Body weights of Par-1a+/+- (black bars),
Par-1a+/-- (striped bars), and Par-1a -/- (open bars) -mice at 6 weeks of age (number of
animals per sex indicated). C. Metabolic rate, D. energy expenditure, E. respiratory
quotients (RQ=VCO2/VO2), and F. food intake in WT- (black bars) and Par-1a null mice
(open bars). G. Insulin tolerance tests were performed by i.p. injection of 0.30 unit/kg
insulin into WT and Par-1a-/--mice (n as indicated); tail bleeds were obtained and
glucose levels were monitored at indicated time points. Glucose levels plotted as % blood
glucose at time 0 before injection.

-145-

-146-

Fig. 4.3 Resistance of Par-1a-/- mice to high-fat diet induced metabolic changes.
A. Body weights during 15 weeks HFD starting at 3 weeks of age in male mice (n per
genotype as indicated; P value designations: **, P<0.005; *, P<0.001). B. Body weight
gain (in %) indicated above weight comparisons of control group (black/white/grey) and
HFD-arm of the trial (red) in 18-week-old male mice. C. Glucose tolerance testing was
performed by i.p. injection of D-glucose at 1mg/g body weight into all genotypes on
chow and high-fat diet (n as indicated). Glucose levels were monitored as indicated and
expressed in % of initial glucose normalized to their littermates on chow; for comparison
a dotted band shows the time course for WT and Par-1a-/- on chow diet. Statistical testing
was performed using original values and P-values are provided for testing between
genotypes on HFD (red) and between WT-HFD vs. WT-CD (black), when significant. D.
Serum insulin levels as determined by ELISA for the first 4 timepoints of the glucose
tolerance test after HFD.
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Fig. 4.4 Reduced adiposity and decreased glucose uptake in Par1a-/- mice.
A. Tissues weights normalized to total body weight in indicated tissues from 18-week old
male WT- (black bar) and Par-1a-/- -mice (open bars) fed with chow diet (black) or HFD
(red; selected tissues); n!7 samples per tissue. Labeling a-e see results. B. Hematoxylin
and eosin (H&E) stain of WAT from Par-1a-/-- and Par-1a+/+-mice; insets, gonadal fat
pads. C. Weight comparisons of WAT between WT, Par-1a-/- and Par-1b-/--mice on
chow (black, white, hatched, respectively) and after 16 weeks of high-fat diet (red);
weights normalized to WT on chow diet. Statistical tests and indicated P values derive
from original weights (provided below bars). D. Invasive biodistribution experiments
following injection of 18F-FDG and dissection of gonadal WAT 1h post-injection; values
expressed as % injected dose per gram of tissue (%ID/g). E. H&E stain of BAT from
Par-1a-/-- and Par-1a+/+-mice; insets, interscapular fat pads. F. Weight comparisons of
BAT between WT, Par-1a-/- and Par-1b-/--mice on chow (black, white, hatched,
respectively) and after 16 weeks of high fat diet (red); weights normalized to WT on
chow diet. Statistical tests and indicated P values derive from original weights (provided
below bars). G. Representative coronal section microPET images of 18F-FDG uptake in
Par-1a-/-- (top) and Par-1b-/--mice (bottom) 1 h after 18F-FDG injection.
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Fig. 4.5 Liver findings in high-fat diet- and starvation experiments.
A. Morphologic comparison of Oil-red-O stained sections shows resistance to hepatic
steatosis in Par-1a-/--mice. Inset: Abundant macrovesicular steatosis. B. Semiautomated
pixel quantification, expressed as percent of Oil-red-O-positive structures (fat) per highpower field (HPF); genotypes, number of animal and diet indicated. C. Periodic acid
Schiff (PAS) staining of liver of 20-week-old WT, Par-1a-/- and Par-1b-/- littermates
following overnight fasting or 2 h after administration of 2 mg/g glucose by i.p. injection.
Images are representative of 96 fields from 8 animals. D. WT-mice show a physiologic
decreased in blood glucose in response to overnight starvation with a nadir at 24 + 4 h
(top) and corresponding increased ketone production (bottom); note restoration of blood
glucose and ketones, 2 h after intraperitoneal glucose injection (2 mg/g). Par-1a-/- mice
show significantly lower blood glucose levels at both timepoints with associated
hypoglycemia at 24 + 4 h. Fasting hypoglycemia is accompanied by a significant
decrease in ketone levels (hypoketotic hypoglycemia). Par-1b-/- mice maintained glucose
levels and exhibited expected lower ketone levels. E. Glycogen content was measured in
livers from 20-week-old Par-1a-/- (open bars), Par-1b-/-(grey bars), and WT (black bars)
littermates following overnight fasting or 2 h after i.p. injection of 2 mg/g glucose.
Tissues were extracted and acid hydrolyzed, and glycosyl units were assayed using an
amyloglucosidase/glucose oxidase method (see Methods). F. Western Blot for glycogen
synthase (GS) and phosphorylated GS (pGS) in overnight fasted liver samples of 4
different animals per genotype; weight markers GS/pGS 100kDa (top), 75kDa (bottom);
actin (37kDa); arrows indicate Par-1a-/- G. Ultrastructureal characterization of liver
tissue from WT (a-c) and Par-1a-/- littermates (d-f) after nutrient starvation for 24 h. Ga.
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Toluidine blue-stained plastic section of starved WT liver at low magnification showing
accumulation of lipid droplets (open arrow) and glycogen (arrow). Gb. Electron
microscopic examination of WT hepatocytes at low-power magnification showing large
number of variable-sized lipid vacuoles (open arrow) and glycogen islands (arrow). Gc.
Detail of cytoplasmic organization with lipid droplets (open arrow) surrounded by
numerous mitochondria (asterisks). Gd. Toluidin blue-stained plastic section of starved
Par-1a-/- at low magnification shows absence of lipid droplets and glycogen. Ge. Electon
microscopic examination of Par-1a-/- hepatocytes at low-power magnification showing
absence of gycogen and lipid vacuoles. Gf. Detailed EM view of cytoplasmic
organization with numerous autophagosomes (arrows) consisting of isolated membranes
surrounding cytosolic material (top: so-called myelin figures; bottom ingested rough
endoplasmic reticulum). Note the close proximity of autophagocytic vacuoles and
mitochondria (asterisk).
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Fig. 4.6 Par-1b-/-/Par-1a-/--double knock-out mice are not viable and breeding
experiments support ranked redundancy between isoforms.
A. Survival analysis of the offspring from matings of double-heterozygous Par-1a/b
mutant mice. The black bars plot the observed frequency of the indicated genotypes as
percentage of the total, whereas the gray background indicates the expected frequency
based on Mendelian inheritance (n=2466). B. Comparison of body weights for five of
the obtained genotypes from B. Weight is normalized to WT-littermates [HK, n=6 mice
at 15-20 weeks vs. control WT (n=6); KH (E17dpc) n=12 vs. age-matched control WT
(n=8; from same litter)].
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Table 4.1 Multifunctionality of Par-1-Polarity Kinase Pathways

A. Regulators
LKB1

Function (‘upstream’)

Reference

Wnt-signaling; Peutz-Jeghers syndrome, Insulin signal transduction, pattern formation

(Alessi, 2001;

Lizcano et al., 2004; Spicer et al., 2003)
TAO1

MEK3/p38 stress-responsive mitogen-activated protein (MAP) kinase pathway

MARKK

Nerve growth factor signaling in neurite development and differentiation

aPKC

(Hutchison et al., 1998)
(Timm et al., 2003)

2+

Ca /DAG-independent signal transduction, cell polarity, glucose metabolism

(Brajenovic et al.,

2004; Goransson et al., 2006; He et al., 2009; Hurov et al., 2004; Kusakabe and Nishida, 2004; Ossipova et al., 2005; Suzuki et al.,
2004)
nPKC/PKD

DAG-dependent, Ca2+-independent signal transduction (GPCR)

(Watkins et al., 2008)

PAR-3/PAR-6/aPKC (-) regulates Par-1; assembly of microtubules, axon-dendrite specification

(Chen et al., 2006)

GSK3!

(Kosuga et al., 2005;

(-) tau-phosphorylation; Alzheimer’s dementia; energy metabolism, body patterning

Timm et al., 2008)
Pim-1 oncogene

(-) G2/M checkpoint; effector of cytokine signaling and Jak/STAT(3/5)

CaMKI

(-) Ca2+-dependent signal transduction; neuronal differentiation

B. Substrates
Cdc25C

(Bachmann et al., 2004)
(Uboha et al., 2007)

Function (‘downstream’)

Reference

Regulation of mitotic entry by activation of the cdc2-cyclin B complex

(Dalal et al., 1999;

Ogg et al., 1994; Peng et al., 1998; Zhang et al., 1997)
Class II HDAC

Control of gene expression and master regulator of subcellular trafficking

(Dequiedt et al., 2006;

Kao et al., 2001)
CRTC2/TORC2

Gluconeogenesis regulator via LKB1/AMPK/TORC2 signaling, PPAR"1a coactivator

Dlg/PSD-95

Synaptogenesis and neuromuscular junction; tumor suppressor

(Jansson et al., 2008)
(Woods and Bryant,

1991)(Zhang et al., 2007)
Disheveled

Wnt-signaling; translocation of Dsh from cytoplasmic vesicles to cortex

(Ossipova et al., 2005; Sun et al.,

2001)
KSR1

Regulation of the Ras-MAPK pathway

(Muller et al., 2001; Muller et al., 2003)

MAP2/4/TAU

‘Dynamic instability’ (Mitchison and Kirschner, 1984; Sammak and Borisy, 1988) of microtubules;

Alzheimer’s dementia (Drewes, 2004) (Biernat et al., 2002; Drewes et al., 1998; Drewes et al., 1997; Drewes et al., 1995; Illenberger
et al., 1996; Murphy et al., 2007; Tian and Deng, 2009)
Mib/Notch

Mind bomb (Mib) degradation and repression of Notch signaling = neurogenesis

2009; Ossipova et al., 2005; Rubio-Aliaga et al., 2007)
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(Krahn and Wodarz,

Par3/OSKAR/Lgl

Cytoplasmic protein segregation, cell polarity and asymmetric cell division

(Benton et al., 2002;

Betschinger et al., 2003)
Pkp2

Desmosome assembly and organization; nuclear shuttling

(Muller et al., 2001; Muller et al., 2003)

PTPH1

Linkage between Ser-/Thr- and Tyr-phosphorylation dependent signaling

(Zhang et al., 1997)

Rab11-FIP

Regulation of endocytosis (Cullis et al., 2002); trafficking of E-cadherin

(Ducharme et al., 2006)

LKB1 also known as Par-4; MARKK also known as Ste20-like; (-): inhibitory/negative regulation has been
shown; GPCR: G-protein coupled receptors; MARKK is highly homologous to the thousand and one amino
acid kinase (TAO-1) (Hutchison et al., 1998)
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Table 4.2 Terminology and Localization of the Mammalian Par-1 Family Members
Synonyms

Subcellular localization

Par-1a, MARK3, C-TAK1, p78/KP78, 1600015G02Rik,
A430080F22Rik, Emk2, ETK-1, KIAA4230,

basolateral1/apical2

mKIAA1860, mKIAA4230, M80359
Par-1b, EMK, MARK2, AU024026, mKIAA4207

basolateral

Par1c, MARK1

basolateral
not asymmetric3

Par1d, MARK4, MARKL1

Par: partitioning defective [not to be confused with protease-activated receptor 1 (PAR1;
(Di Serio et al., 2007)]; C-TAK1: Cdc twenty-five C-associated kinase 1; MARK:
microtubule affinity regulating kinase; MARKL: MAP/microtubule affinity-regulating
kinase like 1; 1to a lesser degree in comparison to Par-1b (Goransson et al., 2006);
2

human KP78 is asymmetrically localized to the apical surface epithelial cells (Parsa,

1988); 3variant that does not show asymmetric localization in epithelial cells when
overexpressed (Suzuki et al., 2004).
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Table 4.3 Metabolic characteristics of Wild-type (WT), Par-1a-/- and Par-1b-/animals.
Insulin

Glucagon

Leptin

Adiponectin

ng/ml

pg/ml

ng/ml

µg/ml
Male

Female

Triglyceride
s
mg/dl

Cholesterol

NEFA

mg/dl

µmol/liter

WT

0.65 ±
0.10

45.5 ±
11.7

3.68 ±
0.26

9.8 ± 0.66$

17.9 ± 1.7

74.9 ± 3.46

83.27 ± 2.4

1303 ±
65.8

Par-1a-

0.61 ±
0.08
0.74

31 ± 4.33

3.64 ±
0.16
0.79

16.5 ± 1.6

18.4 ± 2.2

73.1 ± 3.77

1329 ± 107

0.0008*

0.87

0.74

74.95 ±
2.87
0.03*

0.37 ±
0.04
0.04

34 ± 2.25

3.02 ±
0.16
0.16

11.4 ± 1.3

11.7 ±
0.84
0.005*

62.2 ± 3.39

73.45 ±
2.81
0.011*

1149 ± 66.3

/-

P=

Par-1b/-

P=

0.27

0.39

0.28

0.013*

0.84

0.11

Twenty-week-old mice on regular chow diet were fasted overnight (n!11 per genotype;
all male, unless otherwise indicated); serum values are expressed as the mean ± SEM of
measurements obtained. P represents P value of Student’s t tests comparing Par-1 mice
with WT (asterisk indicates significance). $indicates significantly lower adiponectin
levels in male mice (P=0.0003); note: this gender difference is lost in both Par-1 mice;
NEFA: non-esterified fatty acids.

-158-

References
Abramoff, M. D., Magelhaes, P. J., and Ram, S. J. (2004). Image processing with Image J.
Biophotonics International 11, 36-42.
Alessi, D. R. (2001). Discovery of PDK1, one of the missing links in insulin signal
transduction. Colworth Medal Lecture. Biochem Soc Trans 29, 1-14.
Argiles, J. M., Lopez-Soriano, F. J., and Busquets, S. (2007). Mechanisms to explain
wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care 1, 293-298.
Arimura, N., and Kaibuchi, K. (2007). Neuronal polarity: from extracellular signals to
intracellular mechanisms. Nat Rev Neurosci 8, 194-205.
Bachmann, M., Hennemann, H., Xing, P. X., Hoffmann, I., and Moroy, T. (2004). The
oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of
Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle
checkpoint. J Biol Chem 279, 48319-48328.
Banks, L., and Humbert, P. O. (2008). On the guardians of polarity and the disorientation
of cancer. Oncogene 27, 6876-6877.
Benton, R., Palacios, I. M., and St Johnston, D. (2002). Drosophila 14-3-3/PAR-5 is an
essential mediator of PAR-1 function in axis formation. Dev Cell 3, 659-671.
Bernal-Mizrachi, C., Weng, S., Li, B., Nolte, L. A., Feng, C., Coleman, T., Holloszy, J.
O., and Semenkovich, C. F. (2002). Respiratory uncoupling lowers blood pressure
through a leptin-dependent mechanism in genetically obese mice. Arterioscler Thromb
Vasc Biol 22, 961-968.
Bessone, S., Vidal, F., Le Bouc, Y., Epelbaum, J., Bluet-Pajot, M.-T., and Darmon, M.
(1999). EMK Protein Kinase-Null Mice: Dwarfism and Hypofertility Associated with
Alterations in the Somatotrope and Prolactin Pathways. Developmental Biology 214, 87101.
Betschinger, J., Mechtler, K., and Knoblich, J. A. (2003). The Par complex directs
asymmetric cell division by phosphorylating the cytoskeletal protein Lgl. Nature 422,
326-330.
Biernat, J., Wu, Y. Z., Timm, T., Zheng-Fischhofer, Q., Mandelkow, E., Meijer, L., and
Mandelkow, E. M. (2002). Protein kinase MARK/PAR-1 is required for neurite
outgrowth and establishment of neuronal polarity. Mol Biol Cell 13, 4013-4028.
Bigott, H. M., Prior, J. L., Piwnica-Worms, D. R., and Welch, M. J. (2005). Imaging
multidrug resistance P-glycoprotein transport function using microPET with technetium94m-sestamibi. Mol Imaging 4, 30-39.

-159-

Bradbury, M. W. (2006). Lipid metabolism and liver inflammation. I. Hepatic fatty acid
uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 290, G194-198.
Brajenovic, M., Joberty, G., Kuster, B., Bouwmeester, T., and Drewes, G. (2004).
Comprehensive proteomic analysis of human Par protein complexes reveals an
interconnected protein network. J Biol Chem 279, 12804-12811.
Bronisz, A., Sharma, S. M., Hu, R., Godlewski, J., Tzivion, G., Mansky, K. C., and
Ostrowski, M. C. (2006). Microphthalmia-associated transcription factor interactions
with 14-3-3 modulate differentiation of committed myeloid precursors. Mol Biol Cell 17,
3897-3906.
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., and Bacon,
B. R. (1999). Nonalcoholic steatohepatitis: a proposal for grading and staging the
histological lesions. Am J Gastroenterol 94, 2467-2474.
Chakravarthy, M. V., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J. G., Coleman, T., Turk,
J., and Semenkovich, C. F. (2005). "New" hepatic fat activates PPARalpha to maintain
glucose, lipid, and cholesterol homeostasis. Cell Metab 1, 309-322.
Chen, Y. M., Wang, Q. J., Hu, H. S., Yu, P. C., Zhu, J., Drewes, G., Piwnica-Worms, H.,
and Luo, Z. G. (2006). Microtubule affinity-regulating kinase 2 functions downstream of
the PAR-3/PAR-6/atypical PKC complex in regulating hippocampal neuronal polarity.
Proc Natl Acad Sci U S A 103, 8534-8539.
Cirrito, J. R., Deane, R., Fagan, A. M., Spinner, M. L., Parsadanian, M., Finn, M. B.,
Jiang, H., Prior, J. L., Sagare, A., Bales, K. R., et al. (2005). P-glycoprotein deficiency at
the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse
model. J Clin Invest 115, 3285-3290.
Cline, G. W., Rothman, D. L., Magnusson, I., Katz, L. D., and Shulman, G. I. (1994).
13C-nuclear magnetic resonance spectroscopy studies of hepatic glucose metabolism in
normal subjects and subjects with insulin-dependent diabetes mellitus. J Clin Invest 94,
2369-2376.
Corbett, M. A., Robinson, C. S., Dunglison, G. F., Yang, N., Joya, J. E., Stewart, A. W.,
Schnell, C., Gunning, P. W., North, K. N., and Hardeman, E. C. (2001). A mutation in
alpha-tropomyosin(slow) affects muscle strength, maturation and hypertrophy in a mouse
model for nemaline myopathy. Hum Mol Genet 10, 317-328.
Cullis, D. N., Philip, B., Baleja, J. D., and Feig, L. A. (2002). Rab11-FIP2, an adaptor
protein connecting cellular components involved in internalization and recycling of
epidermal growth factor receptors. J Biol Chem 277, 49158-49166.
D'Agostino, R. B. (1986). Tests for Normal Distribution. In Goodness-of-fit techniques,
R. B. D'Agostino, and M. A. Stephens, eds. (New York, M. Dekker), pp. xviii, 560 p.

-160-

Dalal, S. N., Schweitzer, C. M., Gan, J., and Decaprio, J. (1999). Cytoplasmic
localization of human Cdc25C during interphase requires an intact 14-3-3 binding site.
Mol Cell Biol 19, 4465-4479.
DeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., and Felber, J. P. (1981).
The effect of insulin on the disposal of intravenous glucose. Results from indirect
calorimetry and hepatic and femoral venous catheterization. Diabetes 30, 1000-1007.
Dequiedt, F., Martin, M., Von Blume, J., Vertommen, D., Lecomte, E., Mari, N., Heinen,
M. F., Bachmann, M., Twizere, J. C., Huang, M. C., et al. (2006). New role for hPar-1
kinases EMK and C-TAK1 in regulating localization and activity of class IIa histone
deacetylases. Mol Cell Biol 26, 7086-7102.
Di Serio, C., Pellerito, S., Duarte, M., Massi, D., Naldini, A., Cirino, G., Prudovsky, I.,
Santucci, M., Geppetti, P., Marchionni, N., et al. (2007). Protease-activated receptor 1selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a
protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol 101,
63-69.
Drewes, G. (2004). MARKing tau for tangles and toxicity. Trends Biochem Sci 29, 548555.
Drewes, G., Ebneth, A., and Mandelkow, E. M. (1998). MAPs, MARKs and microtubule
dynamics. Trends Biochem Sci 23, 307-311.
Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E.-M., and Mandelkow, E. (1997).
MARK, a novel family of protein kinases that phosphorylate microtubule-associated
proteins and trigger microtubule disruption. Cell 89, 297-308.
Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., Meyer, H. E.,
Mandelkow, E. M., and Mandelkow, E. (1995). Microtubule-associated
protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that
regulates tau-microtubule interactions and dynamic instability by phosphorylation at the
Alzheimer-specific site serine 262. J Biol Chem 270, 7679-7688.
Ducharme, N. A., Hales, C. M., Lapierre, L. A., Ham, A. J., Oztan, A., Apodaca, G., and
Goldenring, J. R. (2006). MARK2/EMK1/Par-1Balpha phosphorylation of Rab11-family
interacting protein 2 is necessary for the timely establishment of polarity in Madin-Darby
canine kidney cells. Mol Biol Cell 17, 3625-3637.
Fu, A., Ng, A. C., Depatie, C., Wijesekara, N., He, Y., Wang, G. S., Bardeesy, N., Scott,
F. W., Touyz, R. M., Wheeler, M. B., and Screaton, R. A. (2009). Loss of Lkb1 in adult
beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 10,
285-295.

-161-

Geldner, N. (2009). Cell polarity in plants: a PARspective on PINs. Curr Opin Plant Biol
12, 42-48.
Goransson, O., Deak, M., Wullschleger, S., Morrice, N. A., Prescott, A. R., and Alessi, D.
R. (2006). Regulation of the polarity kinases PAR-1/MARK by 14-3-3 interaction and
phosphorylation. J Cell Sci 119, 4059-4070.
Granot, Z., Swisa, A., Magenheim, J., Stolovich-Rain, M., Fujimoto, W., Manduchi, E.,
Miki, T., Lennerz, J. K., Stoeckert, C. J., Jr., Meyuhas, O., et al. (2009). LKB1 regulates
pancreatic beta cell size, polarity, and function. Cell Metab 10, 296-308.
Gustot, T., Lemmers, A., Moreno, C., Nagy, N., Quertinmont, E., Nicaise, C.,
Franchimont, D., Louis, H., Deviere, J., and Le Moine, O. (2006). Differential liver
sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology
43, 989-1000.
He, L., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., Radovick, S., and
Wondisford, F. E. (2009). Metformin and insulin suppress hepatic gluconeogenesis
through phosphorylation of CREB binding protein. Cell 137, 635-646.
Hegarty, B. D., Turner, N., Cooney, G. J., and Kraegen, E. W. (2009). Insulin resistance
and fuel homeostasis: the role of AMP-activated protein kinase. Acta Physiol (Oxf) 196,
129-145.
Hurov, J., and Piwnica-Worms, H. (2007). The Par-1/MARK family of protein kinases:
from polarity to metabolism. Cell Cycle 6, 1966-1969.
Hurov, J. B., Huang, M., White, L. S., Lennerz, J., Choi, C. S., Cho, Y. R., Kim, H. J.,
Prior, J. L., Piwnica-Worms, D., Cantley, L. C., et al. (2007). Loss of the Par-1b/MARK2
polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin
hypersensitivity in vivo. Proc Natl Acad Sci U S A 104, 5680-5685.
Hurov, J. B., Stappenbeck, T. S., Zmasek, C. M., White, L. S., Ranganath, S. H., Russell,
J. H., Chan, A. C., Murphy, K. M., and Piwnica-Worms, H. (2001). Immune system
dysfunction and autoimmune disease in mice lacking Emk (Par-1) protein kinase. Mol
Cell Biol 21, 3206-3219.
Hurov, J. B., Watkins, J. L., and Piwnica-Worms, H. (2004). Atypical PKC
phosphorylates PAR-1 kinases to regulate localization and activity. Curr Biol 14, 736741.
Hutchison, M., Berman, K. S., and Cobb, M. H. (1998). Isolation of TAO1, a protein
kinase that activates MEKs in stress-activated protein kinase cascades. J Biol Chem 273,
28625-28632.

-162-

Illenberger, S., Drewer, G., Trinczek, B., Biernat, J., Meyer, H. E., Olmsted, J. B.,
Mandelkow, E.-M., and Mandelkow, E. (1996). Phosphorylation of microtubuleassociated proteins MAP2 and MAP4 by the protein kinase p110mark. J Biol Chem 271,
10834-10843.
Jansen, M., de Leng, W. W., Baas, A. F., Myoshi, H., Mathus-Vliegen, L., Taketo, M. M.,
Clevers, H., Giardiello, F. M., and Offerhaus, G. J. (2006). Mucosal prolapse in the
pathogenesis of Peutz-Jeghers polyposis. Gut 55, 1-5.
Jansson, D., Ng, A. C., Fu, A., Depatie, C., Al Azzabi, M., and Screaton, R. A. (2008).
Glucose controls CREB activity in islet cells via regulated phosphorylation of TORC2.
Proc Natl Acad Sci U S A 105, 10161-10166.
Kao, G. D., McKenna, W. G., and Yen, T. J. (2001). Detection of repair activity during
the DNA damage-induced G2 delay in human cancer cells. Oncogene 20, 3486-3496.
Kato, T., Satoh, S., Okabe, H., Kitahara, O., Ono, K., Kihara, C., Tanaka, T., Tsunoda, T.,
Yamaoka, Y., Nakamura, Y., and Furukawa, Y. (2001). Isolation of a novel human gene,
MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis.
Neoplasia 3, 4-9.
Kemphues, K. J., Priess, J. R., Morton, D. G., and Cheng, N. (1988). Identification of
genes required for cytoplasmic localization in early embryos of C. elegans. Cell 52, 311320.
Kesarwala, A. H., Prior, J. L., Sun, J., Harpstrite, S. E., Sharma, V., and Piwnica-Worms,
D. (2006). Second-generation triple reporter for bioluminescence, micro-positron
emission tomography, and fluorescence imaging. Mol Imaging 5, 465-474.
Kosuga, S., Tashiro, E., Kajioka, T., Ueki, M., Shimizu, Y., and Imoto, M. (2005). GSK3beta directly phosphorylates and activates MARK2/PAR-1. J Biol Chem 280, 4271542722.
Kotoulas, O. B., Kalamidas, S. A., and Kondomerkos, D. J. (2004). Glycogen autophagy.
Microsc Res Tech 64, 10-20.
Kotoulas, O. B., Kalamidas, S. A., and Kondomerkos, D. J. (2006). Glycogen autophagy
in glucose homeostasis. Pathol Res Pract 202, 631-638.
Krahn, M. P., and Wodarz, A. (2009). Notch signaling: linking delta endocytosis and cell
polarity. Dev Cell 17, 153-154.
Krummel, M. F., and Macara, I. (2006). Maintenance and modulation of T cell polarity.
Nat Immunol 7, 1143-1149.

-163-

Kusakabe, M., and Nishida, E. (2004). The polarity-inducing kinase Par-1 controls
Xenopus gastrulation in cooperation with 14-3-3 and aPKC. Embo J 23, 4190-4201.
Lennerz, J. K., Hurov, J. B., White, L. S., Lewandowski, K. T., Prior, J. L., Planer, G. J.,
Gereau, R. W. t., Piwnica-Worms, D., Schmidt, R. E., and Piwnica-Worms, H. (2010).
Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic
steatosis, and defective gluconeogenesis. Molecular and cellular biology 30, 5043-5056.
Lennerz, J. K., Ruhle, V., Ceppa, E. P., Neuhuber, W. L., Bunnett, N. W., Grady, E. F.,
and Messlinger, K. (2008). Calcitonin receptor-like receptor (CLR), receptor activitymodifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP)
immunoreactivity in the rat trigeminovascular system: differences between peripheral and
central CGRP receptor distribution. J Comp Neurol 507, 1277-1299.
Lin, J., Hou, K. K., Piwnica-Worms, H., and Shaw, A. S. (2009). The polarity protein
Par1b/EMK/MARK2 regulates T cell receptor-induced microtubule-organizing center
polarization. J Immunol 183, 1215-1221.
Lindsey, K. (2004). Polarity in plants (Oxford, Blackwell).
Lizcano, J. M., Goransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley,
S. A., Udd, L., Makela, T. P., Hardie, D. G., and Alessi, D. R. (2004). LKB1 is a master
kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. Embo
J 23, 833-843.
Martin, S. G., and St Johnston, D. (2003). A role for Drosophila LKB1 in anteriorposterior axis formation and epithelial polarity. Nature 421, 379-384.
Meyer, S. L. (1975). Data analysis for scientists and engineers (New York,, Wiley).
Mitchison, T., and Kirschner, M. (1984). Dynamic instability of microtubule growth.
Nature 312, 237-242.
Muller, J., Ory, S., Copeland, T., Piwnica-Worms, H., and Morrison, D. K. (2001). CTAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell 8,
983-993.
Muller, J., Ritt, D. A., Copeland, T. D., and Morrison, D. K. (2003). Functional analysis
of C-TAK1 substrate binding and identification of PKP2 as a new C-TAK1 substrate.
Embo J 22, 4431-4442.
Murphy, J. M., Korzhnev, D. M., Ceccarelli, D. F., Briant, D. J., Zarrine-Afsar, A.,
Sicheri, F., Kay, L. E., and Pawson, T. (2007). Conformational instability of the MARK3
UBA domain compromises ubiquitin recognition and promotes interaction with the
adjacent kinase domain. Proc Natl Acad Sci U S A 104, 14336-14341.

-164-

Nance, J. (2005). PAR proteins and the establishment of cell polarity during C. elegans
development. Bioessays 27, 126-135.
Ogg, S., Gabrielli, B., and Piwnica-Worms, H. (1994). Purification of a serine kinase that
associates with and phosphorylates human Cdc25C on serine 216. J Biol Chem 269,
30461-30469.
Ossipova, O., Dhawan, S., Sokol, S., and Green, J. B. (2005). Distinct PAR-1 proteins
function in different branches of Wnt signaling during vertebrate development. Dev Cell
8, 829-841.
Parsa, I. (1988). Loss of a Mr 78,000 marker in chemically induced transplantable
carcinomas and primary carcinoma of human pancreas. Cancer Res 48, 2265-2272.
Parsons, D. W., Wang, T. L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L.,
Silliman, N., Ptak, J., Szabo, S., Willson, J. K., et al. (2005). Colorectal cancer: mutations
in a signalling pathway. Nature 436, 792.
Peng, C. Y., Graves, P. R., Ogg, S., Thoma, R. S., Byrnes, M. J., 3rd, Wu, Z., Stephenson,
M. T., and Piwnica-Worms, H. (1998). C-TAK1 protein kinase phosphorylates human
Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell Growth Differ 9, 197208.
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton,
K. D., Lindner, J., Cherrington, A. D., and Magnuson, M. A. (1999). Dual roles for
glucokinase in glucose homeostasis as determined by liver and pancreatic beta cellspecific gene knock-outs using Cre recombinase. J Biol Chem 274, 305-315.
Rabinovich, S. G. (2000). Measurement errors and uncertainties : theory and practice,
2nd edn (New York, AIP Press).
Rasband, W. (1997-2007). ImageJ. US National Institutes of Health Bethesda, MD,
(http://rsb.info.nih.gov.ezp-prod1.hul.harvard.edu/ij/).
Rubio-Aliaga, I., Soewarto, D., Wagner, S., Klaften, M., Fuchs, H., Kalaydjiev, S., Busch,
D. H., Klempt, M., Rathkolb, B., Wolf, E., et al. (2007). A genetic screen for modifiers of
the delta1-dependent notch signaling function in the mouse. Genetics 175, 1451-1463.
Saadat, I., Higashi, H., Obuse, C., Umeda, M., Murata-Kamiya, N., Saito, Y., Lu, H.,
Ohnishi, N., Azuma, T., Suzuki, A., et al. (2007). Helicobacter pylori CagA targets
PAR1/MARK kinase to disrupt epithelial cell polarity. Nature 447, 330-333.
Sammak, P. J., and Borisy, G. G. (1988). Direct observation of microtubule dynamics in
living cells. Nature 332, 724-726.

-165-

Sanoudou, D., Corbett, M. A., Han, M., Ghoddusi, M., Nguyen, M. A., Vlahovich, N.,
Hardeman, E. C., and Beggs, A. H. (2006). Skeletal muscle repair in a mouse model of
nemaline myopathy. Hum Mol Genet 15, 2603-2612.
Schmidt, R. E., Green, K. G., Snipes, L. L., and Feng, D. (2009). Neuritic dystrophy and
neuronopathy in Akita (Ins2(Akita)) diabetic mouse sympathetic ganglia. Exp Neurol 216,
207-218.
Segu, L., Pascaud, A., Costet, P., Darmon, M., and Buhot, M. C. (2006). Impairment of
spatial learning and memory in ELKL Motif Kinase1 (EMK1/MARK2) knockout mice.
Neurobiol Aging.
Sharma, V., Luker, G. D., and Piwnica-Worms, D. (2002). Molecular imaging of gene
expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 16,
336-351.
Sharma, V., Prior, J. L., Belinsky, M. G., Kruh, G. D., and Piwnica-Worms, D. (2005).
Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 Pglycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the
blood-brain barrier. J Nucl Med 46, 354-364.
Shin, K., Fogg, V. C., and Margolis, B. (2006). Tight junctions and cell polarity. Annu
Rev Cell Dev Biol 22, 207-235.
Shulman, G. I., Cline, G., Schumann, W. C., Chandramouli, V., Kumaran, K., and
Landau, B. R. (1990). Quantitative comparison of pathways of hepatic glycogen repletion
in fed and fasted humans. Am J Physiol 259, E335-341.
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K.,
Cuervo, A. M., and Czaja, M. J. (2009). Autophagy regulates lipid metabolism. Nature
458, 1131-1135.
Sitnick, M., Bodine, S. C., and Rutledge, J. C. (2009). Chronic high fat feeding attenuates
load-induced hypertrophy in mice. J Physiol 587, 5753-5765.
Sodha, N., Bullock, S., Taylor, R., Mitchell, G., Guertl-Lackner, B., Williams, R. D.,
Bevan, S., Bishop, K., McGuire, S., Houlston, R. S., and Eeles, R. A. (2002). CHEK2
variants in susceptibility to breast cancer and evidence of retention of the wild type allele
in tumours. Br J Cancer 87, 1445-1448.
Spicer, J., Rayter, S., Young, N., Elliott, R., Ashworth, A., and Smith, D. (2003).
Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome
kinase LKB1. Oncogene 22, 4752-4756.

-166-

Sun, T. Q., Lu, B., Feng, J. J., Reinhard, C., Jan, Y. N., Fantl, W. J., and Williams, L. T.
(2001). PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt
signalling. Nat Cell Biol 3, 628-636.
Suzuki, A., Hirata, M., Kamimura, K., Maniwa, R., Yamanaka, T., Mizuno, K.,
Kishikawa, M., Hirose, H., Amano, Y., Izumi, N., et al. (2004). aPKC acts upstream of
PAR-1b in both the establishment and maintenance of mammalian epithelial polarity.
Curr Biol 14, 1425-1435.
Tian, A. G., and Deng, W. M. (2009). Par-1 and Tau regulate the anterior-posterior
gradient of microtubules in Drosophila oocytes. Dev Biol 327, 458-464.
Timm, T., Balusamy, K., Li, X., Biernat, J., Mandelkow, E., and Mandelkow, E. M.
(2008). Glycogen synthase kinase (GSK) 3beta directly phosphorylates Serine 212 in the
regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2. J Biol
Chem 283, 18873-18882.
Timm, T., Li, X. Y., Biernat, J., Jiao, J., Mandelkow, E., Vandekerckhove, J., and
Mandelkow, E. M. (2003). MARKK, a Ste20-like kinase, activates the polarity-inducing
kinase MARK/PAR-1. Embo J 22, 5090-5101.
Uboha, N. V., Flajolet, M., Nairn, A. C., and Picciotto, M. R. (2007). A calcium- and
calmodulin-dependent kinase Ialpha/microtubule affinity regulating kinase 2 signaling
cascade mediates calcium-dependent neurite outgrowth. J Neurosci 27, 4413-4423.
Wang, C., You, Z. L., Xia, Q., Xiong, T., Xia, Y., and Yao, D. Z. (2007). Upregulation of
Mark3 and Rpgrip1 mRNA expression by jujuboside A in mouse hippocampus. Acta
Pharmacol Sin 28, 334-338.
Watkins, J. L., Lewandowski, K. T., Meek, S. E., Storz, P., Toker, A., and PiwnicaWorms, H. (2008). Phosphorylation of the Par-1 polarity kinase by protein kinase D
regulates 14-3-3 binding and membrane association. Proc Natl Acad Sci U S A 105,
18378-18383.
Woods, D. F., and Bryant, P. J. (1991). The discs-large tumor suppressor gene of
Drosophila encodes a guanylate kinase homolog localized at septate junctions. Cell 66,
451-464.
Zhang, S. H., Kobayashi, R., Graves, P. R., Piwnica-Worms, H., and Tonks, N. K. (1997).
Serine phosphorylation-dependent association of the band 4.1-related protein-tyrosine
phosphatase PTPH1 with 14-3-3beta protein. J Biol Chem 272, 27281-27287.
Zhang, Y., Guo, H., Kwan, H., Wang, J. W., Kosek, J., and Lu, B. (2007). PAR-1 kinase
phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila
neuromuscular junction. Neuron 53, 201-215.

-167-
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Fig. 4.S1 UCP2 and LC3 protein levels in livers from mice on high fat diet and
overnight starvation.
Western blot for UCP2 (A.) and LC3 (B.) in overnight fasted liver samples of four
different animals per genotype. Weight markers: UCP2, 30kDa; LC3, 15 kDa; actin,
37 kDa.
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CHAPTER 5
Summary, Discussion, and Future Directions
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Summary
Establishing and maintaining cellular polarity are critical for the homeostasis of
unicellular and multicellular organisms. The major goal of my thesis work was to
investigate functional interactions between the Par-1b protein kinase and the RNF41 E3
ubiquitin ligase. Atypical Protein Kinase C (aPKC) phosphorylates Par-1b on a
conserved threonine residue (T595), and I participated in studies demonstrating that novel
Protein Kinase C (nPKC) activates Protein Kinase D (PKD) to directly phosphorylate
Par-1b on serine 400 (S400), a residue that is conserved in all four mammalian Par-1
kinases as well as the fly ortholog. Phosphorylation of Par-1b on T595 and S400 causes
Par-1b to relocate from membranes to the cytosol and to bind 14-3-3 proteins. In 2004,
Brajenovic, et al. isolated human Par-1d along with associated proteins using tandem
affinity purification (TAP) (Brajenovic et al., 2004). Nrdp1/RNF41, a RING finger E3
ligase was identified in their screen along with 14-3-3 and aPKC. I found that Par-1b
also binds to RNF41 and identified RNF41 as a novel cell polarity determinant. I also
showed that Par-1b phosphorylates RNF41 on S254 both in vitro and in vivo. My work
has demonstrated that phosphorylation of RNF41 on S254 by Par-1b is necessary for
establishing epithelial apical-basal cell polarity.

Discussion
Cell polarity is a structural and functional specialization whose significance is
ubiquitous throughout biology. It is especially common across phyla, thus reflecting a
fundamental requirement to localize different cellular components to distinct regions of a
cell, especially when individual cells come together to form complex multicellular tissues.
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The specialized domains of plasma membrane that result from polarization determine cell
orientation, function, and fate. For example, cell polarization enables long-range
communication in the immune system, transport of ions across epithelial cells, and nichespecific orientation of stem-cell division, which specifies the developmental fate of
daughter cells (Mellman and Nelson, 2008).
Par-1b/MARK2 is essential in the establishment of polarity. In the early C.
elegans embryo, mutation of Par-1, among several other partitioning proteins, disrupts
asymmetric divisions, blastomere fates, localization of P granules, and mitotic spindle
orientation (Kemphues et al., 1988; Kirby et al., 1990). Some Par-1 mutants have
mutations in their kinase domain, suggesting that kinase activity of Par-1 is necessary to
establish polarity (Guo and Kemphues, 1995). Additionally overexpression of Par1b/MARK2 in MDCK cells inhibits apical-basolateral polarization by altering apical
protein transport (Cohen and Musch, 2003).
My thesis work has helped identify and investigate a new phosphorylation site
(S400) on Par-1b (Watkins et al., 2008). This work demonstrated that phosphorylation
on S400 is upregulated with the PKC activator phorbol-12-myristate-13-acetate (PMA)
stimulation. PMA activates nPKC, which then phosphorylates PKD. PKD subsequently
phosphorylates Par-1b on S400. Par-1b is phosphorylated through two arms of the PKC
pathway on T595 and S400 and phosphorylation regulates Par-1b localization and
binding to cytoplasmic 14-3-3/Par-5 proteins (Hurov et al., 2004; Watkins et al., 2008).
Moreover, our studies using polarized breast epithelial cells (MCF-10A) grown in threedimensional (3D) culture, we observed enhanced phosphorylation of Par-1b on both S400
and T595 in 3D cultures relative to the two dimensional (2D) cultures. In the future it
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would be critical to test if phosphorylation of Par-1b on S400 and T595 are essential for
establishing apical/basal epithelial cell polarity or if phosphorylation of Par-1b on S400
and T595 is a result of established cell polarity.
Another goal of my thesis project was to study the Par-1b and RNF41 proteinprotein interaction. I identified a new Par-1b substrate, the E3 ubiquitin ligase RNF41
and demonstrated that Par-1b phosphorylates RNF41 both in vivo and in vitro on S254.
Knockdown of RNF41 in MCF-10A breast epithelial cells using shRNA revealed a novel
role for RNF41 as being essential for establishing apical-basal cell polarity. Moreover,
expression of wild-type RNF41 in these cells rescued apical-basal polarity; however,
expression of the S254A mutant of RNF41 was not able to do so, suggesting that
phosphorylation on S254 is necessary for establishing apical-basal cell polarity and
continuing the theme of phosphorylation regulating polarity proteins. Interestingly,
orthologs of every Par gene, except the RING finger containing Par-2, have been
identified in mammals. Par-2 functions to regulate and stabilize cell polarity in C.
elegans and shares homology with RNF41 in their RING finger domain and part of their
C-terminal domain, leaving open the interesting possibility that RNF41 is an ortholog of
Par-2.
We were unable to detect phosphorylation of endogenous RNF41 on S254 when
cells were grown in 2D cultures. Given the critical role played by Par proteins in
establishing and maintaining apical-basal polarity, we investigated the phosphorylation
status of RNF41 in MCF-10A mammary epithelial cells grown in 3D culture and
observed enhanced phosphorylation on endogenous RNF41 S254. The observation that
cells polarized in 3D culture illustrated the link between phosphorylation of RNF41 on
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S254 and establishment of epithelial cell polarity. Furthermore, this observation
emphasizes the importance and influence of the cell microenvironment, since cellular
context clearly can modulate Par protein function. Another example of this is seen with
Par-6 and aPKC, as both of these proteins are concentrated at tight junctions of epithelial
cells grown in 2D cultures, but are spread over the apical surface in 3D cultures. Within
the much more complicated environment of an organism, such influences are likely to be
widespread and might alter signaling inputs to and outputs from the polarity regulating
proteins such as Par-1 and RNF41.
Cells can adopt different functions in response to specific physiological contexts,
and the plasticity of the loss and re-establishment of cell polarity suggests that common
mechanisms are used but executed differently depending on the physiological context. In
disease states such as metastatic cancers, epithelial cells lose polarity (one way is through
epithelial-mesenchymal transition (EMT)), disengage from multicellular interactions,
migrate, and then reintegrate into a second tissue, in which they undergo reorganization
to reside at the new site (Thiery and Sleeman, 2006; Wodarz and Nathke, 2007). Cells
expressing RNF41 shRNA with and without expression of the S254A mutant of RNF41
do not express the classical protein markers for EMT (low E-cadherin and high Vimentin
and SNAIL protein levels); however, these cells may be undergoing a partial EMT and
warrant further examination since we have observed that these cells are not able to
establish apical-basal polarity in 3D culture.
RNF41 has been studied for its role as an E3 ubiquitin ligase in regulating steady
state neuregulin receptor ErbB3 levels (Diamonti et al., 2002). ErbB3 is overexpressed in
a subset of breast cancers. Moreover, there is a correlation seen between decreased
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RNF41 levels and higher levels of ErbB3 in both an in vivo transgenic mouse model of
ErbB2-induced mammary tumorigenesis and in a panel of primary breast tumors (Yen et
al., 2006). While one mechanism for proliferation and establishment of these tumors may
be due to increased levels of ErbB3, loss of RNF41 and thus lack of cell polarity, may
also contribute to this process.
Over 85% of fatal malignancies in adults in the USA arise from epithelial tissues
(Bryant and Mostov, 2008), and loss of polarity is a hallmark of increased malignancy.
Furthermore, acute injury of major epithelial organ systems is collectively one of the
most important causes of death worldwide (Fausto et al., 2006; Liano and Pascual, 1996;
Matthay and Zimmerman, 2005). Understanding polarization of epithelia, therefore, is
important in analyzing the response of a tissue to injury and in establishing prospects for
regenerative medicine. Many organs, such as the kidney, lung, and liver, can recover
from injury. In the case of the kidney, this involves the local proliferation of epithelial
cells which replace their dead neighbors in a process that involves partial EMT (Bryant
and Mostov, 2008). Learning how to improve the response to injury by controlling the
polarity state of cells offers enormous possibilities to enhance human health.
Understanding cell polarization is one of the major goals of cell biology and will
inevitably have a broad impact not only at the level of basic science but also in
understanding diseases such as cancer. Work from many laboratories has uncovered a
complicated web of signaling systems that surround and intersect with the Par proteins,
yet we still understand very little about what the Par proteins do, how they are localized,
how their various interactions are regulated, and which signaling components operate in
which contexts. After all, the organization of a polarized cell is a complicated process
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that involves cytoskeletal remodeling, membrane traffic, and protein complex assembly
and disassembly, with feedback to gene expression and protein turnover.
Future Directions
The C-terminus of RNF41 binds to the Rhodanese domain of USP8 (the enzyme
which deubiquitinates and thus stabilizes RNF41 protein) and the crystal structure of this
heterodimer has previously been published (Avvakumov et al., 2006). After examining
the crystal structure of the USP8 binding pocket on the C-terminus of RNF41, we noticed
that S254 on RNF41 resides in this pocket and hypothesize that phosphorylation on S254
may affect USP8 binding. Therefore, I will immunoprecipitate wild-type and the S254A
mutant of RNF41-FlagHis6 from MCF-10A cells grown in 3D culture, and I will Western
blot for USP8 in order to compare the levels of binding of USP8 to RNF41. I
hypothesize that phosphorylated RNF41 may bind less USP8 than wild-type or the
S254A mutant. If this is true, then the levels of phosphorylated RNF41 should be lower
than the non-phosphorylated form. However, if the S254A mutant of RNF41 prevents
phosphorylation and still binds to USP8, then its protein levels should be higher than
wild-type RNF41. An alternative hypothesis is that phosphorylated RNF41 may bind
more USP8 than wild-type or the S254A mutant of RNF41. If this is the case, then the
phosphorylated form of RNF41 should be stabilized and the S254A mutant of RNF41
should bind less USP8, and therefore its levels should be lower than the phosphorylated
form of RNF41.
During my thesis work I have shown that Par-1b binds and phosphorylates
RNF41 on S254 in vitro. Furthermore, RNF41 is phosphorylated on S254 in vivo and
overexpression of kinase active Par-1b enhances this phosphorylation in vivo while
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kinase dead Par-1b does not. I have generated MCF-10A cells which stably express two
separate shRNA hairpins for human Par-1b and have shown that Par-1b protein levels are
reduced by greater than 90% in these cells. Thus, I will culture these cells in 3D and
subsequently Western blot for pS254 RNF41. I hypothesize that pS254 RNF41 levels
will decrease in these cells compared to pS254 levels in control MCF-10A cells; however,
it is possible that I may not detect a decrease in the level of pS254 RNF41 due to
compensation by other mammalian Par-1 orthologs. We know from our study and from
work by others that both Par-1b and Par-1d bind to RNF41 (Brajenovic et al., 2004).
Thus, it is possible that other mammalian Par-1 proteins may also bind to RNF41 and
there likely may be some compensation by these other Par-1 proteins when Par-1b is
depleted in cells.
After examining our work with Par-1b and RNF41, still the question remains,
how does RNF41 regulate apical-basal cell polarity? Recently, work by others has shown
that Par-1b kinase activity and protein localization is essential for regulating basement
membrane placement. Furthermore, this study also showed that establishment of the
correct localization of basement membrane is required for the coordination of tissue
polarity (Daley et al, 2012.). Epithelial cell organization and function require positional
information from the surrounding microenvironment (Bryant and Mostov, 2008); such
cues include contacts with both adjacent cells and the basement membrane. I have
preliminary data which suggests that loss of RNF41 results in the loss of Laminin V
deposition (basement membrane) on the cell surface of the MCF-10A acini where it is
needed to establish apical-basal polarity. Moreover, Laminin V accumulation is rescued
when wild-type RNF41 is overexpressed; however, not when cells are rescued with the
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S254A mutant of RNF41 suggesting that phosphorylation of RNF41 on S254 is necessary
for Laminin V deposition. In the future, I will test if accumulation of other basement
membrane proteins (such as collagen IV, fibronectin, and perlecan) is affected by the loss
of RNF41. This will be determined by Western blot, immunofluorescence microscopy,
and qPCR for basement membrane proteins and genes. I hypothesize that the loss of
apical-basal polarity observed in cells expressing RNF41 shRNA is due to the loss of
endogenous basement membrane accumulation. Thus, I will culture the MCF-10A cell
lines expressing Luc shRNA, RNF41 shRNA, RNF41 shRNA + wild-type RNF41, or
RNF41 shRNA + S254A RNF41 in 3D culture using Matrigel instead of collagen type I
and stain for apical and basal polarity markers in order to determine if apical-basal
polarity is rescued when these cells are supplemented with exogenous basement
membrane proteins.
Another possible explanation for the lack of established apical-basal cell polarity
in cells expressing RNF41 shRNA and the S254A mutant of RNF41 is that S254A
RNF41 is mislocalized. Preliminary data indicates that wild-type RNF41 overexpressed
in MCF-10A cells cultured in collagen type I matrix is localized to basolateral
membranes; however, the S254A mutant of RNF41 is mislocalized and accumulates in
the cytoplasm. Future experiments will also be directed at determining if S254
phosphorylation regulates the intracellular localization of RNF41. The failure of the
S254A mutant of RNF41 to localize properly or to bind to key substrates would account
for its failure to rescue polarity in RNF41 deficient MCF-10A cells.
Finally, in the future I propose to determine how RNF41 regulates basement
membrane (Laminin V) deposition. Previous work has demonstrated that Par-1b kinase
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activity is essential for cell surface assembly of laminins by regulating one of the laminin
receptors, the dystroglycan (DG) complex (Masuda-Hirata et al., 2009). I propose to
investigate if RNF41 plays a role in laminin receptor assembly and/or function in order to
regulate basement membrane accumulation on the cell surface. Determining how RNF41
regulates cell polarity and basement membrane deposition is critical for numerous
reasons; however, one implication may be in cancer as loss of apical-basal polarity is a
characteristic of tumor cells. Also, RNF41 protein levels have previously been shown to
be low in some breast cancers. Preliminary data suggests that low RNF41 protein levels
results in loss of basement membrane proteins; thus one might hypothesize that without
basement membrane tumor cells not only are incapable of establishing apical-basal
polarity, but may also be more likely to escape and metastasize.
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